
<html lang="en"     class="pb-page"  data-request-id="e551f663-25f0-47cb-8faa-5e817e569f8f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c02093;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor" /></meta><meta name="dc.Creator" content="Hefeng  Zhang" /></meta><meta name="dc.Creator" content="Xia  Peng" /></meta><meta name="dc.Creator" content="Yang  Dai" /></meta><meta name="dc.Creator" content="Jingwei  Shao" /></meta><meta name="dc.Creator" content="Yinchun  Ji" /></meta><meta name="dc.Creator" content="Yiming  Sun" /></meta><meta name="dc.Creator" content="Bo  Liu" /></meta><meta name="dc.Creator" content="Xu  Cheng" /></meta><meta name="dc.Creator" content="Jing  Ai" /></meta><meta name="dc.Creator" content="Wenhu  Duan" /></meta><meta name="dc.Description" content="The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We..." /></meta><meta name="Description" content="The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 18, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02093" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02093" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02093" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02093" /></link>
        
    
    

<title>Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02093" /></meta><meta property="og:title" content="Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0020.jpeg" /></meta><meta property="og:description" content="The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02093"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02093">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02093&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02093&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02093&amp;href=/doi/10.1021/acs.jmedchem.0c02093" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3956-3975</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02085" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02129" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hefeng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hefeng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hefeng++Zhang">Hefeng Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xia Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xia Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xia++Peng">Xia Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yang Dai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Dai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Dai">Yang Dai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jingwei Shao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingwei Shao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingwei++Shao">Jingwei Shao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yinchun Ji</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yinchun Ji</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yinchun++Ji">Yinchun Ji</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yiming Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yiming Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yiming++Sun">Yiming Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bo Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Liu">Bo Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xu Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xu Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xu++Cheng">Xu Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Ai</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Ai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#98f2f9f1d8ebf1f5f5b6f9fbb6fbf6"><span class="__cf_email__" data-cfemail="8ce6ede5ccffe5e1e1a2edefa2efe2">[email protected]</span></a>. Phone: +86-21-50806600-2426.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Ai">Jing Ai</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wenhu Duan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenhu Duan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#91e6f9f5e4f0ffd1e2f8fcfcbff0f2bff2ff"><span class="__cf_email__" data-cfemail="57203f3322363917243e3a3a793634793439">[email protected]</span></a>. Phone: +86-21-50806032.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenhu++Duan">Wenhu Duan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5084-6026" title="Orcid link">http://orcid.org/0000-0002-5084-6026</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02093&amp;href=/doi/10.1021%2Facs.jmedchem.0c02093" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3956–3975</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 18, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 December 2020</li><li><span class="item_label"><b>Published</b> online</span>18 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02093</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3956%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHefeng%2BZhang%252C%2BXia%2BPeng%252C%2BYang%2BDai%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.0c02093%26title%3DDiscovery%2Bof%2Ba%2BPyrimidinedione%2BDerivative%2Bas%2Ba%2BPotent%2Band%2BOrally%2BBioavailable%2BAxl%2BInhibitor%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3975%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02093"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1553</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02093" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hefeng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Jingwei&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Yinchun&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Yiming&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xu&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Ai&quot;},{&quot;first_name&quot;:&quot;Wenhu&quot;,&quot;last_name&quot;:&quot;Duan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3956-3975&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02093&quot;},&quot;abstract&quot;:&quot;The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02093&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02093" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02093&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02093" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02093&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02093" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02093&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02093&amp;href=/doi/10.1021/acs.jmedchem.0c02093" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02093" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02093" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02093%26sid%3Dliteratum%253Aachs%26pmid%3D33733758%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DDiscovery%2Bof%2Ba%2BPyrimidinedione%2BDerivative%2Bas%2Ba%2BPotent%2Band%2BOrally%2BBioavailable%2BAxl%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D3956%26epage%3D3975%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound <b>9</b> to discover compound <b>13c</b>, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that <b>13c</b> could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound <b>13c</b> significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, <b>13c</b> exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make <b>13c</b> a promising therapeutic candidate for cancer treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Axl is a receptor tyrosine kinase (RTK) that belongs to the TAM (Tyro3, Axl, and Mer) subfamily. Upon binding to its endogenous ligand growth arrest specific protein 6 (Gas6),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Axl dimerizes and gets autophosphorylated, resulting in the activation of downstream signaling pathways.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2−5)</a> Gas6/Axl signaling regulates various biological processes, such as proliferation, differentiation, migration, apoptosis, angiogenesis, and immune response.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a></div><div class="NLM_p">Since the first identification of Axl in chronic myeloid leukemia (CML),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> aberrant Axl signaling has been detected in many other cancers.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15">(9−15)</a> Overexpression of Axl closely correlates with poor prognosis.<a onclick="showRef(event, 'ref3 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref3 ref16 ref17 ref18 ref19 ref20 ref21">(3,16−21)</a> Axl can heterodimerize with many other RTKs, including Met,<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> cooperating to promote tumor growth and metastasis. Moreover, Axl, as a key inducer of epithelial-to-mesenchymal transition (EMT), is potentially required for the metastatic feature of tumors, and blockading Axl could decrease tumor metastasis.<a onclick="showRef(event, 'ref10 ref15 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref10 ref15 ref25 ref26 ref27">(10,15,25−27)</a> Recent evidence has shown the potential important regulatory role of Gas6/Axl in the interaction between cancer cells and stromal/immune cells in the tumor microenvironment, promoting tumor progression and metastasis.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Besides, Axl could mediate de novo and acquire resistance to chemotherapy, immunotherapy, molecular-targeted therapy, and radiation therapy.<a onclick="showRef(event, 'ref21 ref26 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref21 ref26 ref29 ref30">(21,26,29,30)</a> Thus, targeting Axl is a promising strategy for anticancer therapeutics.</div><div class="NLM_p">Several type I and type II ATP-competitive inhibitors that target Axl have been reported (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Type I inhibitors such as <b>1</b> (gilteritinib)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and <b>2</b> (bemcentinib, BGB324)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> bind to the active conformation of Axl, where the aspartate–phenylalanine–glycine (DFG) motif is oriented toward the ATP binding site. The potent FLT3/Axl inhibitor <b>1</b> has been approved by FDA to treat acute myeloid leukemia (AML) with FLT3 mutations. BGB324, which is disclosed as the first selective Axl inhibitor,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> has advanced into phase I and II clinical trials against different types of cancers. Type II inhibitors bind to the inactive conformation of Axl, in which the DFG motif is oriented outward such that the protein could enable additional allosteric interactions. Compound <b>3</b> (cabozantinib)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> is an FDA-approved multikinase inhibitor for treating various cancers, and the inhibitory potency of <b>3</b> against Axl is 200-fold less active than against VEGFR2.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Some other type II Axl inhibitors, such as <b>4</b> (foretinib),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><b>5</b>,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>6</b> (merestinib),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and <b>7</b> (CEP-40783),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> are currently in different phases of clinical trials. Compound <b>8</b> is another potent type II Axl inhibitor with an IC<sub>50</sub> value of 4.0 nM.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The imaging probes derived from <b>8</b> have been successfully applied in proteome profiling and bioimaging of cancer cells and tumor tissues.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative Axl inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Here, we describe the discovery of the orally active pyrimidinedione <b>13c</b> as a type II Axl inhibitor.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design Rationale and Structure–Activity Relationship (SAR) Exploration</h3><div class="NLM_p">A validated sandwich enzyme-linked immunosorbent assay (ELISA)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> was used to determine the kinase inhibitory activities of new derivatives. Gilteritinib and BGB324 served as positive controls and displayed IC<sub>50</sub> values of 4.6 and 4.8 nM, respectively, which are consistent with previously reported data.<a onclick="showRef(event, 'ref32 ref42'); return false;" href="javascript:void(0);" class="ref ref32 ref42">(32,42)</a> The classic gain-of-function model cell line BaF3/TEL-AXL was used to evaluate the antiproliferative effect of new derivatives.</div><div class="NLM_p">No crystal structure is available for the Axl kinase domain in complex with a type II inhibitor to date. To elucidate the interactions between Axl and type II inhibitors, we obtained the Axl kinase domain sequence from the UniProt database (<a href="http://www.uniprot.org/" class="extLink">http://www.uniprot.org/</a>) and performed a BLAST search (<a href="http://blast.ncbi.nlm.nih.gov" class="extLink">http://blast.ncbi.nlm.nih.gov</a>) of the obtained sequence in the PDB database. The results demonstrated that except for the TAM subfamily members, Met had the highest sequence identity to the Axl kinase domain, with an identity value of 45.90%. In addition, 24 out of 28 residues in the DFG-out binding pocket of Met and Axl were identical (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C), which indicated that a type II inhibitor might bind to Met and Axl with similar binding modes. The binding mode of Met with the representative type II Axl/Met inhibitor <b>4</b> has been reported<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). It revealed that type II Axl inhibitors may have the following structural features: (1) a hinge-binding moiety “head”, which is commonly a nitrogen-containing heterocycle as a hydrogen bond acceptor and may be decorated with substituents that stretch into the solvent region; (2) a “tail” containing a dual hydrogen bond acceptor (DHBA) segment and a hydrophobic aryl, where the active conformation of the tail moiety could be constrained by introducing a rigid ring; and (3) an aminophenoxyl linker that joins the head and the tail (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). On the basis of this information, we initially designed and synthesized compound <b>9</b> (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which features a five-membered ring in the tail moiety for constraining the active conformation of the tail moiety and a flexible pyrazole-substituted pyridine in the head moiety. As a type II inhibitor, <b>9</b> also has a relatively low molecular weight (480.5) and has good potential for structural modification. Biochemical assays showed that compound <b>9</b> displayed moderate activity with an IC<sub>50</sub> value of 253.9 nM for Axl.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Analysis of the structural features of the type II Axl inhibitor from the cocrystal structure of Met in complex with the Axl inhibitor <b>4</b>: (A) binding mode of Met with the representative type II Axl inhibitor <b>4</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a>). (B) Compound <b>4</b> was used to display the structural features of classic type II Axl inhibitors. (C) Sequence alignment of Axl and Met kinase domains, where the identical residues are colored in red and the binding pocket residues of the Met DFG-out conformation are boxed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structure of compound <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our first step in optimizing the inhibitory potency of <b>9</b> involved the tail moiety. We adopted a hybrid design strategy by replacing the tail moiety of <b>9</b> with different known DHBA-containing fragments<a onclick="showRef(event, 'ref39 ref43 ref44 ref45 ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref39 ref43 ref44 ref45 ref46 ref47 ref48 ref49">(39,43−49)</a> to generate compounds <b>10a–n</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Ethoxy-substituted pyrazole <b>10a</b> exhibited no activity on Axl, whereas pyrimidine-4-one <b>10b</b> displayed a significant increase in potency, with an IC<sub>50</sub> value of 20.5 nM for Axl. The installation of a methyl at the 6′-position of the pyrimidine-4-one moiety of <b>10b</b> led to a sharp loss in activity (<b>10c</b>), whereas replacement of pyrimidine-4-one of <b>10b</b> with pyrimidine-2,4-dione led to a slight increase in potency (<b>10d</b>, with an IC<sub>50</sub> of 13.0 nM). Given the improved potency of <b>10d</b>, variations at the 1′-position of the pyrimidine-2,4-dione fragment of <b>10d</b> were explored with four selected substituents to form compounds <b>10e–h</b>, among which ethyl and isopropyl substitutions led to a slight increase in potency with IC<sub>50</sub> values of 8.8 and 8.7 nM for <b>10f</b> and <b>10g</b>, respectively. Replacing pyrimidine-2,4-one with its bioisoster 1,2,4-triazine-3,5-dione resulted in a sharp drop in potency (<b>10i</b>). We also synthesized a set of compounds featuring fused heterocyclic moieties (<b>10j–n</b>); replacement of the tail moiety with 7,8-dihydroquinoline-2,5-dione and 1,7-naphthyridin-2-one moieties led to improved activities (<b>10l</b> and <b>10m</b> vs <b>9</b>), whereas replacement with the inden-1-one moiety (<b>10j</b>), 6,7-dihydroisoquinoline-3,8-dione moiety (<b>10k</b>), and quinolin-4-one moiety (<b>10n</b>) led to a complete loss of activity. As a result, <b>10g</b> was identified as the optimal compound for further investigation.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of the Tail Moiety<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0015.gif" alt="" id="GRAPHIC-d7e626-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0016.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The Axl kinase inhibitory IC<sub>50</sub> values are the mean ± SD of two or more independent assays or estimated values.</p></div></div><div></div></div><div class="NLM_p">A better understanding of the binding mode of <b>10g</b> with Axl could pave the way for further rational design; therefore, we carried out an in silico molecular modeling study. As mentioned above, there is no available crystal structure for Axl in complex with a type II inhibitor, and Met has the highest sequence identity to the Axl kinase domain; in addition, 24 out of 28 residues in the DFG-out binding pocket of Met and Axl are identical (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C); thus, a Met DFG-out crystal structure can serve as a template for generating an Axl DFG-out homology model. We first constructed an Axl DFG-out homology model based on a reported DFG-out Met kinase crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82">3F82</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The predicted Axl DFG-out homology model was highly similar to the Met crystal structure in both the overall folding and binding pockets (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_001.pdf" class="ext-link">Figure S1</a>). Next, we docked <b>10g</b> to the Axl DFG-out model. The result showed that <b>10g</b> adopted a canonical type II binding mode and could fit well into the DFG-out pocket (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The tail moiety occupied the allosteric binding site, and the DHBA fragment formed two hydrogen bonds with residues Lys567 and Asp690. The isopropyl and 4-fluorophenyl stretched to two different hydrophobic pockets. A critical hydrogen bond was formed in the hinge region between the nitrogen atom of the pyridine moiety and the backbone NH of the residue Met623. The aminophenoxyl moiety acted as a linker and occupied the hydrophobic tunnel. This simulated result provided useful information for further rational design: (1) as the 1-methyl pyrazole moiety of <b>10g</b> did not present strong interactions with the binding pocket, we envisioned that shifting this moiety to the ortho-position of the pyridine nitrogen might allow the inhibitor to approach the pocket surface more closely to enhance van der Waals interactions; (2) the hydrophobic tunnel occupied by the aminophenoxyl linker could only tolerate small substituents; and (3) the carbonyl oxygen of Met623 might be a potential hydrogen bond acceptor, and the potency could presumably be improved by installing an additional hydrogen bond donor at the ortho-position of the pyridine nitrogen.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic illustration of the proposed binding mode of <b>10g</b> with the Axl DFG-out homology model (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82">3F82</a>): (A) Type II binding model of compound 1<b>0g</b>. (B) Compound <b>10g</b> with the hinge region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">First, the effect of shifting the 1-methyl pyrazole moiety to the ortho-position of the pyridine nitrogen was examined, and the result showed that <i>ortho</i>-pyrazole-substituted pyridine <b>11a</b> (IC<sub>50</sub>: 1.9 nM) exhibited a significant increase in potency compared to its metasubstituted analogue <b>10g</b> (IC<sub>50</sub>: 8.7 nM), as shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Then, selected SAR from substitution on the aminophenoxyl linker is summarized as in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Fluoro substitution is more favorable at the R<sup>2</sup>-position than at the R<sup>3</sup>-position (IC<sub>50</sub>: 0.8 nM for <b>11b</b> vs 5.5 nM for <b>11c</b>). Chloro and methyl substitutions resulted in 27- and 57-fold decreases in potency for <b>11d</b> and <b>11e</b>, respectively. Methoxy substitution, as in <b>11f</b>, resulted in a complete loss of activity. Difluoro-substituted derivatives <b>11g</b>, <b>11h</b>, and <b>11i</b> displayed a slight decrease in potency compared to the monofluoro derivative <b>11b</b>. The monofluoro derivative <b>11b</b> represented the optimal substitution pattern on the aminophenoxyl linker, and the narrow SAR is consistent with expectations, given the limited space available for the linker in this region.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of the Linker Moiety <b>11a–</b>i<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0017.gif" alt="" id="GRAPHIC-d7e764-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">R<sup>4</sup></th><th class="colsep0 rowsep0" align="center">Axl kinase inhibitory IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5.5 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">21.9 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">45.6<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4.9 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">2.75 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.6 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.8 ± 0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Unless otherwise specified, the Axl kinase inhibitory IC<sub>50</sub> values are the mean ± SD of two or more independent assays or estimated values.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The result is obtained from a single assay.</p></div></div></div><div class="NLM_p">We next explored the effect of substituents on the pyrazole fragment (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The introduction of a methyl group at the R<sup>5</sup>-position (<b>12a</b>) resulted in a 32-fold loss in potency for Axl kinase, while a slight increase in cellular potency (BaF3/TEL-AXL IC<sub>50</sub>: 1 nM for <b>12a</b> vs 1.9 nM for <b>11b</b>). The derivatives substituted with three selected larger groups at the R<sup>6</sup>-position (<b>12b–d</b>) were less active than the methyl-substituted derivative <b>11b</b> in both enzymatic and cellular assays. According to the concept of “heteroatom release”,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> the group on the heteronitrogen atom, as the methyl group in <b>11b</b> at the R<sup>6</sup>-position, is potentially metabolically labile; consequently, a methyl-free compound <b>12e</b> was synthesized. Compound <b>12e</b> displayed a slight decrease in potency for kinase inhibitory activity, but significantly improved potency in the BaF3/TEL-AXL assay (IC<sub>50</sub> < 0.2 nM). On account of their in vitro potencies and metabolic labile site, compound <b>12e</b> was identified as the optimal pyrazole derivatives.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of the Pyrazole Fragment<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0018.gif" alt="" id="GRAPHIC-d7e1004-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">inhibitory IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center">R<sup>5</sup></th><th class="colsep0 rowsep0" align="center">R<sup>6</sup></th><th class="colsep0 rowsep0" align="center" char="±">Axl kinase</th><th class="colsep0 rowsep0" align="center">BaF3/TEL-AXL proliferation</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">25.6 ± 4.5</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cyclopropyl</td><td class="colsep0 rowsep0" align="char" char="±">10.5 ± 1.1</td><td class="colsep0 rowsep0" align="left">6.3 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-hydroxy-2-methylpropyl</td><td class="colsep0 rowsep0" align="char" char="±">17.4 ± 6.2</td><td class="colsep0 rowsep0" align="left">2.8 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-(4-methylpiperazin-1-yl)ethyl</td><td class="colsep0 rowsep0" align="char" char="±">26.0 ± 3.1</td><td class="colsep0 rowsep0" align="left">19.5 ± 8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.3</td><td class="colsep0 rowsep0" align="left"><0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.6</td><td class="colsep0 rowsep0" align="left">7.6 ± 4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 0.8</td><td class="colsep0 rowsep0" align="left">117.2 ± 8.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values are the mean ± SD of two or more independent assays or estimated values.</p></div></div></div><div class="NLM_p">Finally, we attempted to add an additional hydrogen bond donor at the ortho-position of the pyridine fragment, as indicated in the docking studies, to form bidentate hydrogen bonds with Met623 in the hinge region of Axl. The results showed that replacement of the pyrazole fragment with amide or urea fragments was successful; as summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, almost all new derivatives displayed high potency in both enzymatic and cellular assays, with the exception of <b>13d</b>, which showed moderate cellular activity. The most potent compound <b>13c</b> was docked to the Axl DFG-out homology model, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, and <b>13c</b> shared the same allosteric interactions with <b>10g</b> and formed bidentate hydrogen bonds with Met623 at the hinge region as expected.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Schematic illustration of the proposed binding mode of <b>13c</b> with the Axl DFG-out homology model (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82">3F82</a>): (A) Type II binding model of compound <b>13c</b>. (B) Compound <b>13c</b> with the hinge region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Axl Inhibitory Activities of Inhibitors <b>13a–e</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0019.gif" alt="" id="GRAPHIC-d7e1209-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">inhibitory IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center">R<sup>7</sup></th><th class="colsep0 rowsep0" align="center" char="±">Axl kinase</th><th class="colsep0 rowsep0" align="center">BaF3/TEL-AXL proliferation</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 0.3</td><td class="colsep0 rowsep0" align="left"><0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 1.1</td><td class="colsep0 rowsep0" align="left"><0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="left">cyclopropyl</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.1</td><td class="colsep0 rowsep0" align="left"><0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13d</b></td><td class="colsep0 rowsep0" align="left">cyclobutyl</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 0.9</td><td class="colsep0 rowsep0" align="left">43.2 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13e</b></td><td class="colsep0 rowsep0" align="left">pyrrolidin-1-yl</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="left"><0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13f</b></td><td class="colsep0 rowsep0" align="left">morpholino</td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 2.8</td><td class="colsep0 rowsep0" align="left"><0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.6</td><td class="colsep0 rowsep0" align="left">7.6 ± 4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 0.8</td><td class="colsep0 rowsep0" align="left">117.2 ± 8.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values are the mean ± SD of two or more independent assays or estimated values.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetic Study</h3><div class="NLM_p">Compounds <b>12e</b> and <b>13c</b> were chosen for in vivo pharmacokinetic studies because of their excellent enzymatic and cellular activities. Preliminary pharmacokinetic evaluations were conducted in male Sprague–Dawley (SD) rats. The pharmacokinetic parameters are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Both compounds displayed good maximum concentrations and oral exposures; <b>13c</b> had a favorable half-life of 13.8 h, whereas compound <b>12e</b> exhibited a long half-life of 18.2 h, which may bring about a potential risk of cumulative toxicity. Consequently, compound <b>13c</b> was selected for subsequent pharmacokinetics assessment in male Institute of Cancer Research (ICR) mice. <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> shows the good pharmacokinetic parameters displayed by <b>13c</b> in the ICR mice.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Data of <b>12e</b> and <b>13c</b> in Rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><b>12e</b></th><th class="colsep0 rowsep0" align="center" char="."><b>13c</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char=".">po 3 mg/kg</th><th class="colsep0 rowsep0" align="center" char=".">po 3 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char=".">31,641</td><td class="colsep0 rowsep0" align="char" char=".">32,647</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char=".">52,165</td><td class="colsep0 rowsep0" align="char" char=".">43,931</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">18.2</td><td class="colsep0 rowsep0" align="char" char=".">13.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1.67</td><td class="colsep0 rowsep0" align="char" char=".">1.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">2573</td><td class="colsep0 rowsep0" align="char" char=".">4557</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Three animals were used for each dose group. The data shown are mean values.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Data of <b>13c</b> in Mice<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><b>13c</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char=".">po 3 mg/kg</th><th class="colsep0 rowsep0" align="center" char=".">iv 1 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char=".">24,044</td><td class="colsep0 rowsep0" align="char" char=".">7006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char=".">25,106</td><td class="colsep0 rowsep0" align="char" char=".">7356</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">5.20</td><td class="colsep0 rowsep0" align="char" char=".">5.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1.67</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">2990</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/h/kg)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> %</td><td class="colsep0 rowsep0" align="char" char=".">114.4</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Three animals were used for each group. The data are mean values.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Kinase Selectivity Profile of 13c</h3><div class="NLM_p">The kinase selectivity of <b>13c</b> was further evaluated over a panel of 41 kinases, including the TAM subfamily members Mer and Tyro3 and the highly homologous kinase Met. Compound <b>13c</b> also significantly inhibited the kinases activity of Mer, Tyro3, and Met. The potency of <b>13c</b> against Met was equal to that against Axl (Met IC<sub>50</sub>: 0.8 ± 0.1 nM). In contrast, no obvious inhibitory effect was observed in the other 38 tested tyrosine kinases belonging to different families (IC<sub>50</sub> > 1 μM or 100 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). These results indicated that <b>13c</b> was a potent TAM and Met inhibitor. Next, we used representative Axl- and Met-driven in vitro and in vivo scenarios to evaluate the antitumor effect of <b>13c</b> against Axl and Met.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Kinase Selectivity Profile of <b>13c</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">inhibitory IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">inhibitory IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">inhibitory IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Axl</td><td class="colsep0 rowsep0" align="left">0.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">HER4(ErbB4)</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Met</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.1</td><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mer</td><td class="colsep0 rowsep0" align="left"><10</td><td class="colsep0 rowsep0" align="left">Abl</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">Ret</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tyro3</td><td class="colsep0 rowsep0" align="left">1–10</td><td class="colsep0 rowsep0" align="left">EphA2</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">p90RSK</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">Syk</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">A-Raf</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">ZAK</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CaMK1</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CLK1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CDK1/cyclinB</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CDK2/cyclinA</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">GCK</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CDK4/cyclinD3</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Kit</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CDK6/cyclinD3C</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">CDK12/cyclinK</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-3</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">ERK2</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">PI3K(p110d/p85a)</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values are presented as the mean ± SD or estimated values.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Compound <b>13c</b> Inhibited Cellular Axl and Met Signaling</h3><div class="NLM_p">We evaluated the cellular effects of <b>13c</b> against Axl and Met signaling for Axl-driven or Met-dependent scenarios, respectively. First, the classic gain-of-function model cell BaF3/TEL-AXL, in which proliferation is driven by <i>AXL</i> fusion, was used. Treatment with <b>13c</b> led to a robust decrease in the phosphorylation of Axl and its key downstream molecule Akt<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> in BaF3/TEL-AXL cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Furthermore, we extended to Gas6-stimulated Axl activation context. The nonsmall cell lung cancer cell line NCI-H1299 is sensitive to Gas6 stimulation, as evidenced by the markedly enhanced phosphorylation of Axl and the downstream molecule Akt. Treatment with <b>13c</b> inhibited the Gas6-induced upregulation of Axl and Akt phosphorylation. The activity of <b>13c</b> was more potent than that of BGB324 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Next, we determined whether <b>13c</b> could inhibit the Met signaling pathway in the Met-driven context using MKN45 and EBC-1 cells, both with <i>MET</i> amplification. The reported Met inhibitor crizotinib<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> served as a positive control. As shown, <b>13c</b> suppressed the phosphorylation of Met and downstream signaling molecules of Met (ERK and Akt) in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C,D). These data demonstrated that <b>13c</b> inhibited both cellular Axl and Met signaling pathways.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>13c</b> suppressed Axl/Met phosphorylation and downstream signaling in BaF3/TEL-AXL cells (A), NCI-H1299 cells (B), MKN45 cells (C), and EBC-1 cells (D). BaF3/TEL-AXL, MKN45, and EBC-1 cells were treated with compounds at different concentrations for 2 h; NCI-H1299 cells were serum-deprived for 24 h prior to 2 h of treatment with compounds and then stimulated with Gas6 for 15 min. Then, the cells were lysed and subjected to western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Compound <b>13c</b> Restrained Axl/Met-Driven Cell Proliferation with Selectivity</h3><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> shows that <b>13c</b> exhibited high potency against Axl-mediated cell proliferation. Given the activity of <b>13c</b> against c-Met kinase, we next evaluated the activity of <b>13c</b> against EBC-1 and MKN45 cell proliferation driven by <i>MET</i> amplification. Compound <b>13c</b> inhibited the proliferation of MKN45 and EBC-1 cells with IC<sub>50</sub> values of 64.0 ± 5.4 and 106.8 ± 19.4 nM, respectively.</div><div class="NLM_p">Furthermore, we extended to 14 other cancer cell lines without <i>MET</i> or <i>AXL</i> aberrations. We found that <b>13c</b> exerted little antiproliferative effect in these cell lines (IC<sub>50</sub> > 10 μM, see <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). The cell line inhibitory profile results, together with the biochemical kinase profile results, confirmed that <b>13c</b> selectively inhibited Axl/Met.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cell Line Proliferation Inhibitory and Selectivity Profile of <b>13c</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">inhibitory IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT474</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC78</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JHH7</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H1975</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H1299</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC827</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT549</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KMS11</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RT112</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MM.1S</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HL60</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC4006</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values are estimated values.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Compound <b>13c</b> Attenuated Gas6/Axl-Mediated Cancer Cell Migration and Invasion</h3><div class="NLM_p">Given the critical role of Axl in the tumor metastatic phenotype, we evaluated the effect of <b>13c</b> on Gas6/Axl axis-mediated tumor cell migration and invasion. A cell migration assay using NCI-H1299 cells was first performed. Gas6 stimulation strongly enhanced the motility of NCI-H1299 cells, whereas <b>13c</b> markedly decreased the NCI-H1299 cell motility induced by Gas6. We observed a similar trend in the cell invasion assay. The invasion of the SNU449 cell line was enhanced by the addition of Gas6. Treatment with <b>13c</b> inhibited cell invasion (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The activity of <b>13c</b> was more potent than that of BGB324. In addition, <b>13c</b> showed no effect on cell proliferation under the same conditions (data not shown), largely excluding the possibility that the inhibitory effect of <b>13c</b> on cell movement was caused by inhibition of cell proliferation. Therefore, <b>13c</b> could inhibit the motility of cancer cells driven by the activation of the Axl pathway in vitro, indicating the therapeutic potential of <b>13c</b> for tumor metastasis.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>13c</b> inhibited Axl-dependent neoplastic phenotypes of metastasis: (A) Compound <b>13c</b> suppressed Gas6-induced NCI-H1299 cell migration. (B) Compound <b>13c</b> inhibited Gas6-induced SNU449 cell invasion. Representative images are shown (scale bars, 10 μm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>13c</b> Inhibited Axl-Driven or Met-Driven Tumor Growth In Vivo</h3><div class="NLM_p">We investigated the antitumor activity of <b>13c</b> in vivo against established xenograft models derived from BaF3/TEL-AXL. Once the tumor volume reached 150–200 mm<sup>3</sup>, tumor-bearing BALB/c nude mice were randomly assigned to five groups and treated with a vehicle or the indicated compound for 14 consecutive days. <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A shows that <b>13c</b> significantly suppressed tumor growth. The tumor growth inhibition (TGI) rates of <b>13c</b> were 106.4, 105.9, and 90.9% at doses of 25, 5, and 1 mg/kg, respectively; four out of six mice exhibited complete tumor regression in both the 25 and 5 mg/kg treatment groups. The efficacy of 5 mg/kg <b>13c</b> was comparable to that of 50 mg/kg BGB324. These results indicated that <b>13c</b> is a potent Axl inhibitor with potential for further development. Encouraged by the high activity of <b>13c</b> to reverse the Met-dependent tumor phenotype in vitro, we evaluated the antitumor efficacy of <b>13c</b> in vivo. The U87MG model driven by dysregulation of Met was used. Compound <b>13c</b> significantly inhibited tumor growth of the U87MG model in a dose-dependent manner, where the TGI rates of 100, 25, and 5 mg/kg were 99.1, 89.8, and 62.3% respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Additionally, <b>13c</b> was well tolerated, with no substantial body weight loss in all the treated groups, even at the highest dose of 100 mg/kg (data not shown).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>13c</b> significantly inhibited Axl/Met-mediated tumor growth in vivo: (A) Tumor growth was inhibited after <b>13c</b> treatment in BaF3/TEL-AXL xenografts. (B) Tumor growth was inhibited after <b>13c</b> treatment in U87MG xenografts. The tumor volumes are expressed as the mean ± SEM. Significant differences from the vehicle group were determined using a <i>t</i>-test, ***<i>P</i> < 0.001 and **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p">The syntheses of <b>9</b> and <b>10a–n</b> are illustrated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The starting compound 3-chloro-4-bromopyridine (<b>14</b>) was reacted with 4-aminophenol to provide <b>15</b>. Suzuki coupling of <b>15</b> with 1-methyl-4-pyrazole boronic acid pinacol ester afforded amine <b>16</b>, which was condensed with acids <b>17a–o</b> to produce amides <b>9</b> and <b>10a–n</b>.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of <b>9</b> and <b>10a–n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminophenol, potassium <i>tert</i>-butoxide, dimethylacetamide (DMA), room temperature (RT) to 85 °C; (b) 1-methyl-4-pyrazole boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane/water, 90 °C; and (c) <i>O</i>-(7-aza-1<i>H</i>-benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetramethyluronium hexafluorophosphate (HATU), triethylamine (TEA), <i>N</i>,<i>N</i>-dimethylformamide (DMF), RT.</p></p></figure><div class="NLM_p">The syntheses of <b>11a–g</b>, <b>11i</b>, and <b>12a–e</b> were similar to those described for <b>9</b>, as illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The reaction of 2,4-dichloropyridine (<b>18</b>) with various 4-aminophenols produced <b>19a–h</b>, which were further coupled with different boronic acid pinacol esters to afford amines <b>20a–m</b>. Condensation of <b>20a–m</b> with <b>17h</b> provided <b>11a–g</b>, <b>11i</b>, and <b>12a–e</b>.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of <b>11a–g</b>, <b>11i</b>, and <b>12a–e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate 4-aminophenol, potassium <i>tert</i>-butoxide, DMA, RT to 85 °C; (b) 1-methyl-4-pyrazole boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane/water, 90 °C; and (c) acid <b>17h</b>, HATU, TEA, DMF, RT.</p></p></figure><div class="NLM_p">Compound <b>11h</b> was synthesized according to the procedures outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The starting compound 2-chloro-4-hydroxypyridine (<b>21</b>) was reacted with 1,2,4-trifluoro-5-nitrobenzene, and the resulting nitrobenzene <b>22</b> was then reduced to provide amine <b>23</b>, which was reacted with 1-methyl-4-pyrazole boronic acid pinacol ester by Suzuki coupling to afford amine <b>24</b>. Finally, acid <b>17h</b> was condensed with amine <b>24</b> to produce <b>11h</b>.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>11h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, 1,2,4-trifluoro-5-nitrobenzene, DMF, RT; (b) SnCl<sub>2</sub>, EtOH, 80 °C; (c) 1-methyl-4-pyrazole boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane/water, 90 °C; and (d) acid <b>17h</b>, HATU, TEA, DMF, RT.</p></p></figure><div class="NLM_p">Compounds <b>13a–c</b> were synthesized according to the procedures outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Amine <b>25</b> was condensed with appropriate acid chlorides, and the resulting amides <b>26a–c</b> were then reacted with 2-fluoro-4-nitrophenol to afford nitro compounds <b>27a–c</b>, which were reduced to amines <b>28a–c</b> with iron powder. Amines <b>28a–c</b> were condensed with acid <b>17h</b> to yield <b>13a–c</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of <b>13a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate acid chloride, TEA, dichloromethane, 0 °C to RT; (b) 2-fluoro-4-nitrophenol, chlorobenzene, 140 °C; (c) iron powder, acetic acid, ethyl acetate, 80 °C; and (d) acid <b>17h</b>, HATU, TEA, DMF, RT.</p></p></figure><div class="NLM_p">Compounds <b>13d–f</b> were synthesized according to the procedures outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. 4-Chloropicolinamide (<b>29</b>) was reacted to yield amine <b>30</b>, which was then condensed with acid <b>17h</b> to afford amide <b>31</b>. Amide <b>31</b> was converted to amine <b>32</b> by a Hoffman rearrangement reaction. Compound <b>13d</b> was synthesized by coupling amine <b>32</b> with cyclobutane carboxylic acid. Compounds <b>13e</b> and <b>13f</b> were synthesized by reaction of <b>32</b> with pyrrolidine and morpholine, respectively.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Syntheses of <b>13d–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-amino-2-fluorophenol, potassium <i>tert</i>-butoxide, dimethyl sulfoxide (DMSO), RT to 80 °C; (b) acid <b>17h</b>, HATU, TEA, DMF, RT; (c) iodobenzene diacetate, ethyl acetate/acetonitrile/water, 0 °C to RT; (d) cyclobutane carboxylic acid, HATU, TEA, DMF, RT; and (e) appropriate amine, phenyl chloroformate, TEA, tetrahydrofuran (THF), 0 °C to RT.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04352" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04352" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we designed and synthesized a series of Axl inhibitors of the type II class. Molecular modeling-assisted optimization led to the identification of <b>13c</b>, which was highly potent in both biochemical and cellular assays (Axl IC<sub>50</sub>: 0.9 nM, BaF3/TEL-AXL IC<sub>50</sub> < 0.005 nM). Compound <b>13c</b> displayed good pharmacokinetic parameters in both rats and mice. Further evaluation revealed that <b>13c</b> exhibited kinase selectivity for TAM subfamily members and the homologous kinase Met. Compound <b>13c</b> significantly suppressed cellular Axl and Met signaling and inhibited the proliferation of cells driven by <i>AXL</i>-fusion or <i>MET</i> amplification. In contrast, <b>13c</b> had almost no influence on cell proliferation in cell lines without <i>AXL</i> or <i>MET</i> aberration, even at high concentrations, confirming the selectivity of <b>13c</b> against Axl and Met. Compound <b>13c</b> also restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, <b>13c</b> exhibited significant antitumor activity in vivo in Axl-driven or Met-driven tumor xenografts, causing tumor stasis or regression at well-tolerant doses. Compound <b>13c</b> may serve as a potential Axl/Met dual inhibitor for further drug development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15434" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15434" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all starting materials, reagents, and solvents were commercially available and used without further purification. Chemical reactions were monitored by thin-layer chromatography (TLC) or liquid chromatography (LC)/mass spectrometry (MS). TLC was performed using silica gel plates with fluorescence F254 and UV light visualization. LC/MS was performed on an Agilent 1200 HPLC/6110 MSD system (column: ZORBAX Eclipse Plus column, C18, 4.6 mm × 100 mm, 3.5 μm). Column chromatography was performed by automated flash chromatography on a Biotage Isolera One instrument using silica gel (300–400 mesh). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained using CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, CD<sub>3</sub>OD, or acetone-<i>d</i><sub>6</sub> on Varian Mercury Plus 300 M or 400 M or Bruker AVANCE III 400 M, 500 M, or 600 M NMR spectrometers. In the tabulated NMR results, multiplicities are indicated by s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublet), ddd (doublet of doublet of doublet), t (triplet), dt (doublet of triplets), q (quartet), p (pentet), and m (multiplet). High-resolution ESI-MS was performed on an Agilent G6520 Q-TOF spectrometer. The purity of all the final compounds was confirmed to be >95% as determined by HPLC on an Agilent infinity 1260 HPLC system (column: ZORBAX Eclipse Plus column, C18, 4.6 mm × 150 mm, 5 μm; detector: diode array detector). The mobile phase of methanol and water was used with a flow rate of 1.0 mL/min.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 1,5-Dimethyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazole-4-carboxamide (<b>9</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17a</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 86% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.82 (s, 1H), 8.86 (s, 1H), 8.29–8.19 (m, 2H), 8.03 (d, <i>J</i> = 0.8 Hz, 1H), 7.74–7.66 (m, 2H), 7.63–7.48 (m, 3H), 7.48–7.38 (m, 2H), 7.21–7.11 (m, 2H), 6.73–6.64 (m, 1H), 3.89 (s, 3H), 3.36 (s, 3H), 2.71 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.03, 161.69, 161.00, 155.14, 149.41, 148.78, 148.47, 137.71, 136.42, 133.17, 129.91, 129.87 (s, 2C), 129.15, 126.60 (s, 2C), 121.59 (s, 2C), 121.33 (s, 2C), 118.95, 114.89, 110.76, 99.78, 39.16, 33.60, 12.02. HRMS: (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>25</sub>N<sub>6</sub>O<sub>3</sub>, 481.1983; found, 481.1989.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-Ethoxy-1-(4-fluorophenyl)-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>10a</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17b</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 88% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.99 (s, 1H), 8.87 (s, 1H), 8.50 (s, 1H), 8.26 (d, <i>J</i> = 5.8 Hz, 2H), 8.07–7.98 (m, 3H), 7.94–7.86 (m, 2H), 7.42 (t, <i>J</i> = 8.8 Hz, 2H), 7.24–7.19 (m, 2H), 6.71 (d, <i>J</i> = 5.6 Hz, 1H), 4.11 (q, <i>J</i> = 7.0 Hz, 2H), 3.90 (s, 3H), 1.40 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 161.74 (d, <i>J</i> = 247.5 Hz, 1C), 160.80, 159.05, 150.21, 149.10, 148.66, 146.42, 137.89, 136.16 (d, <i>J</i> = 2.8 Hz, 1C), 135.60, 134.93, 129.87, 121.73 (s, 2C), 121.49 (s, 2C), 121.17 (d, <i>J</i> = 8.4 Hz, 2C), 119.13, 116.52 (d, <i>J</i> = 23.2 Hz, 2C), 114.98, 112.82, 110.95, 68.85, 39.25, 14.99. HRMS: (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>24</sub>FN<sub>6</sub>O<sub>3</sub>, 499.1888; found, 499.1886.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-(4-Fluorophenyl)-2-methyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide (<b>10b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17c</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 50% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.17 (s, 1H), 8.86 (s, 1H), 8.82 (s, 1H), 8.30–8.22 (m, 2H), 8.02 (d, <i>J</i> = 0.8 Hz, 1H), 7.80 (d, <i>J</i> = 8.9 Hz, 2H), 7.61 (dd, <i>J</i> = 8.9, 5.1 Hz, 2H), 7.47 (t, <i>J</i> = 8.7 Hz, 2H), 7.19 (d, <i>J</i> = 8.9 Hz, 2H), 6.70 (d, <i>J</i> = 5.6 Hz, 1H), 3.88 (s, 3H), 2.23 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 163.37, 163.31 (d, <i>J</i> = 251.7 Hz, 1C), 162.81, 160.74, 160.60, 158.47, 150.36, 148.96, 148.51, 137.83, 135.51, 132.23 (d, <i>J</i> = 3.4 Hz), 129.83, 129.05 (d, <i>J</i> = 8.7 Hz, 2C), 122.17 (s, 2C), 121.36 (s, 2C), 119.15, 117.88 (d, <i>J</i> = 23.1 Hz, 2C), 115.89, 114.86, 110.97, 39.18, 24.73. HRMS: (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>3</sub>, 497.1732; found, 497.1732.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1-(4-Fluorophenyl)-2,4-dimethyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide (<b>10c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17d</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 69% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.73 (s, 1H), 8.85 (s, 1H), 8.23 (d, <i>J</i> = 5.6 Hz, 2H), 8.02 (s, 1H), 7.77 (d, <i>J</i> = 8.6 Hz, 2H), 7.44 (q, <i>J</i> = 8.8, 7.1 Hz, 4H), 7.17 (d, <i>J</i> = 8.6 Hz, 2H), 6.68 (d, <i>J</i> = 5.7 Hz, 1H), 3.89 (s, 3H), 2.41 (s, 3H), 2.14 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 171.26, 163.37, 163.16 (d, <i>J</i> = 251.5 Hz, 1C), 162.51, 160.84, 159.02, 149.99, 148.87, 148.47, 137.77, 135.88, 132.50 (d, <i>J</i> = 3.5 Hz, 1C), 129.84, 129.13 (d, <i>J</i> = 8.8 Hz, 2C), 122.35 (s, 2C), 121.28 (s, 2C), 119.01, 117.72 (d, <i>J</i> = 23.2 Hz, 2C), 114.85, 113.51, 110.82, 39.17, 26.11, 24.31. HRMS: (M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>24</sub>FN<sub>6</sub>O<sub>3</sub>, 511.1888; found, 511.1886.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(4-Fluorophenyl)-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>10d</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17e</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 69% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.37 (s, 1H), 10.86 (s, 1H), 8.84 (s, 1H), 8.41 (s, 1H), 8.26–8.20 (m, 2H), 8.03–7.99 (m, 1H), 7.78–7.72 (m, 2H), 7.45–7.29 (m, 4H), 7.19–7.11 (m, 2H), 6.67 (d, <i>J</i> = 5.7 Hz, 1H), 3.86 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.79, 161.77 (d, <i>J</i> = 245.0 Hz, 1C), 160.17, 159.59, 150.32, 149.59, 148.87, 148.42, 147.68, 137.33, 135.31, 131.00 (d, <i>J</i> = 3.0 Hz, 1C), 130.91 (d, <i>J</i> = 9.0 Hz, 2C), 130.09, 121.47 (s, 2C), 121.02 (s, 2C), 118.76, 115.87 (d, <i>J</i> = 22.9 Hz, 2C), 113.83, 110.84, 104.19, 38.60. HRMS: (M + H)<sup>+</sup> calcd for C<sub>26</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>4</sub>, 499.1525; found, 499.1519.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-(4-Fluorophenyl)-1-methyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>10e</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17f</b> by following a similar procedure as described for <b>13c</b>. Light brown solid, 47% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.90 (s, 1H), 8.85 (s, 2H), 8.25 (d, <i>J</i> = 2.8 Hz, 2H), 8.04–7.98 (m, 1H), 7.77 (dd, <i>J</i> = 8.9, 2.0 Hz, 2H), 7.46–7.30 (m, 4H), 7.22–7.12 (m, 2H), 6.70 (dd, <i>J</i> = 5.6, 2.0 Hz, 1H), 3.88 (s, 3H), 3.53 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 163.56, 162.95 (d, <i>J</i> = 249.6 Hz, 1C), 160.68, 159.84, 150.70 (s, 2C), 150.50, 149.11, 148.62, 137.90, 135.32, 130.08 (d, <i>J</i> = 3.3 Hz, 1C), 130.00 (d, <i>J</i> = 8.8 Hz, 2C), 129.80, 122.19 (s, 2C), 121.41 (s, 2C), 119.19, 117.02 (d, <i>J</i> = 22.9 Hz, 2C), 114.93, 111.02, 105.59, 39.23, 38.31. HRMS: (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>4</sub>, 513.1681; found, 513.1686.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-Ethyl-3-(4-fluorophenyl)-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>10f</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17g</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 72% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.90 (s, 1H), 8.86 (s, 2H), 8.26–8.22 (m, 2H), 8.04–7.99 (m, 1H), 7.82–7.73 (m, 2H), 7.48–7.30 (m, 4H), 7.18 (d, <i>J</i> = 8.9 Hz, 2H), 6.70 (d, <i>J</i> = 5.7 Hz, 1H), 4.01 (q, <i>J</i> = 6.9 Hz, 2H), 3.88 (s, 3H), 1.29 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 163.48, 162.87 (d, <i>J</i> = 249.6 Hz, 1C), 160.75, 159.95, 150.39, 150.26, 149.69, 148.93, 148.45, 137.87, 135.36, 130.13 (d, <i>J</i> = 3.3 Hz, 1C), 130.02 (d, <i>J</i> = 8.7 Hz, 2C), 129.79, 122.16 (s, 2C), 121.39 (s, 2C), 119.20, 116.93 (d, <i>J</i> = 23.1 Hz, 2C), 114.84, 110.99, 105.70, 46.58, 39.19, 14.51. HRMS: (M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>24</sub>FN<sub>6</sub>O<sub>4</sub>, 527.1838; found, 527.1837.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-(4-Fluorophenyl)-1-isopropyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>10g</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 75% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.90 (s, 1H), 8.84 (s, 1H), 8.64 (s, 1H), 8.25–8.20 (m, 2H), 8.01 (d, <i>J</i> = 0.8 Hz, 1H), 7.76 (d, <i>J</i> = 9.0 Hz, 2H), 7.47–7.29 (m, 4H), 7.16 (d, <i>J</i> = 8.9 Hz, 2H), 6.69 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (p, <i>J</i> = 6.7 Hz, 1H), 3.86 (s, 3H), 1.40 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 163.07, 162.82 (d, <i>J</i> = 249.2 Hz, 1C), 160.64, 160.02, 150.44, 150.38, 149.06, 148.58, 146.28, 137.84, 135.39, 130.32 (d, <i>J</i> = 3.0 Hz, 1C), 130.00 (d, <i>J</i> = 8.9 Hz, 2C), 129.76, 122.06 (s, 2C), 121.35 (s, 2C), 119.13, 116.89 (d, <i>J</i> = 23.1 Hz, 2C), 114.87, 110.96, 105.74, 50.52, 39.17, 21.64 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>4</sub>, 541.1994; found, 542.0000.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-(4-Fluorophenyl)-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1-((tetrahydro-2<i>H</i>-pyran-4-yl)methyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>10h</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17i</b> by following a similar procedure as described for <b>13c</b>. White solid, 71% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.93 (s, 1H), 8.86 (s, 1H), 8.80 (s, 1H), 8.28–8.22 (m, 2H), 8.02 (d, <i>J</i> = 0.8 Hz, 1H), 7.77 (d, <i>J</i> = 9.0 Hz, 2H), 7.47–7.32 (m, 4H), 7.18 (d, <i>J</i> = 9.0 Hz, 2H), 6.70 (d, <i>J</i> = 5.7 Hz, 1H), 3.95–3.81 (m, 7H), 3.26 (t, <i>J</i> = 11.4 Hz, 2H), 1.99 (s, 1H), 1.59 (d, <i>J</i> = 11.8 Hz, 2H), 1.35–1.20 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 163.34, 162.93 (d, <i>J</i> = 249.8 Hz, 1C), 160.72, 159.79, 150.64, 150.52, 150.16, 149.12, 148.61, 137.93, 135.30, 130.08–129.92 (m, 3C), 129.78, 122.18 (s, 2C), 121.42 (s, 2C), 119.25, 117.00 (d, <i>J</i> = 23.1 Hz, 2C), 114.88, 111.04, 105.51, 67.29 (s, 2C), 56.69, 39.24, 34.98, 30.35 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>32</sub>H<sub>30</sub>FN<sub>6</sub>O<sub>5</sub>, 597.2256; found, 597.2262.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-(4-Fluorophenyl)-2-isopropyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (<b>10i</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17j</b> by following a similar procedure as described for <b>13c</b>. Yellow solid, 60% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.70 (s, 1H), 8.85 (s, 1H), 8.27–8.20 (m, 2H), 8.01 (s, 1H), 7.83–7.73 (m, 2H), 7.47–7.32 (m, 4H), 7.20 (d, <i>J</i> = 9.0 Hz, 2H), 6.70 (d, <i>J</i> = 5.6 Hz, 1H), 4.88 (p, <i>J</i> = 6.6 Hz, 1H), 3.87 (s, 3H), 1.36 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 163.16 (d, <i>J</i> = 250.7 Hz, 1C), 160.53, 156.85, 156.63, 150.94, 149.12, 148.60, 147.59, 137.89, 134.88, 132.50, 129.77, 129.66 (d, <i>J</i> = 8.9 Hz, 2C), 128.26 (d, <i>J</i> = 3.4 Hz, 1 C), 122.22 (s, 2C), 121.40 (s, 2C), 119.24, 117.13 (d, <i>J</i> = 23.2 Hz, 2C), 114.85, 111.10, 54.01, 39.20, 20.81 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>25</sub>FN<sub>7</sub>O<sub>4</sub>, 542.1947; found, 542.1951.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(4-((3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-1-oxo-3-phenyl-1<i>H</i>-indene-2-carboxamide (<b>10j</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17k</b> by following a similar procedure as described for <b>13c</b>. Red solid, 36% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.44 (s, 1H), 8.86 (s, 1H), 8.27–8.22 (m, 2H), 8.02 (s, 1H), 7.73–7.47 (m, 10H), 7.38 (d, <i>J</i> = 7.2 Hz, 1H), 7.21–7.13 (m, 2H), 6.68 (d, <i>J</i> = 5.6 Hz, 1H), 3.89 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 197.19, 169.87, 160.70, 159.27, 150.11, 148.90, 148.46, 143.92, 137.73, 135.51, 134.56, 131.58, 131.48, 130.64, 130.28, 129.74, 128.50 (s, 2C), 128.11 (s, 2C), 124.26, 123.79, 122.11 (s, 2C), 122.07, 121.24 (s, 2C), 118.95, 114.82, 110.74, 39.11. HRMS: (M + H)<sup>+</sup> calcd for C<sub>31</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>, 499.1765; found, 499.1764.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(4-((3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3,8-dioxo-2-phenyl-2,3,5,6,7,8-hexahydroisoquinoline-4-carboxamide (<b>10k</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17l</b> by following a similar procedure as described for <b>13c</b>. Light brown solid, 58% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 11.29 (s, 1H), 8.77 (s, 1H), 8.50 (s, 1H), 8.24 (d, <i>J</i> = 5.5 Hz, 1H), 7.93 (d, <i>J</i> = 13.7 Hz, 2H), 7.72 (d, <i>J</i> = 8.9 Hz, 2H), 7.63–7.50 (m, 3H), 7.38 (dd, <i>J</i> = 7.8, 1.8 Hz, 2H), 7.07 (d, <i>J</i> = 8.9 Hz, 2H), 6.65 (d, <i>J</i> = 5.7 Hz, 1H), 3.95 (s, 3H), 3.63 (t, <i>J</i> = 6.2 Hz, 2H), 2.65 (t, <i>J</i> = 6.4 Hz, 2H), 2.12 (p, <i>J</i> = 6.3 Hz, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 195.03, 162.96, 162.33, 161.47, 160.94, 150.20, 148.99, 148.56, 143.24, 139.58, 137.89, 135.81, 130.04, 129.99 (s, 2C), 129.87, 126.40 (s, 2C), 122.51 (s, 2C), 121.36 (s, 2C), 119.17, 118.53, 116.59, 114.90, 110.95, 39.24, 38.18, 29.72, 21.68. HRMS: (M + H)<sup>+</sup> calcd for C<sub>31</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub>, 532.1979; found, 532.1979.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(4-Fluorophenyl)-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide (<b>10l</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17m</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 23% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 11.38 (s, 1H), 9.33 (s, 1H), 8.78 (d, <i>J</i> = 1.6 Hz, 1H), 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 7.93 (d, <i>J</i> = 14.8 Hz, 2H), 7.77 (d, <i>J</i> = 9.1 Hz, 2H), 7.40–7.28 (m, 4H), 7.07 (d, <i>J</i> = 8.6 Hz, 2H), 6.65 (d, <i>J</i> = 5.7 Hz, 1H), 3.96 (d, <i>J</i> = 1.7 Hz, 3H), 2.67–2.53 (m, 4H), 2.19–2.07 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 192.86, 163.56, 163.18 (d, <i>J</i> = 251.6 Hz, s, 1C), 160.77, 160.71, 159.71, 150.21, 148.90, 148.48, 142.09, 137.78, 135.67, 132.71 (d, <i>J</i> = 3.2 Hz, 1C), 129.86, 129.43 (d, <i>J</i> = 8.9 Hz, 2C), 122.16 (s, 2C), 121.32 (s, 2C), 119.96, 119.11, 117.77 (d, <i>J</i> = 23.1 Hz, 2C), 115.78, 114.85, 110.92, 39.18, 36.51, 29.44, 21.15. HRMS: (M + H)<sup>+</sup> calcd for C<sub>31</sub>H<sub>25</sub>FN<sub>5</sub>O<sub>4</sub>, 550.1885; found, 550.1881.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(4-Fluorophenyl)-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2-oxo-1,2-dihydro-1,7-naphthyridine-3-carboxamide (<b>10m</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17n</b> by following a similar procedure as described for <b>13c</b>. Yellow solid, 80% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.78 (s, 1H), 9.13 (s, 1H), 8.87 (s, 1H), 8.56 (d, <i>J</i> = 5.1 Hz, 1H), 8.30–8.23 (m, 2H), 8.10 (d, <i>J</i> = 4.7 Hz, 1H), 8.07–8.01 (m, 2H), 7.87 (d, <i>J</i> = 9.0 Hz, 2H), 7.65–7.51 (m, 4H), 7.22 (d, <i>J</i> = 9.0 Hz, 2H), 6.72 (d, <i>J</i> = 5.7 Hz, 1H), 3.89 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 163.31 (d, <i>J</i> = 251.3 Hz, 1C), 162.11, 160.71, 159.94, 150.66, 149.07, 148.59, 143.87, 143.66, 139.07, 137.89, 136.34, 135.33, 131.34 (d, <i>J</i> = 3.3 Hz, 1C), 130.34 (d, <i>J</i> = 8.9 Hz, 2C), 129.82, 126.75, 123.94, 122.42 (s, 2C), 121.89, 121.42 (s, 2C), 119.23, 118.10 (d, <i>J</i> = 23.2 Hz, 2C), 114.85, 111.05, 39.24. HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>3</sub>, 533.1732; found, 533.1729.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-Ethyl-1,2-dimethyl-<i>N</i>-(4-((3-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>10n</b>)</h4><div class="NLM_p last">The compound was prepared from <b>16</b> and <b>17o</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 50% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.81 (s, 1H), 8.84 (s, 1H), 8.29–8.19 (m, 2H), 8.06 (d, <i>J</i> = 2.2 Hz, 1H), 8.02 (s, 1H), 7.81 (dd, <i>J</i> = 9.0, 3.8 Hz, 3H), 7.65 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 6.68 (d, <i>J</i> = 5.6 Hz, 1H), 3.89 (s, 3H), 3.82 (s, 3H), 2.75 (q, <i>J</i> = 7.6 Hz, 2H), 2.62 (s, 3H), 1.23 (t, <i>J</i> = 7.7 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 176.55, 165.08, 161.00, 157.96, 149.60, 148.88, 148.55, 141.43, 138.71, 137.75, 136.83, 133.60, 129.94, 126.37, 125.28, 122.43 (s, 2C), 121.30 (s, 2C), 118.92, 115.89, 114.99, 113.98, 110.79, 39.19, 35.79, 28.36, 20.42, 15.42. HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>28</sub>N<sub>5</sub>O<sub>3</sub>, 494.2187; found, 494.2189.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3-(4-Fluorophenyl)-1-isopropyl-<i>N</i>-(4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11a</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20a</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 87% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.92 (s, 1H), 8.66 (s, 1H), 8.36 (d, <i>J</i> = 5.7 Hz, 1H), 8.25 (s, 1H), 7.96 (d, <i>J</i> = 0.8 Hz, 1H), 7.77 (d, <i>J</i> = 9.0 Hz, 2H), 7.47–7.31 (m, 4H), 7.23 (d, <i>J</i> = 2.3 Hz, 1H), 7.18 (d, <i>J</i> = 9.0 Hz, 2H), 6.63 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.77 (p, <i>J</i> = 6.9 Hz, 1H), 3.85 (s, 3H), 1.42 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.62, 163.09, 162.87 (d, <i>J</i> = 249.5 Hz, 1C), 160.06, 153.95, 151.19, 150.50, 150.44, 146.30, 137.66, 135.35, 130.35 (d, <i>J</i> = 3.5 Hz, 1C), 130.03 (d, <i>J</i> = 8.8 Hz, 2C), 129.16, 123.38, 122.01 (s, 2C), 121.45 (s, 2C), 116.94 (d, <i>J</i> = 23.1 Hz, 2C), 109.78, 107.68, 105.80, 50.55, 39.26, 21.68 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>4</sub>, 541.1994; found, 541.1993.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(3-Fluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20b</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 95% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 10.93 (s, 1H), 8.68 (s, 1H), 8.37 (dd, <i>J</i> = 5.7, 0.6 Hz, 1H), 7.92–7.80 (m, 3H), 7.31–7.22 (m, 5H), 7.12 (t, <i>J</i> = 8.6 Hz, 1H), 6.97 (d, <i>J</i> = 2.4 Hz, 1H), 6.61 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 4.95 (p, <i>J</i> = 6.8 Hz, 1H), 3.92 (s, 3H), 1.49 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.13, 163.10, 162.89 (d, <i>J</i> = 249.5 Hz, 1C), 160.21, 154.44 (d, <i>J</i> = 249.3 Hz, 1C), 154.05, 151.27, 150.42, 146.52, 137.68, 137.04 (d, <i>J</i> = 12.5 Hz, 1C), 136.62 (d, <i>J</i> = 9.6 Hz, 1C), 130.26 (d, <i>J</i> = 3.3 Hz, 1C), 130.00 (d, <i>J</i> = 8.9 Hz, 2C), 129.18, 123.64, 123.40, 116.97 (d, <i>J</i> = 23.2 Hz, 2C), 116.39 (d, <i>J</i> = 3.6 Hz, 1C), 109.77 (d, <i>J</i> = 23.3 Hz, 1C), 108.75, 106.83, 105.50, 50.65, 39.26, 21.69 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>25</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, 559.1900; found, 559.1902.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(2-Fluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20c</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 76% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.16 (s, 1H), 8.69 (s, 1H), 8.45 (t, <i>J</i> = 9.1 Hz, 1H), 8.38 (d, <i>J</i> = 5.5 Hz, 1H), 8.26 (s, 1H), 7.97 (s, 1H), 7.48–7.24 (m, 6H), 7.07 (d, <i>J</i> = 9.1 Hz, 1H), 6.75–6.67 (m, 1H), 4.78 (p, <i>J</i> = 6.5 Hz, 1H), 3.86 (s, 3H), 1.42 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.01, 162.85 (d, <i>J</i> = 249.4 Hz, 1C), 162.83, 160.31, 154.16, 153.44 (d, <i>J</i> = 248.8 Hz, 1C), 151.34, 150.53, 150.45, 146.37, 137.66, 130.29 (d, <i>J</i> = 3.3 Hz, 1C), 130.08 (d, <i>J</i> = 8.9 Hz, 2C), 129.20, 123.91 (d, <i>J</i> = 10.4 Hz, 1C), 123.29–123.18 (m, 2C), 116.89 (d, <i>J</i> = 23.0 Hz, 2C), 116.48 (d, <i>J</i> = 3.6 Hz, 1C), 109.93, 108.47 (d, <i>J</i> = 21.8 Hz, 1C), 107.90, 105.73, 50.55, 39.26, 21.67 (s, 2C). HRMS: (M – H)<sup>−</sup> calcd for C<sub>29</sub>H<sub>23</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, 557.1754; found, 557.1757.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(3-Chloro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11d</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20d</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 59% yield. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 11.05 (s, 1H), 8.66 (s, 1H), 8.37 (d, <i>J</i> = 5.7 Hz, 1H), 8.23 (d, <i>J</i> = 2.5 Hz, 1H), 8.11 (s, 1H), 7.93 (d, <i>J</i> = 0.8 Hz, 1H), 7.66 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 7.50–7.40 (m, 2H), 7.39–7.26 (m, 3H), 7.14 (d, <i>J</i> = 2.4 Hz, 1H), 6.59 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.93 (p, <i>J</i> = 6.8 Hz, 1H), 3.90 (s, 3H), 1.50 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.88, 163.13, 162.93 (d, <i>J</i> = 249.7 Hz, 1C), 160.25, 154.10, 151.31, 150.44, 146.54, 145.89, 137.72, 136.46, 130.26 (d, <i>J</i> = 3.7 Hz, 1C), 130.02 (d, <i>J</i> = 8.8 Hz, 2C), 129.20, 127.65, 123.44, 123.38, 122.63, 119.96, 117.00 (d, <i>J</i> = 23.3 Hz, 2C), 109.00, 107.08, 105.53, 50.67, 39.29, 21.73 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>25</sub>ClFN<sub>6</sub>O<sub>4</sub>, 575.1604; found, 575.1603.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-(4-Fluorophenyl)-1-isopropyl-<i>N</i>-(3-methyl-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11e</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20e</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 70% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.91 (s, 1H), 8.66 (s, 1H), 8.33 (d, <i>J</i> = 5.8 Hz, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 7.71–7.62 (m, 2H), 7.47–7.32 (m, 4H), 7.18 (d, <i>J</i> = 2.5 Hz, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.51 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.78 (p, <i>J</i> = 6.8 Hz, 1H), 3.85 (s, 3H), 2.10 (s, 3H), 1.42 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.53, 163.08, 162.86 (d, <i>J</i> = 249.5 Hz, 1C), 160.03, 153.91, 151.17, 150.50, 148.34, 146.23, 137.66, 135.57, 131.54, 130.36 (d, <i>J</i> = 3.4 Hz, 1C), 130.03 (d, <i>J</i> = 8.9 Hz, 2C), 129.16, 123.48, 123.39, 121.96, 119.40, 116.93 (d, <i>J</i> = 23.1 Hz, 2C), 108.97, 106.91, 105.86, 50.50, 39.25, 21.69 (s, 2C), 16.33. HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>4</sub>, 555.2151; found, 555.2155.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-(4-Fluorophenyl)-1-isopropyl-<i>N</i>-(3-methoxy-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11f</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20f</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. White solid, 72% yield. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.96 (s, 1H), 8.66 (s, 1H), 8.30 (d, <i>J</i> = 5.7 Hz, 1H), 8.08 (s, 1H), 7.90 (s, 1H), 7.70 (d, <i>J</i> = 2.4 Hz, 1H), 7.52–7.38 (m, 3H), 7.38–7.28 (m, 2H), 7.13 (d, <i>J</i> = 8.6 Hz, 1H), 7.06 (d, <i>J</i> = 2.4 Hz, 1H), 6.53 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.94 (p, <i>J</i> = 6.8 Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 1.51 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.69, 163.14, 162.91 (d, <i>J</i> = 249.5 Hz, 1C), 160.11, 153.75, 151.94, 151.03, 150.50, 146.27, 138.40, 137.68, 136.76, 130.35 (d, <i>J</i> = 3.4 Hz, 1C), 130.03 (d, <i>J</i> = 8.8 Hz, 2C), 129.10, 123.58, 122.99, 117.00 (d, <i>J</i> = 23.2 Hz, 2C), 112.53, 108.79, 106.87, 105.79, 105.47, 56.02, 50.51, 39.26, 21.72 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>5</sub>, 571.2100; found, 571.2106.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-(2,3-Difluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11g</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20g</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 52% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.27 (s, 1H), 8.71 (s, 1H), 8.40 (d, <i>J</i> = 5.7 Hz, 1H), 8.31–8.19 (m, 2H), 7.99 (s, 1H), 7.48–7.32 (m, 4H), 7.32–7.22 (m, 2H), 6.77 (dd, <i>J</i> = 5.9, 2.4 Hz, 1H), 4.78 (p, <i>J</i> = 6.9 Hz, 1H), 3.86 (s, 3H), 1.43 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.76, 162.88 (d, <i>J</i> = 249.3 Hz, 1C), 162.85, 160.56, 154.21, 151.38, 150.46, 146.60, 144.25 (dd, <i>J</i> = 99.4, 12.6 Hz, 1C), 142.25 (dd, <i>J</i> = 97.9, 12.5 Hz, 1C), 138.13 (d, <i>J</i> = 9.5 Hz 1C), 137.68, 130.19 (d, <i>J</i> = 3.3 Hz, 1C), 130.06 (d, <i>J</i> = 8.7 Hz, 2C), 129.25, 125.72 (d, <i>J</i> = 8.0 Hz, 1C), 123.26, 117.57 (d, <i>J</i> = 3.8 Hz, 2C), 116.93 (d, <i>J</i> = 23.2 Hz, 1C), 116.64 (d, <i>J</i> = 3.9 Hz, 1C), 108.85, 106.97, 105.45, 50.65, 39.26, 21.67 (s, 2C). HRMS: (M – H)<sup>−</sup> calcd for C<sub>29</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>4</sub>, 575.1660; found, 575.1667.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(2,5-Difluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11h</b>)</h4><div class="NLM_p last">The compound was prepared from <b>24</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Light brown solid, 56% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (s, 1H), 8.72 (s, 1H), 8.48 (dd, <i>J</i> = 12.5, 7.2 Hz, 1H), 8.39 (d, <i>J</i> = 5.7 Hz, 1H), 8.28 (s, 1H), 7.99 (s, 1H), 7.61 (dd, <i>J</i> = 11.1, 7.4 Hz, 1H), 7.47–7.33 (m, 4H), 7.27 (d, <i>J</i> = 2.4 Hz, 1H), 6.74 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 4.78 (p, <i>J</i> = 6.7 Hz, 1H), 3.86 (s, 3H), 1.43 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.66, 162.86 (d, <i>J</i> = 249.4 Hz, 1C), 162.82, 160.40, 154.20, 151.36, 150.45, 149.56–147.46 (m, 2C), 146.61, 137.68, 136.10 (dd, <i>J</i> = 14.3, 10.2 Hz, 1C), 130.19 (d, <i>J</i> = 3.6 Hz, 1C), 130.05 (d, <i>J</i> = 8.8 Hz, 2C), 129.23, 124.82 (t, <i>J</i> = 11.2 Hz, 1C), 123.28, 116.91 (d, <i>J</i> = 23.2 Hz, 2C), 110.58 (d, <i>J</i> = 26.2 Hz, 1C), 110.17 (d, <i>J</i> = 23.3 Hz, 1C), 108.76, 106.86, 105.40, 50.68, 39.26, 21.67 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>4</sub>, 577.1806; found, 577.1812.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(3,5-Difluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>11i</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20h</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 62% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.11 (s, 1H), 8.69 (s, 1H), 8.39 (d, <i>J</i> = 5.7 Hz, 1H), 8.29 (s, 1H), 8.00 (d, <i>J</i> = 0.7 Hz, 1H), 7.79 (d, <i>J</i> = 10.3 Hz, 2H), 7.48–7.28 (m, 5H), 6.74 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 4.78 (p, <i>J</i> = 6.8 Hz, 1H), 3.86 (s, 3H), 1.43 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.60, 163.07, 162.89 (d, <i>J</i> = 249.7 Hz, 1C), 160.39, 155.70 (dd, <i>J</i> = 249.7, 5.9 Hz, 2C), 154.13, 151.31, 150.34, 146.73, 137.69, 136.28 (t, <i>J</i> = 12.3 Hz, 1C), 130.15 (d, <i>J</i> = 3.5 Hz, 1C), 129.96 (d, <i>J</i> = 8.7 Hz, 2C), 129.23, 125.69 (t, <i>J</i> = 15.6 Hz, 1C), 123.29, 116.96 (d, <i>J</i> = 23.2 Hz, 2C), 107.96, 106.23, 105.15, 104.73–104.45 (m, 2C), 50.74, 39.24, 21.65 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>4</sub>, 577.1806; found, 577.1809.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-((2-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>12a</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20i</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 97% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.01 (s, 1H), 8.66 (s, 1H), 8.39 (d, <i>J</i> = 5.8 Hz, 1H), 8.12 (s, 1H), 7.97 (dd, <i>J</i> = 12.9, 2.5 Hz, 1H), 7.53–7.30 (m, 6H), 7.04 (d, <i>J</i> = 2.4 Hz, 1H), 6.67 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 4.76 (p, <i>J</i> = 6.7 Hz, 1H), 3.75 (s, 3H), 2.35 (s, 3H), 1.41 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.88, 163.06, 162.84 (d, <i>J</i> = 249.7 Hz, 1C), 160.15, 155.02, 154.41 (d, <i>J</i> = 249.1 Hz, 1C), 151.12, 150.37, 146.66, 146.48, 137.00 (d, <i>J</i> = 12.6 Hz, 1C), 136.58 (d, <i>J</i> = 9.5 Hz, 1C), 130.87, 130.23 (d, <i>J</i> = 3.3 Hz, 1C), 129.97 (d, <i>J</i> = 8.7 Hz, 2C), 123.61, 120.54, 116.91 (d, <i>J</i> = 23.1 Hz, 2C), 116.30 (d, <i>J</i> = 3.4 Hz, 1C), 109.64 (d, <i>J</i> = 23.3 Hz, 1 C), 108.17, 107.80, 105.44, 50.61, 38.80, 21.63 (s, 2C), 14.03. HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, 573.2056; found, 573.2062.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-((2-(1-Cyclopropyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>12b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20j</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 73% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.94 (s, 1H), 8.69 (s, 1H), 8.38 (d, <i>J</i> = 5.7 Hz, 1H), 7.97 (s, 1H), 7.89–7.81 (m, 2H), 7.26–7.23 (m, 5H), 7.13 (t, <i>J</i> = 8.7 Hz, 1H), 6.97 (d, <i>J</i> = 2.4 Hz, 1H), 6.62 (dd, <i>J</i> = 6.0, 2.3 Hz, 1H), 4.97 (p, <i>J</i> = 6.8 Hz, 1H), 3.70–3.57 (m, 1H), 1.50 (d, <i>J</i> = 6.8 Hz, 6H), 1.19–1.12 (m, 2H), 1.07–1.00 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.13, 163.09, 162.89 (d, <i>J</i> = 249.5 Hz, 1C), 160.20, 154.43 (d, <i>J</i> = 249.1 Hz, 1C), 154.00, 151.26, 150.41, 146.52, 137.66, 137.04 (d, <i>J</i> = 12.5 Hz, 1C), 136.62 (d, <i>J</i> = 9.6 Hz, 1C), 130.25 (d, <i>J</i> = 3.6 Hz, 1C), 130.00 (d, <i>J</i> = 8.9 Hz, 2C), 128.62, 123.62, 122.85, 116.96 (d, <i>J</i> = 23.2 Hz, 1C), 116.38 (d, <i>J</i> = 3.4 Hz, 2C), 109.76 (d, <i>J</i> = 23.3 Hz, 1C), 108.79, 106.86, 105.50, 50.65, 33.08, 21.69 (s, 2C), 6.66 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>31</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, 585.2056; found, 585.2060.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(3-Fluoro-4-((2-(1-(2-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>12c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20k</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 89% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.03 (s, 1H), 8.68 (s, 1H), 8.37 (d, <i>J</i> = 5.7 Hz, 1H), 8.22 (s, 1H), 8.05–7.92 (m, 2H), 7.59–7.20 (m, 7H), 6.65 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 4.78 (p, <i>J</i> = 6.6 Hz, 1H), 4.72 (s, 1H), 4.03 (s, 2H), 1.42 (d, <i>J</i> = 6.7 Hz, 6H), 1.07 (s, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.19, 163.09, 162.89 (d, <i>J</i> = 249.6 Hz, 1C), 160.21, 154.42 (d, <i>J</i> = 249.1 Hz, 1C), 153.79, 151.29, 150.41, 146.53, 138.08, 136.97 (d, <i>J</i> = 12.5 Hz, 1C), 136.67 (d, <i>J</i> = 9.9 Hz, 1C), 130.25 (d, <i>J</i> = 3.6 Hz, 1C), 130.06 (d, <i>J</i> = 5.1 Hz, 2C), 129.97, 123.64, 122.94, 116.96 (d, <i>J</i> = 23.2 Hz, 2C), 116.40 (d, <i>J</i> = 3.3 Hz, 1C), 109.78 (d, <i>J</i> = 23.2 Hz, 1C), 108.90, 106.98, 105.48, 70.77, 62.28, 50.66, 26.96 (s, 2C), 21.68 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>32</sub>H<sub>31</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>, 617.2319; found, 617.2325.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(3-Fluoro-4-((2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>12d</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20l</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Tan solid, 75% yield. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.72 (s, 1H), 8.34 (d, <i>J</i> = 5.8 Hz, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 7.93 (dd, <i>J</i> = 12.6, 2.5 Hz, 1H), 7.39–7.32 (m, 3H), 7.30–7.23 (m, 3H), 7.20 (d, <i>J</i> = 2.5 Hz, 1H), 6.72 (dd, <i>J</i> = 5.9, 2.5 Hz, 1H), 4.95–4.89 (m, 1H), 4.30 (t, <i>J</i> = 6.0 Hz, 2H), 3.08–2.91 (m, 4H), 2.89 (t, <i>J</i> = 6.0 Hz, 2H), 2.79–2.55 (m, 7H), 1.48 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 165.11, 162.96, 162.73 (d, <i>J</i> = 249.4 Hz, 1C), 160.13, 154.22 (d, <i>J</i> = 248.6 Hz, 1C), 153.66, 150.93, 150.30, 146.49, 137.55, 136.75 (d, <i>J</i> = 12.6 Hz, 1C), 136.53 (d, <i>J</i> = 9.6 Hz, 1C), 130.17 (d, <i>J</i> = 3.2 Hz, 1C), 129.91 (d, <i>J</i> = 8.8 Hz, 2C), 128.89, 123.52, 122.78, 116.80 (d, <i>J</i> = 23.1 Hz, 2C), 116.32 (d, <i>J</i> = 2.5 Hz, 1C), 109.61 (d, <i>J</i> = 23.1 Hz, 1C), 108.66, 106.85, 105.29, 56.82, 54.04 (s, 2C), 50.71 (s, 2C), 50.59, 49.83, 44.21, 21.51 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>35</sub>H<sub>37</sub>F<sub>2</sub>N<sub>8</sub>O<sub>4</sub>, 671.2900; found, 671.2909.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(4-((2-(1<i>H</i>-Pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>12e</b>)</h4><div class="NLM_p last">The compound was prepared from <b>20m</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Light brown solid, 26% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.07 (s, 1H), 11.03 (s, 1H), 8.68 (s, 1H), 8.40–8.31 (m, 2H), 8.07–7.94 (m, 2H), 7.54–7.31 (m, 7H), 6.62 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 4.78 (p, <i>J</i> = 6.8 Hz, 1H), 1.42 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, acetone-<i>d</i><sub>6</sub>): δ 165.98, 164.11, 163.33 (d, <i>J</i> = 245.7 Hz, 1C), 161.39, 155.49, 155.03 (d, <i>J</i> = 246.0 Hz, 1C), 152.11, 151.27, 147.80, 138.24 (d, <i>J</i> = 9.9 Hz, 1C), 137.85, 137.31 (d, <i>J</i> = 12.5 Hz, 1C), 132.66 (d, <i>J</i> = 3.2 Hz, 1C), 131.69 (d, <i>J</i> = 8.9 Hz, 2C), 125.81, 124.59, 123.40, 117.14 (d, <i>J</i> = 3.3 Hz, 1C), 116.71 (d, <i>J</i> = 23.2 Hz, 2C), 109.63 (d, <i>J</i> = 23.6 Hz, 1C), 108.97, 107.40, 105.67, 51.53, 21.28 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>23</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, 545.1743; found, 545.1747.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(4-((2-Acetamidopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>13a</b>)</h4><div class="NLM_p last">The compound was prepared from <b>28a</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 40% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.03 (s, 1H), 10.58 (s, 1H), 8.68 (s, 1H), 8.18 (d, <i>J</i> = 5.8 Hz, 1H), 7.98 (dd, <i>J</i> = 12.9, 2.5 Hz, 1H), 7.65 (d, <i>J</i> = 2.4 Hz, 1H), 7.56–7.31 (m, 6H), 6.68 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 4.77 (p, <i>J</i> = 6.7 Hz, 1H), 2.03 (s, 3H), 1.42 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 168.86, 166.41, 163.07, 162.91 (d, <i>J</i> = 249.8 Hz, 1C), 160.13, 154.39 (d, <i>J</i> = 249.1 Hz, 1C), 153.31, 150.48, 149.04, 146.49, 137.04 (d, <i>J</i> = 12.5 Hz, 1C), 136.71 (d, <i>J</i> = 9.6 Hz, 1C), 130.30 (d, <i>J</i> = 3.7 Hz, 1C), 130.04 (d, <i>J</i> = 8.9 Hz, 2C), 123.64, 116.97 (d, <i>J</i> = 23.1 Hz, 2C), 116.35 (d, <i>J</i> = 3.4 Hz, 1C), 109.72 (d, <i>J</i> = 23.4 Hz, 1C), 107.87, 105.60, 101.28, 50.66, 24.79, 21.71 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>24</sub>F<sub>2</sub>N<sub>5</sub>O<sub>5</sub>, 536.1740; found, 536.1742.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(3-Fluoro-4-((2-propionamidopyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>13b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>28b</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Off-white solid, 30% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.03 (s, 1H), 10.51 (s, 1H), 8.68 (s, 1H), 8.18 (d, <i>J</i> = 5.7 Hz, 1H), 7.98 (dd, <i>J</i> = 12.9, 2.5 Hz, 1H), 7.66 (d, <i>J</i> = 2.5 Hz, 1H), 7.55–7.30 (m, 6H), 6.70 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 4.78 (p, <i>J</i> = 6.7 Hz, 1H), 2.34 (q, <i>J</i> = 7.5 Hz, 2H), 1.42 (d, <i>J</i> = 6.7 Hz, 6H), 1.00 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 172.56, 166.40, 163.07, 162.89 (d, <i>J</i> = 249.6 Hz, 1C), 160.12, 154.38 (d, <i>J</i> = 249.6 Hz, 1C), 153.37, 150.48, 149.01, 146.49, 137.03 (d, <i>J</i> = 12.6 Hz, 1C), 136.68 (d, <i>J</i> = 9.8 Hz, 1C), 130.30 (d, <i>J</i> = 3.6 Hz, 1C), 130.04 (d, <i>J</i> = 8.8 Hz, 2C), 123.63, 116.95 (d, <i>J</i> = 23.1 Hz, 2C), 116.36 (d, <i>J</i> = 3.3 Hz, 1C), 109.72 (d, <i>J</i> = 23.3 Hz, 1C), 107.92, 105.59, 101.10, 50.65, 30.84, 21.69 (s, 2C), 9.36. HRMS: (M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>5</sub>, 550.1897; found, 550.1901.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(4-((2-(Cyclopropanecarboxamido)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>13c</b>)</h4><div class="NLM_p last">A mixture of <b>28c</b> (634 mg, 1.89 mmol), <b>17h</b> (553 mg, 1.89 mmol), HATU (863 mg, 2.27 mmol), and TEA (383 mg, 3.78 mmol) in DMF (18 mL) was stirred at RT overnight. The reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3 × 80 mL). The combined organic layer was washed with brine (5 × 100 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 98:2) to afford the title compound <b>13c</b> (778 mg, 73%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 11.07 (s, 1H), 9.77 (s, 1H), 8.66 (s, 1H), 8.14 (d, <i>J</i> = 5.7 Hz, 1H), 8.05 (dd, <i>J</i> = 13.0, 2.5 Hz, 1H), 7.84 (d, <i>J</i> = 2.4 Hz, 1H), 7.52–7.40 (m, 3H), 7.36–7.25 (m, 3H), 6.64 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.93 (p, <i>J</i> = 6.8 Hz, 1H), 2.02–1.94 (m, 1H), 1.50 (d, <i>J</i> = 6.8 Hz, 6H), 0.91–0.77 (m, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 172.58, 166.25, 162.94, 162.75 (d, <i>J</i> = 249.4 Hz, 1C), 160.00, 154.21 (d, <i>J</i> = 249.0 Hz, 1C), 153.63, 150.37, 148.76, 146.39, 136.88 (d, <i>J</i> = 12.5 Hz, 1C), 136.52 (d, <i>J</i> = 9.7 Hz, 1C), 130.20 (d, <i>J</i> = 3.3 Hz, 1C), 129.93 (d, <i>J</i> = 8.8 Hz, 2C), 123.47, 116.81 (d, <i>J</i> = 23.1 Hz, 2C), 116.24 (d, <i>J</i> = 3.4 Hz, 1C), 109.58 (d, <i>J</i> = 23.3 Hz, 1C), 107.68, 105.45, 101.17, 50.55, 21.54 (s, 2C), 15.66, 8.31 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>5</sub>, 562.1897; found, 562.1894.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-(4-((2-(Cyclobutanecarboxamido)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>13d</b>)</h4><div class="NLM_p last">A mixture of <b>32</b> (70 mg, 0.14 mmol), cyclobutanecarboxylic acid (142 mg, 1.41 mmol), HATU (647 mg, 1.7 mmol), and TEA (394 mg, 2.84 mmol) in DMF (1.5 mL) was stirred at 35 °C overnight. The reaction mixture was poured into water (15 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layer was washed with brine (5 × 30 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 98:2) to afford the title compound <b>13d</b> (27 mg, 34%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.04 (s, 1H), 10.40 (s, 1H), 8.68 (s, 1H), 8.18 (d, <i>J</i> = 5.8 Hz, 1H), 7.99 (dd, <i>J</i> = 12.9, 2.5 Hz, 1H), 7.69 (d, <i>J</i> = 2.4 Hz, 1H), 7.56–7.32 (m, 6H), 6.71 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.78 (p, <i>J</i> = 6.8 Hz, 1H), 3.32–3.26 (m, 1H), 2.23–1.98 (m, 4H), 1.96–1.81 (m, 1H), 1.81–1.69 (m, 1H), 1.43 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 173.71, 166.39, 163.07, 162.89 (d, <i>J</i> = 249.5 Hz, 1C), 160.12, 154.39 (d, <i>J</i> = 249.0 Hz, 1C), 153.34, 150.48, 149.03, 146.49, 137.03 (d, <i>J</i> = 12.5 Hz, 1C), 136.68 (d, <i>J</i> = 9.6 Hz, 1C), 130.30 (d, <i>J</i> = 3.3 Hz, 1C), 130.04 (d, <i>J</i> = 8.8 Hz, 2C), 123.64, 116.96 (d, <i>J</i> = 23.2 Hz, 2C), 116.37 (d, <i>J</i> = 3.3 Hz, 1C), 109.74 (d, <i>J</i> = 23.2 Hz, 1C), 107.97, 105.60, 100.95, 50.65, 40.92, 25.20 (s, 2C), 21.70 (s, 2C), 18.06. HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>5</sub>, 576.2053; found, 576.2049.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-(3-Fluoro-4-((2-(pyrrolidine-1-carboxamido)pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>13e</b>)</h4><div class="NLM_p last">To a stirred solution of <b>32</b> (100 mg, 0.20 mmol) and TEA (41 mg, 0.41 mmol) in THF (7 mL) under argon was slowly added phenyl chloroformate (34 mg, 0.22 mmol) at 0 °C. The resulting mixture was warmed up to RT and stirred for 2 h. Then, pyrrolidine (43 mg, 0.60 mmol) was added, and the resulting mixture was stirred at RT overnight. The reaction mixture was poured into saturated aq ammonium chloride (50 mL) and extracted with dichloromethane (3 × 50 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 99:1) to afford the title compound <b>13e</b> (29 mg, 24%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 11.07 (s, 1H), 8.66 (s, 1H), 8.08–8.01 (m, 2H), 7.75 (d, <i>J</i> = 2.4 Hz, 1H), 7.62 (s, 1H), 7.49–7.41 (m, 3H), 7.35–7.25 (m, 3H), 6.53 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 4.93 (p, <i>J</i> = 6.8 Hz, 1H), 3.45 (s, 4H), 1.92 (s, 4H), 1.50 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 166.22, 163.04, 162.88 (d, <i>J</i> = 249.7 Hz, 1C), 160.07, 154.67, 154.39 (d, <i>J</i> = 249.2 Hz, 1C), 153.01, 150.48, 148.76, 146.45, 137.26 (d, <i>J</i> = 12.5 Hz, 1C), 136.44 (d, <i>J</i> = 9.5 Hz, 1C), 130.30, 130.04 (d, <i>J</i> = 8.9 Hz, 2C), 123.60, 116.94 (d, <i>J</i> = 23.1 Hz, 2C), 116.35 (d, <i>J</i> = 3.5 Hz, 1C), 109.73 (d, <i>J</i> = 23.3 Hz, 1C), 106.90, 105.62, 99.77, 50.63 (s, 2C), 45.91 (s, 2C), 25.65, 21.68 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>29</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>, 591.2162; found, 591.2162.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i>-(4-(2-Fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-2-yl)morpholine-4-carboxamide (<b>13f</b>)</h4><div class="NLM_p last">To a stirred solution of <b>32</b> (100 mg, 0.20 mmol) and TEA (41 mg, 0.41 mmol) in THF (7 mL) under argon was slowly added phenyl chloroformate (34 mg, 0.22 mmol) at 0 °C. The resulting mixture was warmed up to RT and stirred for 2 h. Then, morpholine (52 mg, 0.60 mmol) was added. The resulting mixture was stirred at RT overnight and further heated at 75 °C for 1.5 h. The reaction mixture was poured into saturated aq ammonium chloride (30 mL) and extracted with dichloromethane (3 × 30 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 99:1) to afford the title compound <b>13f</b> (31 mg, 25.5%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.03 (s, 1H), 9.31 (s, 1H), 8.68 (d, <i>J</i> = 1.0 Hz, 1H), 8.13 (d, <i>J</i> = 5.7 Hz, 1H), 7.98 (dd, <i>J</i> = 12.9, 2.4 Hz, 1H), 7.56–7.29 (m, 7H), 6.63 (dd, <i>J</i> = 5.9, 2.3 Hz, 1H), 4.78 (p, <i>J</i> = 6.8 Hz, 1H), 3.55 (t, <i>J</i> = 4.7 Hz, 4H), 3.40 (t, <i>J</i> = 4.8 Hz, 4H), 1.43 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 166.30, 163.06, 162.88 (d, <i>J</i> = 249.4 Hz, 1C), 160.13, 154.56, 154.36 (d, <i>J</i> = 249.1 Hz, 1C), 154.00, 150.47, 148.66, 146.48, 137.13 (d, <i>J</i> = 12.5 Hz, 1C), 136.53 (d, <i>J</i> = 9.6 Hz, 1C), 130.29 (d, <i>J</i> = 3.3 Hz, 1C), 130.02 (d, <i>J</i> = 8.8 Hz, 2C), 123.60, 116.94 (d, <i>J</i> = 23.0 Hz, 2C), 116.38 (d, <i>J</i> = 3.3 Hz, 1C), 109.75 (d, <i>J</i> = 23.3 Hz, 1C), 107.06, 105.56, 100.32, 66.56 (s, 2C), 50.64 (s, 2C), 44.26, 21.67 (s, 2C). HRMS: (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>29</sub>F<sub>2</sub>N<sub>6</sub>O<sub>6</sub>, 607.2111; found, 607.2113.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-((3-Chloropyridin-4-yl)oxy)aniline (<b>15</b>)</h4><div class="NLM_p last">To a solution of 4-aminophenol (2.65 g, 24.3 mmol) in DMA (40 mL) was added potassium <i>tert</i>-butoxide (2.8 g, 24.9 mmol). The resulting mixture was stirred at RT for 0.5 h. Then, 4-bromo-3-chloropyridine (4.0 g, 20.7 mmol) was added, and the resulting mixture was stirred at 85 °C for 4 h. The reaction mixture was poured into water (400 mL) and extracted with ethyl acetate (4 × 100 mL). The combined organic layer was washed with brine (5 × 400 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to afford the title compound <b>15</b> (5.8 g, 100%) as a black solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.65 (s, 1H), 8.31 (d, <i>J</i> = 5.6 Hz, 1H), 6.86 (d, <i>J</i> = 8.7 Hz, 2H), 6.74–6.51 (m, 3H), 5.21 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 265.0 [M + H]<sup>+</sup>, 267.0 [M + 2 + H]<sup>+</sup>.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-((3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>16</b>)</h4><div class="NLM_p last">A mixture of <b>15</b> (1.2 g, 4.4 mmol), 1-methyl-4-pyrazole boronic acid pinacol ester (1.15 g, 5.55 mmol), and tetrakis(triphenylphosphine)palladium (0.5 g, 0.4 mmol) in 1,4-dioxane (20 mL)/water (4 mL) under argon was stirred at 90 °C for 9 h. After cooling, the resulting mixture was poured into saturated aq sodium bicarbonate (150 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 97:3) to afford the title compound <b>16</b> (1.1 g, 97%) as a brown solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.79 (s, 1H), 8.23 (s, 1H), 8.18 (d, <i>J</i> = 5.6 Hz, 1H), 8.02–8.01 (m, 1H), 6.86 (d, <i>J</i> = 8.7 Hz, 2H), 6.63 (d, <i>J</i> = 8.8 Hz, 2H), 6.56 (d, <i>J</i> = 5.7 Hz, 1H), 5.15 (s, 2H), 3.89 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 267.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-((2-Chloropyridin-4-yl)oxy)aniline (<b>19a</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-aminophenol by following a similar procedure as described for <b>15</b>. Black solid, 96% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.23 (d, <i>J</i> = 5.5 Hz, 1H), 6.91–6.80 (m, 4H), 6.67–6.58 (m, 2H), 5.20 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 221.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 4-((2-Chloropyridin-4-yl)oxy)-3-fluoroaniline (<b>19b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-2-fluorophenol by following a similar procedure as described for <b>15</b>. Black solid, 100% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.26 (d, <i>J</i> = 5.7 Hz, 1H), 7.01 (t, <i>J</i> = 9.0 Hz, 1H), 6.96–6.88 (m, 2H), 6.55–6.39 (m, 2H), 5.53 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 239.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 4-((2-Chloropyridin-4-yl)oxy)-2-fluoroaniline (<b>19c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-3-fluorophenol by following a similar procedure as described for <b>15</b>. Beige solid, 83% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.25 (d, <i>J</i> = 5.7 Hz, 1H), 7.02 (dd, <i>J</i> = 11.9, 2.5 Hz, 1H), 6.94–6.87 (m, 2H), 6.87–6.75 (m, 2H), 5.23 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 239.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 3-Chloro-4-((2-chloropyridin-4-yl)oxy)aniline (<b>19d</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-2-chlorophenol by following a similar procedure as described for <b>15</b>. Black solid, 97% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.19 (d, <i>J</i> = 6.5 Hz, 1H), 6.92 (d, <i>J</i> = 8.7 Hz, 1H), 6.78 (d, <i>J</i> = 2.7 Hz, 1H), 6.75–6.70 (m, 2H), 6.59 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 3.84 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 255.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-((2-Chloropyridin-4-yl)oxy)-3-methylaniline (<b>19e</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-2-methylphenol by following a similar procedure as described for <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.23 (d, <i>J</i> = 6.0 Hz, 1H), 6.84–6.74 (m, 3H), 6.55–6.42 (m, 2H), 5.12 (s, 2H), 1.93 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 235.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-((2-Chloropyridin-4-yl)oxy)-3-methoxyaniline (<b>19f</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-2-methoxyphenol by following a similar procedure as described for <b>15</b>. Black solid, 91% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.17–8.13 (m, 1H), 6.84 (d, <i>J</i> = 8.4 Hz, 1H), 6.74–6.71 (m, 2H), 6.33 (d, <i>J</i> = 2.5 Hz, 1H), 6.25 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 3.78 (s, 2H), 3.70 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 251.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 4-((2-Chloropyridin-4-yl)oxy)-2,3-difluoroaniline (<b>19g</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-2,3-difluorophenol by following a similar procedure as described for <b>15</b>. Light brown solid, 94% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87 (d, <i>J</i> = 5.8 Hz, 1H), 7.65 (s, 1H), 7.60–7.48 (m, 2H), 7.22 (t, <i>J</i> = 8.9 Hz, 1H), 6.21 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 257.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-((2-Chloropyridin-4-yl)oxy)-3,5-difluoroaniline (<b>19h</b>)</h4><div class="NLM_p last">The compound was prepared from <b>18</b> and 4-amino-2,6-difluorophenol by following a similar procedure as described for <b>15</b>. Pale beige solid, 90% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.30 (d, <i>J</i> = 5.8 Hz, 1H), 7.10 (d, <i>J</i> = 2.3 Hz, 1H), 7.00 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 6.44–6.33 (m, 2H), 5.86 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 257.0 [M + H]<sup>+</sup>. LC/MS (ESI, <i>m</i>/<i>z</i>): 257.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 4-((2-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20a</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19a</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Light yellow solid, 75% yield. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.30 (d, <i>J</i> = 5.7 Hz, 1H), 8.21 (s, 1H), 7.96–7.88 (m, 1H), 7.12 (d, <i>J</i> = 2.4 Hz, 1H), 6.90–6.80 (m, 2H), 6.67–6.57 (m, 2H), 6.53 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 5.15 (br s, 2H), 3.85 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 267.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-Fluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19b</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Brown solid, 100% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.32 (dd, <i>J</i> = 5.8, 0.5 Hz, 1H), 7.86–7.81 (m, 2H), 6.95–6.87 (m, 2H), 6.57 (ddd, <i>J</i> = 5.8, 2.5, 0.6 Hz, 1H), 6.48 (dd, <i>J</i> = 11.9, 2.6 Hz, 1H), 6.42 (ddd, <i>J</i> = 8.6, 2.7, 1.2 Hz, 1H), 3.88 (s, 3H), 2.64 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 285.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2-Fluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19c</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Dark brown solid, 94% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.32 (d, <i>J</i> = 5.7 Hz, 1H), 8.23 (s, 1H), 7.94 (s, 1H), 7.14 (d, <i>J</i> = 2.4 Hz, 1H), 6.97 (dd, <i>J</i> = 11.9, 2.6 Hz, 1H), 6.88–6.73 (m, 2H), 6.58 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 5.17 (br s, 2H), 3.86 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 285.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-Chloro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20d</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19d</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Brown solid, 91% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.35 (d, <i>J</i> = 5.8 Hz, 1H), 7.86 (d, <i>J</i> = 4.2 Hz, 2H), 6.98–6.90 (m, 2H), 6.79 (d, <i>J</i> = 2.7 Hz, 1H), 6.60 (dd, <i>J</i> = 8.6, 2.7 Hz, 1H), 6.55 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 3.92 (s, 3H), 3.81 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 301.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 3-Methyl-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20e</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19e</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Tan solid, 71% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.29 (d, <i>J</i> = 5.7 Hz, 1H), 8.21 (s, 1H), 7.92 (d, <i>J</i> = 0.7 Hz, 1H), 7.10 (d, <i>J</i> = 2.3 Hz, 1H), 6.76 (d, <i>J</i> = 8.5 Hz, 1H), 6.53–6.42 (m, 3H), 5.06 (br s, 2H), 3.86 (s, 3H), 1.96 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 281.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 3-Methoxy-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20f</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19f</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Dark brown solid, 64% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (d, <i>J</i> = 5.8 Hz, 1H), 7.88–7.84 (m, 2H), 6.95 (d, <i>J</i> = 2.4 Hz, 1H), 6.89 (d, <i>J</i> = 8.4 Hz, 1H), 6.57 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 6.37 (d, <i>J</i> = 2.5 Hz, 1H), 6.29 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 3.93 (s, 3H), 3.74 (s, 3H), 3.72 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 297.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 2,3-Difluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20g</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19g</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Light brown solid, 80% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.33 (d, <i>J</i> = 5.7 Hz, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.19 (d, <i>J</i> = 1.9 Hz, 1H), 6.89 (t, <i>J</i> = 8.6 Hz, 1H), 6.66–6.58 (m, 2H), 5.54 (br s, 2H), 3.85 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 303.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 3,5-Difluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20h</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19h</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Beige solid, 94% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.36 (d, <i>J</i> = 5.7 Hz, 1H), 8.27 (s, 1H), 7.97 (s, 1H), 7.23 (d, <i>J</i> = 2.5 Hz, 1H), 6.64 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 6.42–6.33 (m, 2H), 5.80 (br s, 2H), 3.86 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 303.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 4-((2-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluoroaniline (<b>20i</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19b</b> and 1,3-dimethylpyrazole-4-boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Light brown solid, 72% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.37 (d, <i>J</i> = 5.7 Hz, 1H), 8.10 (s, 1H), 7.14–6.86 (m, 2H), 6.68–6.33 (m, 3H), 5.47 (br s, 2H), 3.77 (s, 3H), 2.35 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 299.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 4-((2-(1-Cyclopropyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluoroaniline (<b>20j</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19b</b> and 1-cyclopropylpyrazole-4-boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Pale yellow solid, 89% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.34 (d, <i>J</i> = 5.8 Hz, 1H), 7.95 (s, 1H), 7.83 (s, 1H), 6.98–6.90 (m, 2H), 6.59 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 6.51 (dd, <i>J</i> = 11.9, 2.7 Hz, 1H), 6.44 (ddd, <i>J</i> = 8.6, 2.7, 1.2 Hz, 1H), 3.85 (br s, 2H), 3.64–3.58 (m, 1H), 1.15–1.10 (m, 2H), 1.05–0.99 (m, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 311.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 1-(4-(4-(4-Amino-2-fluorophenoxy)pyridin-2-yl)-1<i>H</i>-pyrazol-1-yl)-2-methylpropan-2-ol (<b>20k</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19b</b> and 1-(2-hydroxy-2-methylpropyl)pyrazole-4-boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Pale pink solid, 51% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.33 (d, <i>J</i> = 5.7 Hz, 1H), 8.18 (s, 1H), 7.96 (s, 1H), 7.17 (d, <i>J</i> = 2.4 Hz, 1H), 7.00 (t, <i>J</i> = 9.0 Hz, 1H), 6.59–6.40 (m, 3H), 5.46 (br s, 2H), 4.73 (s, 1H), 4.04 (s, 2H), 1.07 (s, 6H). LC/MS (ESI, <i>m</i>/<i>z</i>): 343.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 3-Fluoro-4-((2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>20l</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19b</b> and 1-(2-(4-methylpiperazin-1-yl)ethyl)pyrazole-4-boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Brown oil, 56% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.35 (d, <i>J</i> = 5.7 Hz, 1H), 7.96 (s, 1H), 7.86 (s, 1H), 7.00–6.91 (m, 2H), 6.64–6.44 (m, 3H), 4.25 (t, <i>J</i> = 6.7 Hz, 2H), 3.82 (s, 2H), 2.86 (t, <i>J</i> = 6.7 Hz, 2H), 2.66–2.40 (m, 8H), 2.31 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 397.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-((2-(1<i>H</i>-Pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluoroaniline (<b>20m</b>)</h4><div class="NLM_p last">The compound was prepared from <b>19b</b> and 4-pyrazoleboronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Tan solid, 44% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.06 (s, 1H), 8.36–8.28 (m, 2H), 8.01 (s, 1H), 7.26 (d, <i>J</i> = 2.4 Hz, 1H), 7.00 (t, <i>J</i> = 9.0 Hz, 1H), 6.56–6.47 (m, 2H), 6.46–6.39 (m, 1H), 5.46 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 271.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 2-Chloro-4-(2,5-difluoro-4-nitrophenoxy)pyridine (<b>22</b>)</h4><div class="NLM_p last">To a solution of <b>21</b> (1.0 g, 7.7 mmol) in DMF (20 mL) was added potassium carbonate (1.28 g, 9.3 mmol) in one portion. After stirring at RT for 5 min, 1,2,4-trifluoro-5-nitrobenzene (1.37 g, 7.7 mmol) was slowly added with stirring. Then, the resulting mixture was stirred at RT for 0.5 h. The reaction mixture was poured into ice water (250 mL) and filtered. The filter cake was dried and purified by silica gel chromatography (petroleum ether/ethyl acetate 90:10) to afford the title compound <b>22</b> (1.24 g, 73%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.48 (dd, <i>J</i> = 10.2, 7.1 Hz, 1H), 8.42 (d, <i>J</i> = 5.7 Hz, 1H), 7.90 (dd, <i>J</i> = 11.5, 6.7 Hz, 1H), 7.41 (d, <i>J</i> = 2.3 Hz, 1H), 7.27 (dd, <i>J</i> = 5.7, 2.3 Hz, 1H). LC/MS (ESI, <i>m</i>/<i>z</i>): 287.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 4-((2-Chloropyridin-4-yl)oxy)-2,5-difluoroaniline (<b>23</b>)</h4><div class="NLM_p last">A mixture of <b>22</b> (2.00 g, 6.98 mmol) and stannous chloride (5.29 g, 27.91 mmol) in ethanol (144 mL) under argon was stirred at 80 °C for 8 h. Then, the reaction mixture was poured into saturated aq sodium bicarbonate (300 mL)/ethyl acetate (200 mL). The mixture was stirred and filtered. The filtrate was separated, and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layer was washed with brine (2 × 300 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 90:10) to afford the title compound <b>23</b> (1.19 g, 66%) as a dark brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.29 (d, <i>J</i> = 5.8 Hz, 1H), 7.25 (dd, <i>J</i> = 11.2, 7.4 Hz, 1H), 7.04 (d, <i>J</i> = 2.3 Hz, 1H), 6.96 (dd, <i>J</i> = 5.8, 2.3 Hz, 1H), 6.75 (dd, <i>J</i> = 12.3, 8.3 Hz, 1H), 5.58 (br s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 257.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 2,5-Difluoro-4-((2-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-4-yl)oxy)aniline (<b>24</b>)</h4><div class="NLM_p last">The compound was prepared from <b>23</b> and 1-methyl-4-pyrazole boronic acid pinacol ester by following a similar procedure as described for <b>16</b>. Tan solid, 84% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.35 (d, <i>J</i> = 5.7 Hz, 1H), 8.27 (s, 1H), 7.97 (d, <i>J</i> = 0.8 Hz, 1H), 7.25–7.16 (m, 2H), 6.74 (dd, <i>J</i> = 12.3, 8.3 Hz, 1H), 6.62 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 5.52 (br s, 2H), 3.87 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 303.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>N</i>-(4-Chloropyridin-2-yl)acetamide (<b>26a</b>)</h4><div class="NLM_p last">To a solution of <b>25</b> (1.30, 10 mmol) and TEA (4.0 g, 40 mmol) in dichloromethane (45 mL) was slowly added acetyl chloride (0.9 g, 12 mmol) at 0 °C. The resulting mixture was warmed up to RT and stirred for 17 h. The reaction mixture was poured into 200 mL of water and extracted with dichloromethane (3 × 100 mL). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 83:17) to afford the title compound <b>26a</b> (342 mg, 20%) as a rose red solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.76 (s, 1H), 8.29 (d, <i>J</i> = 5.4 Hz, 1H), 8.16 (d, <i>J</i> = 2.0 Hz, 1H), 7.22 (dd, <i>J</i> = 5.4, 2.0 Hz, 1H), 2.10 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 171.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(4-Chloropyridin-2-yl)propionamide (<b>26b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>25</b> and propionyl chloride by following a similar procedure as described for <b>26a</b>. Light brown semi-solid, 14% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.70 (s, 1H), 8.29 (d, <i>J</i> = 5.3 Hz, 1H), 8.19 (d, <i>J</i> = 2.0 Hz, 1H), 7.21 (dd, <i>J</i> = 5.4, 2.0 Hz, 1H), 2.40 (q, <i>J</i> = 7.5 Hz, 2H), 1.06 (t, <i>J</i> = 7.5 Hz, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 185.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>N</i>-(4-Chloropyridin-2-yl)cyclopropanecarboxamide (<b>26c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>25</b> and cyclopropanecarbonyl chloride by following a similar procedure as described for <b>26a</b>. Light yellow solid, 74% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.07 (s, 1H), 8.30 (d, <i>J</i> = 5.3 Hz, 1H), 8.16 (d, <i>J</i> = 1.9 Hz, 1H), 7.22 (dd, <i>J</i> = 5.3, 2.0 Hz, 1H), 2.01 (p, <i>J</i> = 6.2 Hz, 1H), 0.83 (d, <i>J</i> = 6.2 Hz, 4H). LC/MS (ESI, <i>m</i>/<i>z</i>): 197.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>N</i>-(4-(2-Fluoro-4-nitrophenoxy)pyridin-2-yl)acetamide (<b>27a</b>)</h4><div class="NLM_p last">A mixture of <b>26a</b> (300 mg, 1.76 mmol) and 2-fluoro-4-nitrophenol (691 mg, 4.40 mmol) in chlorobenzene (4.4 mL) was heated in a sealed tube at 140 °C for 40 h. The resulting mixture was evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 98:2) to afford the title compound <b>27a</b> (286 mg, 56%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.71 (s, 1H), 8.44 (dd, <i>J</i> = 10.5, 2.7 Hz, 1H), 8.29 (d, <i>J</i> = 5.7 Hz, 1H), 8.24–8.16 (m, 1H), 7.78 (d, <i>J</i> = 2.4 Hz, 1H), 7.61 (t, <i>J</i> = 8.5 Hz, 1H), 6.84 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 2.06 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 292.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> <i>N</i>-(4-(2-Fluoro-4-nitrophenoxy)pyridin-2-yl)propionamide (<b>27b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>26b</b> and 2-fluoro-4-nitrophenol by following a similar procedure as described for <b>27a</b>. Yellow solid, 51% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.65 (s, 1H), 8.44 (dd, <i>J</i> = 10.3, 2.7 Hz, 1H), 8.28 (d, <i>J</i> = 5.8 Hz, 1H), 8.20 (d, <i>J</i> = 9.1 Hz, 1H), 7.79 (d, <i>J</i> = 2.3 Hz, 1H), 7.62 (t, <i>J</i> = 8.5 Hz, 1H), 6.89–6.82 (m, 1H), 2.37 (q, <i>J</i> = 7.6 Hz, 2H), 1.01 (t, <i>J</i> = 7.5 Hz, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 306.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>N</i>-(4-(2-Fluoro-4-nitrophenoxy)pyridin-2-yl)cyclopropanecarboxamide (<b>27c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>26c</b> and 2-fluoro-4-nitrophenol by following a similar procedure as described for <b>27a</b>. Yellow solid, 44% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.02 (s, 1H), 8.43 (dd, <i>J</i> = 10.5, 2.7 Hz, 1H), 8.30 (d, <i>J</i> = 5.7 Hz, 1H), 8.19 (ddd, <i>J</i> = 9.0, 2.7, 1.4 Hz, 1H), 7.76 (d, <i>J</i> = 2.4 Hz, 1H), 7.66–7.57 (m, 1H), 6.86 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 2.04–1.93 (m, 1H), 0.84–0.72 (m, 4H). LC/MS (ESI, <i>m</i>/<i>z</i>): 318.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>N</i>-(4-(4-Amino-2-fluorophenoxy)pyridin-2-yl)acetamide (<b>28a</b>)</h4><div class="NLM_p last">A mixture of <b>27a</b> (100 mg, 0.34 mmol), iron powder (96 mg, 1.72 mmol), and acetic acid (206 mg, 3.43 mmol) in ethyl acetate (1.8 mL)/water (0.36 mL) under argon was stirred at 80 °C for 2 h. The resulting mixture was filtered and washed with ethyl acetate (3 × 5 mL) and water (3 × 10 mL). The filtrate was extracted with ethyl acetate (3 × 20 mL). The combined organic layer was washed with saturated aq sodium bicarbonate (50 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to afford the title compound <b>28a</b> (86 mg, 96%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.50 (s, 1H), 8.13 (d, <i>J</i> = 5.7 Hz, 1H), 7.63–7.58 (m, 1H), 6.96 (t, <i>J</i> = 9.0 Hz, 1H), 6.61 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 6.49 (dd, <i>J</i> = 13.2, 2.6 Hz, 1H), 6.44–6.37 (m, 1H), 5.45 (br s, 2H), 2.03 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 262.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>N</i>-(4-(4-Amino-2-fluorophenoxy)pyridin-2-yl)propionamide (<b>28b</b>)</h4><div class="NLM_p last">The compound was prepared from <b>27b</b> by following a similar procedure as described for <b>28a</b>. Black solid, 96% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.43 (s, 1H), 8.13 (d, <i>J</i> = 5.8 Hz, 1H), 7.62 (d, <i>J</i> = 2.4 Hz, 1H), 6.96 (t, <i>J</i> = 9.0 Hz, 1H), 6.62 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 6.50 (dd, <i>J</i> = 13.2, 2.5 Hz, 1H), 6.41 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 5.46 (br s, 2H), 2.33 (q, <i>J</i> = 7.5 Hz, 2H), 1.00 (t, <i>J</i> = 7.5 Hz, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 276.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> <i>N</i>-(4-(4-Amino-2-fluorophenoxy)pyridin-2-yl)cyclopropanecarboxamide (<b>28c</b>)</h4><div class="NLM_p last">The compound was prepared from <b>27c</b> by following a similar procedure as described for <b>28a</b>. Brown solid, 94% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.79 (s, 1H), 8.14 (d, <i>J</i> = 5.8 Hz, 1H), 7.59 (d, <i>J</i> = 2.4 Hz, 1H), 6.95 (t, <i>J</i> = 9.0 Hz, 1H), 6.64 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 6.48 (dd, <i>J</i> = 13.2, 2.5 Hz, 1H), 6.40 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 5.45 (br s, 2H), 1.98–1.91 (m, 1H), 0.80–0.73 (m, 4H). LC/MS (ESI, <i>m</i>/<i>z</i>): 288.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 4-(4-Amino-2-fluorophenoxy)picolinamide (<b>30</b>)</h4><div class="NLM_p last">To a solution of 4-amino-2-fluorophenol (1.91 g, 15.0 mmol) in DMSO (19 mL) was added potassium <i>tert</i>-butoxide (1.795 g, 16 mmol). The resulting mixture was stirred at RT for 15 min. Then, 4-chloropicolinamide (1.57 g, 10.0 mmol) was added, and the resulting mixture was stirred at 80 °C for 1 h. The reaction mixture was poured into 0.5 M aq NaOH (38 mL) and stirred for 2 h. The precipitate was filtered and washed with water, and the cake was dried to afford the title compound <b>30</b> (2.14 g, 86%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.49 (d, <i>J</i> = 5.6 Hz, 1H), 8.12 (s, 1H), 7.72 (s, 1H), 7.34 (s, 1H), 7.15 (dd, <i>J</i> = 5.6, 2.7 Hz, 1H), 7.02 (t, <i>J</i> = 9.0 Hz, 1H), 6.53 (d, <i>J</i> = 12.4 Hz, 1H), 6.44 (d, <i>J</i> = 8.3 Hz, 1H), 5.53 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 248.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-(4-((2-Carbamoylpyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>31</b>)</h4><div class="NLM_p last">The compound was prepared from <b>30</b> and <b>17h</b> by following a similar procedure as described for <b>13c</b>. Light yellow solid, 32% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.06 (s, 1H), 8.69 (s, 1H), 8.54 (d, <i>J</i> = 5.6 Hz, 1H), 8.15 (d, <i>J</i> = 1.8 Hz, 1H), 8.01 (dd, <i>J</i> = 12.9, 2.5 Hz, 1H), 7.74 (d, <i>J</i> = 1.6 Hz, 1H), 7.58–7.52 (m, 1H), 7.47–7.32 (m, 6H), 7.23 (dd, <i>J</i> = 5.6, 2.7 Hz, 1H), 4.78 (p, <i>J</i> = 6.7 Hz, 1H), 1.42 (d, <i>J</i> = 6.8 Hz, 6H). LC/MS (ESI, <i>m</i>/<i>z</i>): 522.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>N</i>-(4-((2-Aminopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (<b>32</b>)</h4><div class="NLM_p last">To a mixture of <b>31</b> (170 mg, 0.33 mmol) in ethyl acetate (3 mL)/acetonitrile (3 mL)/water (1.5 mL) under argon was added iodobenzene diacetate (315 mg, 0.98 mmol) at 0 °C, and the resulting mixture was stirred at RT for 15 h. The reaction mixture was evaporated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (dichloromethane/methanol 95:5) to afford the title compound <b>32</b> (57 mg, 36%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.01 (s, 1H), 8.68 (s, 1H), 7.96 (dd, <i>J</i> = 12.9, 2.0 Hz, 1H), 7.82 (d, <i>J</i> = 6.0 Hz, 1H), 7.52–7.28 (m, 6H), 6.22 (dd, <i>J</i> = 5.9, 2.5 Hz, 3H), 5.85 (d, <i>J</i> = 1.8 Hz, 1H), 4.78 (p, <i>J</i> = 6.8 Hz, 1H), 1.42 (d, <i>J</i> = 6.8 Hz, 6H). LC/MS (ESI, <i>m</i>/<i>z</i>): 494.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Kinase Inhibition Assay</h3><div class="NLM_p last">The activity of Axl and Met kinases was tested using ELISA as previously reported.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The IC<sub>50</sub> values were calculated from inhibition curves obtained from two separate experiments using a modified four-parameter logistic model. If the inhibitory rate is above 50% at the minimum tested compound concentration, the conclusion is that the IC<sub>50</sub> is lower than the tested minimum compound concentration. Moreover, if the inhibitory rate is below 50% at the maximum tested drug concentration, it shows that the IC<sub>50</sub> is higher than the tested maximum compound concentration. The kinase selectivity profile of <b>13c</b> (1000, 100, and 10 nmol/L) was screened against the abovementioned 40 other kinases by ELISA in local or radiometric protein kinase assays performed by Eurofins (UK) according to the manufacturer’s instructions.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Western Blot Analysis</h3><div class="NLM_p last">Cells were cultured under regular growth conditions to the exponential growth phase. The cells were then treated with the indicated dose of <b>13c</b> for 2 h and lysed in 1× sodium dodecyl sulfate (SDS) sample buffer. If Gas6 treatment was required, cells were serum-deprived for 24 h prior to 2 h of treatment with compounds and then stimulated with Gas6 for 15 min. The cell lysates were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. Proteins were first probed with specific antibodies [against p-Axl(Y702), Axl, p-Met(Y1234/1235), p-Akt(S473), Akt, p-ERK1/2(T202/Y204), ERK1/2, β-actin, GAPDH (all from Cell Signaling Technology, USA), and Met (Santa Cruz Biotechnology, USA)], followed by a secondary horseradish peroxidase-conjugated antibody. Finally, immunoreactive proteins were detected using an enhanced chemiluminescence detection reagent (Thermo Fisher Scientific, USA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Cell Proliferation Assays</h3><div class="NLM_p last">Cells were seeded in 96-well plates at a low density in growth media. The next day, appropriate controls or designated concentrations of compounds were added to each well, and the cells were incubated for 72 h. Finally, cell proliferation was determined using a sulforhodamine B assay (SRB, Sigma-Aldrich, USA) or a cell counting kit (CCK-8, Dojindo, Japan) assay. The IC<sub>50</sub> values were calculated by concentration–response curve fitting using a SoftMax pro-based four-parameter method (SoftMax Pro Software, version 5.4.1).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Cell Migration and Matrigel Invasion Assays</h3><div class="NLM_p last">For the migration assay, cells suspended in a serum-free medium (1.5 × 10<sup>5</sup> cells per well) were seeded in 24-well transwell plates (pore size, 8 μm; Corning). The bottom chambers were filled with the serum-free medium supplemented with Gas6 (500 ng/mL) or cocultured cells, and appropriate controls or designated concentrations of compounds were added to both sides of the membrane. The cultures were maintained for 24 h, after which the nonmotile cells at the top of the filter were removed using a cotton swab. The migrating cells were fixed in paraformaldehyde (4%) and stained with crystal violet (0.1%) for 15 min at RT. For the invasion assay, cells were cultured in the top chambers containing Matrigel-coated membrane inserts. The ensuing procedure was identical to that of the migration assay. The assay was performed in triplicate. Images were obtained using an Olympus BX51 microscope.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> In Vivo Antitumor Activity Studies</h3><div class="NLM_p last">Animal procedures were approved by the Institutional Animal Care and Use Committee of the Shanghai Institute of Materia Medica (approval no. 2019-05-DJ-48). Cells at a density of 5–10 × 10<sup>6</sup> in 200 μL were first implanted subcutaneously (sc) into the right flank of a nude mice and allowed to grow to 700–800 mm<sup>3</sup>, which was defined as a well-developed tumor volume. The well-developed tumors were cut into 1.5 mm<sup>3</sup> fragments and transplanted sc into the right flank of nude mice. When the tumor volume reached 100–200 mm<sup>3</sup>, the mice were randomly assigned into vehicle and treatment groups (<i>n</i> = 6 in the treated group and <i>n</i> = 12 in the vehicle group). The vehicle groups were given the vehicle alone, and the treatment groups received compounds at the indicated doses via po administration once daily for the indicated days. The tumor sizes were measured twice a week using a microcaliper. The tumor volume (TV) was calculated as TV = (length × width<sup>2</sup>)/2. The percent (%) TGI rates were measured on the final day of the study for the compound-treated mice relative to the vehicle-treated mice and were calculated as 100 × {1 – [(TV<sub>Treated Final day</sub> – TV<sub>Treated Day 0</sub>)/(TV<sub>Vehicle Final day</sub> – TV<sub>Vehicle Day 0</sub>)]}. Significant differences between the treated versus the vehicle groups (<i>P</i> ≤ 0.05) were determined using Student’s <i>t</i>-test.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Determination of Pharmacokinetic Parameters in Rats</h3><div class="NLM_p last">Male rats (SD rats, body-weight range of 330–390 g, <i>n</i> = 3) were administered compounds <b>12e</b> or <b>13c</b> by oral gavage at 3 mg/kg. A mixed solvent of 2.5% DMSO/97.5% [0.5% hydroxypropyl methyl cellulose (HPMC)] was used as the medium. Blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing. The plasma was separated by centrifugation, and the serum was collected in vials. The serum samples were frozen and stored at −70 °C before analysis. The test sample concentrations were determined by LC/MS. Animal procedures were performed according to the institutional ethical guidelines on animal care and approved by the Institute Animal Care and Use Committee at Shanghai Institute of Materia Medica (approval no. 2019-02-YY-07). The pharmacokinetic parameters were calculated using WinNonlin (version 6.4) software.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Determination of Pharmacokinetic Parameters in Mice</h3><div class="NLM_p last">Male mice (ICR mice, body-weight range of 18–22 g, iv, <i>n</i> = 3, po, <i>n</i> = 3) were administered compound <b>13c</b> intravenously via the tail vein at 1 mg/kg or by oral gavage at 3 mg/kg. A mixed solvent of 5% DMSO/5% ethanol/40% PEG-300/50% (0.9% NaCl) was used as the injection medium. A mixed solvent of 2.5% DMSO/97.5% (0.5% HPMC) was used as the oral administration medium. For the po group, blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing. For the iv group, blood samples were collected at 0.25, 0.5, 0.75, 2, 4, 8, and 24 h after dosing. The plasma was separated by centrifugation, and the serum was collected in vials. The serum samples were frozen and stored at −70 °C before analysis. The test sample concentrations were determined by LC/MS. Animal procedures were performed according to the institutional ethical guidelines on animal care and approved by the Institute Animal Care and Use Committee at Shanghai Institute of Materia Medica (approval no. 2019-02-YY-08). The pharmacokinetic parameters were calculated using WinNonlin (version 6.4) software.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Molecular Modeling</h3><div class="NLM_p">The template Met crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82">3F82</a>) lacks residues Leu1225 to Ala1243. Thus, we decided to exclude this segment. The Axl/Met aligned sequences (as in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) were taken out as two parts (part one: Val536 to Gly692 of Axl and Val1078 to Gly1224 of Met; part two: Lys710 to Leu799 of Axl and Lys1224 to Leu1333 of Met). We performed homology modeling of these two parts separately using the “Target/Template Alignment” method in SWISS-MODEL workspace via the ExPASy web server.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The two predicted structures were combined into one portion using Discovery Studio Visualizer (version 4.5.0, BIOVIA).</div><div class="NLM_p last">The docking study was performed using AutoDock (version 4.2) and AutoDockTools.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The predicted Axl DFG-out homology model was defined as the receptor. The docking site was defined using a grid box size of 35 × 61 × 60, spacing of 0.375 Å, and grid center of 0, 9, and 5. The Lamarckian genetic algorithm (GA) method was used in the docking protocol. <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> were obtained from PyMOL (The PyMOL Molecular Graphics System, version 2.5, <a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>) and Adobe Photoshop (version 2015.1.2).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02093" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02093?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02093</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Preparation of intermediate compounds, NMR spectra, and HPLC determination of compound <b>13c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Table of molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Axl DFG-out homology model in the PDB format and docking poses for <b>10g</b> and <b>13c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_003.zip" class="ext-link">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_001.pdf">jm0c02093_si_001.pdf (1.36 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_002.csv">jm0c02093_si_002.csv (4.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_003.zip">jm0c02093_si_003.zip (116.65 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02093" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Ai</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4228232b02312b2f2f6c23216c212c"><span class="__cf_email__" data-cfemail="701a11193003191d1d5e11135e131e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhu Duan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5084-6026" title="Orcid link">http://orcid.org/0000-0002-5084-6026</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#abdcc3cfdecac5ebd8c2c6c685cac885c8c5"><span class="__cf_email__" data-cfemail="02756a6677636c42716b6f6f2c63612c616c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hefeng Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia Peng</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Dai</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingwei Shao</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</span>; 
    <span>Present Address:
                        Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, 200 South Cedar, Little Rock, Arkansas, 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinchun Ji</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiming Sun</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Liu</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xu Cheng</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.Z. and X.P. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the funds from the Science and Technology Commission of Shanghai Municipality (no. 18431907100), the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” of China (no. 2018ZX09711002-011-016), the Natural Science Foundation of China for Innovation Research Group (no. 81821005), and the Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning (no. 2020CXJQ02).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TAM</td><td class="NLM_def"><p class="first last">Tyro3, Axl, and Mer</p></td></tr><tr><td class="NLM_term">Gas6</td><td class="NLM_def"><p class="first last">growth arrest specific protein 6</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial-to-mesenchymal transition</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">aspartate–phenylalanine–glycine</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">atructure–activity relationship</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">DHBA</td><td class="NLM_def"><p class="first last">dual hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague–Dawley</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">ICR</td><td class="NLM_def"><p class="first last">Institute of Cancer Research</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-aza-1<i>H</i>-benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">liquid chromatography</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">SDS</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate</p></td></tr><tr><td class="NLM_term">SRB</td><td class="NLM_def"><p class="first last">sulforhodamine B</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">thiazolyl blue tetrazolium bromide</p></td></tr><tr><td class="NLM_term">sc</td><td class="NLM_def"><p class="first last">subcutaneously</p></td></tr><tr><td class="NLM_term">TV</td><td class="NLM_def"><p class="first last">tumor volume</p></td></tr><tr><td class="NLM_term">HPMC</td><td class="NLM_def"><p class="first last">hydroxypropyl methyl cellulose</p></td></tr><tr><td class="NLM_term">GA</td><td class="NLM_def"><p class="first last">genetic algorithm</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 54 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varnum, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartley, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clogston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toso, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagihara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merewether, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H. K.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase stimulated by the vitamin-K-dependent protein encoded by growth-arrest-specific gene 6</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/373623a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1038%2F373623a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=7854420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=623-626&author=B.+C.+Varnumauthor=C.+Youngauthor=G.+Elliottauthor=A.+Garciaauthor=T.+D.+Bartleyauthor=Y.-W.+Fridellauthor=R.+W.+Huntauthor=G.+Trailauthor=C.+Clogstonauthor=R.+J.+Tosoauthor=D.+Yanagiharaauthor=L.+Bennettauthor=M.+Sylberauthor=L.+A.+Merewetherauthor=A.+Tsengauthor=E.+Escobarauthor=E.+T.+Liuauthor=H.+K.+Yamane&title=Axl+receptor+tyrosine+kinase+stimulated+by+the+vitamin-K-dependent+protein+encoded+by+growth-arrest-specific+gene+6&doi=10.1038%2F373623a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ax1 receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</span></div><div class="casAuthors">Varnum, Brian C.; Young, Cynthia; Elliott, Gary; Garcia, Andy; Bartley, Timothy D.; Fridell, Yih-Woei; Hunt, Robert W.; Trail, Geraldine; Clogston, Chris; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">6515</span>),
    <span class="NLM_cas:pages">623-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukemia cells by DNA-mediated transformation of NIH 3T3 cells.  Ax1 is the founding member of a family of related receptors that includes Eyk, encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer, encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines.  The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation.  The function of Ax1 in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor.  We report here the purifn. of an Ax1 stimulatory factor, and its identification as the product of growth-arrest-specific gene 6.  This is, to our knowledge, the first description of a ligand for the Ax1 family of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-4cxnEY4sPbVg90H21EOLACvtfcHk0lg8vf8sNlZ_sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D&md5=0d8ecf55926f43384ca646ffa3692529</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F373623a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F373623a0%26sid%3Dliteratum%253Aachs%26aulast%3DVarnum%26aufirst%3DB.%2BC.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DBartley%26aufirst%3DT.%2BD.%26aulast%3DFridell%26aufirst%3DY.-W.%26aulast%3DHunt%26aufirst%3DR.%2BW.%26aulast%3DTrail%26aufirst%3DG.%26aulast%3DClogston%26aufirst%3DC.%26aulast%3DToso%26aufirst%3DR.%2BJ.%26aulast%3DYanagihara%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DL.%26aulast%3DSylber%26aufirst%3DM.%26aulast%3DMerewether%26aufirst%3DL.%2BA.%26aulast%3DTseng%26aufirst%3DA.%26aulast%3DEscobar%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DYamane%26aufirst%3DH.%2BK.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520stimulated%2520by%2520the%2520vitamin-K-dependent%2520protein%2520encoded%2520by%2520growth-arrest-specific%2520gene%25206%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D623%26epage%3D626%26doi%3D10.1038%2F373623a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quilliam, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCloskey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spizz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span> <span> </span><span class="NLM_article-title">Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1128/mcb.16.1.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1128%2FMCB.16.1.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=8524290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK28XhtVGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=135-145&author=Y.+W.+Fridellauthor=Y.+Jinauthor=L.+A.+Quilliamauthor=A.+Burchertauthor=P.+McCloskeyauthor=G.+Spizzauthor=B.+Varnumauthor=C.+Derauthor=E.+T.+Liu&title=Differential+activation+of+the+Ras%2Fextracellular-signal-regulated+protein+kinase+pathway+is+responsible+for+the+biological+consequences+induced+by+the+Axl+receptor+tyrosine+kinase&doi=10.1128%2Fmcb.16.1.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase</span></div><div class="casAuthors">Fridell, Yih-Woei C.; Jin, Yan; Quilliam, Lawrence A.; Burchert, Andreas; McCloskey, Patrick; Spizz, Gwendolyn; Varnum, Brian; Der, Channing; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-45</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">To understand the mechanism of Axl signaling, we have initiated studies to delineate downstream components in interleukin-3-dependent 32D cells by using a chimeric receptor contg. the recombinant epidermal growth factor (EGF) receptor extracellular and transmembrane domains and the Axl kinase domain (EAK [for EGF receptor-Axl kinase]).  We have previously shown that upon exogenous EGF stimulation, 32D-EAK cells are capable of proliferation in the absence of interleukin-3.  With this system, we detd. that EAK-induced cell survival and mitogenesis are dependent upon the Ras/extracellular-signal-regulated protein kinase (ERK) cascade.  Although the phosphatidylinositol-3 kinase pathway is activated upon EAK signaling, it appears to be dispensable for the biol. actions of the Axl kinase.  Furthermore, we demonstrated that different threshold levels of Ras/ERK activation are needed to induce a block to apoptosis or proliferation in 32D cells.  Recently, we have identified an Axl ligand, GAS6.  Surprisingly, GAS6-stimulated 32D-Axl cells exhibited no blockage to apoptosis or mitogenic response which is correlated with the absence of Ras/ERK activation.  Taken together, these data suggest that different extracellular domains dramatically alter the intracellular response of the Axl kinase.  Furthermore, our data suggest that the GAS6-Axl interaction does not induce mitogenesis and that its exact role remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCI2en51B0vLVg90H21EOLACvtfcHk0lg8vf8sNlZ_sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtVGqsQ%253D%253D&md5=c7523c9c82a2e9f7010c9a4000e82b8a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.1.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.1.135%26sid%3Dliteratum%253Aachs%26aulast%3DFridell%26aufirst%3DY.%2BW.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DQuilliam%26aufirst%3DL.%2BA.%26aulast%3DBurchert%26aufirst%3DA.%26aulast%3DMcCloskey%26aufirst%3DP.%26aulast%3DSpizz%26aufirst%3DG.%26aulast%3DVarnum%26aufirst%3DB.%26aulast%3DDer%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DDifferential%2520activation%2520of%2520the%2520Ras%252Fextracellular-signal-regulated%2520protein%2520kinase%2520pathway%2520is%2520responsible%2520for%2520the%2520biological%2520consequences%2520induced%2520by%2520the%2520Axl%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D135%26epage%3D145%26doi%3D10.1128%2Fmcb.16.1.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Axl and mTOR pathway overcomes primary and acquired resistance to Wee1 inhibition in small-cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6239</span>– <span class="NLM_lpage">6253</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-17-1284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F1078-0432.CCR-17-1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28698200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6239-6253&author=T.+Senauthor=P.+Tongauthor=L.+Diaoauthor=L.+Liauthor=Y.+Fanauthor=J.+Hoffauthor=J.+V.+Heymachauthor=J.+Wangauthor=L.+A.+Byers&title=Targeting+Axl+and+mTOR+pathway+overcomes+primary+and+acquired+resistance+to+Wee1+inhibition+in+small-cell+lung+cancer&doi=10.1158%2F1078-0432.ccr-17-1284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer</span></div><div class="casAuthors">Sen, Triparna; Tong, Pan; Diao, Lixia; Li, Lerong; Fan, Youhong; Hoff, Jennifer; Heymach, John V.; Wang, Jing; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6239-6253</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Drugs targeting DNA repair and cell-cycle checkpoints have emerged as promising therapies for small-cell lung cancer (SCLC).  Among these, the WEE1 inhibitor AZD1775 has shown clin. activity in a subset of SCLC patients, but resistance is common.  Understanding primary and acquired resistance mechanisms will be crit. for developing effective WEE1 inhibitor combinations.  AZD1775 sensitivity in SCLC cell lines was correlated with baseline expression level of 200 total or phosphorylated proteins measured by reverse-phase protein array (RPPA) to identify predictive markers of primary resistance.  We further established AZD1775 acquired resistance models to identify mechanism of acquired resistance.  Combination regimens were tested to overcome primary and acquired resistance to AZD1775 in in vitro and in vivo SCLC models.  High-throughput proteomic profiling demonstrate that SCLC models with primary resistance to AZD1775 express high levels of AXL and phosphorylated S6 and that WEE1/AXL or WEE1/mTOR inhibitor combinations overcome resistance in vitro and in vivo.  Furthermore, AXL, independently and via mTOR, activates the ERK pathway, leading to recruitment and activation of another G2-checkpoint protein, CHK1.  AZD1775 acquired resistance models demonstrated upregulation of AXL, pS6, and MET, and resistance was overcome with the addn. of AXL (TP0903), dual-AXL/MET (cabozantinib), or mTOR (RAD001) inhibitors.  AXL promotes resistance to WEE1 inhibition via downstream mTOR signaling and resulting activation of a parallel DNA damage repair pathway, CHK1.  These findings suggest rational combinations to enhance the clin. efficacy of AZD1775, which is currently in clin. trials for SCLC and other malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXHr15nrmjyrVg90H21EOLACvtfcHk0ljIG-l04GT57g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrbK&md5=4206192309431713c6877b7ee8958ee7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1284%26sid%3Dliteratum%253Aachs%26aulast%3DSen%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DHoff%26aufirst%3DJ.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DTargeting%2520Axl%2520and%2520mTOR%2520pathway%2520overcomes%2520primary%2520and%2520acquired%2520resistance%2520to%2520Wee1%2520inhibition%2520in%2520small-cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D6239%26epage%3D6253%26doi%3D10.1158%2F1078-0432.ccr-17-1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linger, R. M. A.</span>; <span class="NLM_string-name">Keating, A. K.</span>; <span class="NLM_string-name">Earp, H. S.</span>; <span class="NLM_string-name">Graham, D. K.</span></span> <span> </span><span class="NLM_article-title">TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer</span>. In  <i>Advances in Cancer Research, Vol. 100</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">VandeWoude, G. F.</span>, <span class="NLM_string-name">Klein, G.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier Academic Press Inc.</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2008</span>; Vol.  <span class="NLM_volume">100</span>, pp  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">83</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2FS0065-230X%2808%2900002-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=35-83&author=R.+M.+A.+Linger&author=A.+K.+Keating&author=H.+S.+Earp&author=D.+K.+Grahamauthor=G.+F.+VandeWoude&author=G.+Klein&title=Advances+in+Cancer+Research%2C+Vol.+100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2808%2900002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0065-230X%252808%252900002-X%26sid%3Dliteratum%253Aachs%26aulast%3DLinger%26aufirst%3DR.%2BM.%2BA.%26atitle%3DTAM%2520receptor%2520tyrosine%2520kinases%253A%2520biologic%2520functions%252C%2520signaling%252C%2520and%2520potential%2520therapeutic%2520targeting%2520in%2520human%2520cancer%26btitle%3DAdvances%2520in%2520Cancer%2520Research%252C%2520Vol.%2520100%26aulast%3DVandeWoude%26aufirst%3DG.%2BF.%26pub%3DElsevier%2520Academic%2520Press%2520Inc%26date%3D2008%26volume%3D100%26spage%3D35%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X. W.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">153</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-1090-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1186%2Fs12943-019-1090-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=31684958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BB3MjkvFyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=153&author=C.+J.+Zhuauthor=Y.+Q.+Weiauthor=X.+W.+Wei&title=Axl+receptor+tyrosine+kinase+as+a+promising+anti-cancer+approach%3A+functions%2C+molecular+mechanisms+and+clinical+applications&doi=10.1186%2Fs12943-019-1090-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications</span></div><div class="casAuthors">Zhu Chenjing; Wei Yuquan; Wei Xiawei; Zhu Chenjing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular targeted therapy for cancer has been a research hotspot for decades.  AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6).  The Gas6/AXL signalling pathway is associated with tumour cell growth, metastasis, invasion, epithelial-mesenchymal transition (EMT), angiogenesis, drug resistance, immune regulation and stem cell maintenance.  Different therapeutic agents targeting AXL have been developed, typically including small molecule inhibitors, monoclonal antibodies (mAbs), nucleotide aptamers, soluble receptors, and several natural compounds.  In this review, we first provide a comprehensive discussion of the structure, function, regulation, and signalling pathways of AXL.  Then, we highlight recent strategies for targeting AXL in the treatment of cancer.AXL-targeted drugs, either as single agents or in combination with conventional chemotherapy or other small molecule inhibitors, are likely to improve the survival of many patients.  However, future investigations into AXL molecular signalling networks and robust predictive biomarkers are warranted to select patients who could receive clinical benefit and to avoid potential toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWZj0ShdbIUTjk2McQZ6XmfW6udTcc2ebQjZO1g4X1G7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjkvFyhsA%253D%253D&md5=7fc0485d2e05aab8ccca4577280f3988</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1090-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1090-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DC.%2BJ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DWei%26aufirst%3DX.%2BW.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520anti-cancer%2520approach%253A%2520functions%252C%2520molecular%2520mechanisms%2520and%2520clinical%2520applications%26jtitle%3DMol.%2520Cancer%26date%3D2019%26volume%3D18%26spage%3D153%26doi%3D10.1186%2Fs12943-019-1090-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinato, D. J.</span></span> <span> </span><span class="NLM_article-title">Gene of the month: Axl</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1136/jclinpath-2016-203629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1136%2Fjclinpath-2016-203629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26951083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVyktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=391-397&author=M.+Brownauthor=J.+R.+M.+Blackauthor=R.+Sharmaauthor=J.+Stebbingauthor=D.+J.+Pinato&title=Gene+of+the+month%3A+Axl&doi=10.1136%2Fjclinpath-2016-203629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Gene of the month: axl</span></div><div class="casAuthors">Brown, Matthew; Black, James R. M.; Sharma, Rohini; Stebbing, Justin; Pinato, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">391-397</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">The interaction between Axl receptor tyrosine kinase and its main ligand Gas6 has been implicated in the progression of a wide no. of malignancies.  More recently, overexpression of Axl has emerged as a key mol. determinant underlying the development of acquired resistance to targeted anticancer agents.  The activation of Axl is overexpression-dependent and controls a no. of hallmarks of cancer progression including proliferation, migration, resistance to apoptosis and survival through a complex network of intracellular second messengers.  Axl has been noted to influence clin. meaningful end points including metastatic recurrence and survival in the vast majority of tumor types.  With Axl inhibitors having gained momentum as novel anticancer therapies, we provide an overview of the biol. and clin. relevance of this mol. pathway, outlining the main directions of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMgYKvX3NBebVg90H21EOLACvtfcHk0ljIG-l04GT57g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVyktLw%253D&md5=0711fa811911dc6a383b48c1ce7ed3a9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2016-203629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2016-203629%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DBlack%26aufirst%3DJ.%2BR.%2BM.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DPinato%26aufirst%3DD.%2BJ.%26atitle%3DGene%2520of%2520the%2520month%253A%2520Axl%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2016%26volume%3D69%26spage%3D391%26epage%3D397%26doi%3D10.1136%2Fjclinpath-2016-203629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramjiawan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffioen, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, D. G.</span></span> <span> </span><span class="NLM_article-title">Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?</span>. <i>Angiogenesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1007/s10456-017-9552-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1007%2Fs10456-017-9552-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28361267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1cvjtVWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=185-204&author=R.+R.+Ramjiawanauthor=A.+W.+Griffioenauthor=D.+G.+Duda&title=Anti-angiogenesis+for+cancer+revisited%3A+is+there+a+role+for+combinations+with+immunotherapy%3F&doi=10.1007%2Fs10456-017-9552-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?</span></div><div class="casAuthors">Ramjiawan Rakesh R; Duda Dan G; Ramjiawan Rakesh R; Griffioen Arjan W</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-204</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and has been characterized as an essential process for tumor cell proliferation and viability.  This has led to the development of pharmacological agents for anti-angiogenesis to disrupt the vascular supply and starve tumor of nutrients and oxygen, primarily through blockade of VEGF/VEGFR signaling.  This effort has resulted in 11 anti-VEGF drugs approved for certain advanced cancers, alone or in combination with chemotherapy or other targeted therapies.  But this success had only limited impact on overall survival of cancer patients and rarely resulted in durable responses.  Given the recent success of immunotherapies, combinations of anti-angiogenics with immune checkpoint blockers have become an attractive strategy.  However, implementing such combinations will require a better mechanistic understanding of their interaction.  Due to overexpression of pro-angiogenic factors in tumors, their vasculature is often tortuous and disorganized, with excessively branched leaky vessels.  This enhances vascular permeability, which in turn is associated with high interstitial fluid pressure, and a reduction in blood perfusion and oxygenation.  Judicious dosing of anti-angiogenic treatment can transiently normalize the tumor vasculature by decreasing vascular permeability and improving tumor perfusion and blood flow, and synergize with immunotherapy in this time window.  However, anti-angiogenics may also excessively prune tumor vessels in a dose and time-dependent manner, which induces hypoxia and immunosuppression, including increased expression of the immune checkpoint programmed death receptor ligand (PD-L1).  This review focuses on revisiting the concept of anti-angiogenesis in combination with immunotherapy as a strategy for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa4t3uAUqTpoYPsCkJIw00fW6udTcc2ebNWzPAyC6DTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvjtVWgug%253D%253D&md5=6ecf5a8cbecdf525a7d132d5211d7096</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs10456-017-9552-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-017-9552-y%26sid%3Dliteratum%253Aachs%26aulast%3DRamjiawan%26aufirst%3DR.%2BR.%26aulast%3DGriffioen%26aufirst%3DA.%2BW.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26atitle%3DAnti-angiogenesis%2520for%2520cancer%2520revisited%253A%2520is%2520there%2520a%2520role%2520for%2520combinations%2520with%2520immunotherapy%253F%26jtitle%3DAngiogenesis%26date%3D2017%26volume%3D20%26spage%3D185%26epage%3D204%26doi%3D10.1007%2Fs10456-017-9552-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’bryan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebeau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span> <span> </span><span class="NLM_article-title">Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5016</span>– <span class="NLM_lpage">5031</span>, <span class="refDoi"> DOI: 10.1128/mcb.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Lebeauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=Axl%2C+a+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2Fmcb.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0lhixMwYDHfBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLebeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DAxl%252C%2520a%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2Fmcb.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Axl Inhibitors in cancer: a medicinal chemistry perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3593</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3593-3608&author=S.+H.+Myersauthor=V.+G.+Bruntonauthor=A.+Unciti-Broceta&title=Axl+Inhibitors+in+cancer%3A+a+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.5b01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Myers, Samuel H.; Brunton, Valerie G.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of the AXL receptor tyrosine kinase has been assocd. with many types of cancer.  It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance.  The entry of the first AXL-branded inhibitor in clin. trials in 2013 marked an important milestone for the clin. validation of AXL as an anticancer target.  Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clin. development have AXL as either a prominent secondary or even the primary target.  Through this review, the chem. and biol. properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7-ZTTNRD9LLVg90H21EOLACvtfcHk0ljhCtMYIGkHTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI&md5=4643d9d9950251a14c3991c306c4cec0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DAxl%2520Inhibitors%2520in%2520cancer%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.5b01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gjerdrum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoiby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklem, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glackin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J. B.</span></span> <span> </span><span class="NLM_article-title">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1073/pnas.0909333107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1073%2Fpnas.0909333107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=20080645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1124-1129&author=C.+Gjerdrumauthor=C.+Tironauthor=T.+Hoibyauthor=I.+Stefanssonauthor=H.+Haugenauthor=T.+Sandalauthor=K.+Collettauthor=S.+Liauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=D.+R.+Micklemauthor=L.+A.+Akslenauthor=C.+Glackinauthor=J.+B.+Lorens&title=Axl+is+an+essential+epithelial-to-mesenchymal+transition-induced+regulator+of+breast+cancer+metastasis+and+patient+survival&doi=10.1073%2Fpnas.0909333107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span></div><div class="casAuthors">Gjerdrum, Christine; Tiron, Crina; Hoeiby, Torill; Stefansson, Ingunn; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet; Gjertsen, Bjoern Tore; Micklem, David R.; Akslen, Lars A.; Glackin, Carlotta; Lorens, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129, S1124/1-S1124/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Metastasis underlies the majority of cancer-related deaths.  Thus, furthering our understanding of the mol. mechanisms that enable tumor cell dissemination is a vital health issue.  Epithelial-to-mesenchymal transitions (EMTs) endow carcinoma cells with enhanced migratory and survival attributes that facilitate malignant progression.  Characterization of EMT effectors is likely to yield new insights into metastasis and novel avenues for treatment.  We show that the presence of the receptor tyrosine kinase Axl in primary breast cancers independently predicts strongly reduced overall patient survival, and that matched patient metastatic lesions show enhanced Axl expression.  We demonstrate that Axl is strongly induced by EMT in immortalized mammary epithelial cells that establishes an autocrine signaling loop with its ligand, Gas6.  Epiallelic RNA interference anal. in metastatic breast cancer cells delineated a distinct threshold of Axl expression for mesenchymal-like in vitro cell invasiveness and formation of tumors in foreign and tissue-engineered micro-environments in vivo.  Importantly, in two different optical imaging-based exptl. breast cancer models, Axl knockdown completely prevented the spread of highly metastatic breast carcinoma cells from the mammary gland to lymph nodes and several major organs and increased overall survival.  These findings suggest that Axl represents a downstream effector of the tumor cell EMT that is required for breast cancer metastasis.  Thus, the detection and targeted treatment of Axl-expressing tumors represents an important new therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPiST_cnXhqrVg90H21EOLACvtfcHk0ljhCtMYIGkHTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D&md5=dbd7113028010a800e22ff1f206b9337</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909333107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909333107%26sid%3Dliteratum%253Aachs%26aulast%3DGjerdrum%26aufirst%3DC.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DHoiby%26aufirst%3DT.%26aulast%3DStefansson%26aufirst%3DI.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DCollett%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGlackin%26aufirst%3DC.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DAxl%2520is%2520an%2520essential%2520epithelial-to-mesenchymal%2520transition-induced%2520regulator%2520of%2520breast%2520cancer%2520metastasis%2520and%2520patient%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D1124%26epage%3D1129%26doi%3D10.1073%2Fpnas.0909333107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase as a therapeutic target in NSCLC</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S60438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.2147%2FLCTT.S60438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28210148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1c3nvVyqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=27-34&author=R.+A.+Okimotoauthor=T.+G.+Bivona&title=Axl+receptor+tyrosine+kinase+as+a+therapeutic+target+in+NSCLC&doi=10.2147%2FLCTT.S60438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor tyrosine kinase as a therapeutic target in NSCLC</span></div><div class="casAuthors">Okimoto Ross A; Bivona Trever G</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer (Auckland, N.Z.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-34</span>
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    </div><div class="casAbstract">The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial-mesenchymal transition-associated drug resistance.  Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models.  These findings implicate AXL as a promising therapeutic target in lung cancer.  In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHsEgSYJcabOLt9HypzAgQfW6udTcc2eaJDc9Ptiatd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3nvVyqsQ%253D%253D&md5=60fcef522f3feebeb40f86ef7880e90f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S60438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S60438%26sid%3Dliteratum%253Aachs%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520NSCLC%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D6%26spage%3D27%26epage%3D34%26doi%3D10.2147%2FLCTT.S60438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reichl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zijl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Führlinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieghart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck-Radosavljevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulits, W.</span></span> <span> </span><span class="NLM_article-title">Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1002/hep.27492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1002%2Fhep.27492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=25251599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=930-941&author=P.+Reichlauthor=M.+Denglerauthor=F.+van+Zijlauthor=H.+Huberauthor=G.+F%C3%BChrlingerauthor=C.+Reichelauthor=W.+Sieghartauthor=M.+Peck-Radosavljevicauthor=M.+Grubingerauthor=W.+Mikulits&title=Axl+activates+autocrine+transforming+growth+factor-beta+signaling+in+hepatocellular+carcinoma&doi=10.1002%2Fhep.27492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma</span></div><div class="casAuthors">Reichl, Patrick; Dengler, Mirko; van Zijl, Franziska; Huber, Heidemarie; Fuehrlinger, Gerhard; Reichel, Christian; Sieghart, Wolfgang; Peck-Radosavljevic, Markus; Grubinger, Markus; Mikulits, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">930-941</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epithelial to mesenchymal transition (EMT) of malignant hepatocytes.  Several mechanisms have been identified to be essentially involved in hepatocellular EMT, among them transforming growth factor (TGF)-β signaling.  Here we show the up-regulation and activation of the receptor tyrosine kinase Axl in EMT-transformed hepatoma cells.  Knockdown of Axl expression resulted in abrogation of invasive and transendothelial migratory abilities of mesenchymal HCC cells in vitro and Axl overexpression-induced metastatic colonization of epithelial hepatoma cells in vivo.  Importantly, Axl knockdown severely impaired resistance to TGF-β-mediated growth inhibition.  Anal. of the Axl interactome revealed binding of Axl to 14-3-3ζ, which is essentially required for Axl-mediated cell invasion, transendothelial migration, and resistance against TGF-β.  Axl/14-3-3ζ signaling caused phosphorylation of Smad3 linker region (Smad3L) at Ser213, resulting in the up-regulation of tumor-progressive TGF-β target genes such as PAI1, MMP9, and Snail as well as augmented TGF-β1 secretion in mesenchymal HCC cells.  Accordingly, high Axl expression in HCC patient samples correlated with elevated vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong phosphorylation of Smad3L, and lower survival.  In addn., elevated expression of both Axl and 14-3-3ζ showed strongly reduced survival of HCC patients.  Conclusion: Our data suggest that Axl/14-3-3ζ signaling is central for TGF-β-mediated HCC progression and a promising target for HCC therapy. (Hepatol. 2015;61:930-941).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYINc0VpFLaLVg90H21EOLACvtfcHk0lj5GmIAQO02Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D&md5=9a7978862c05e63ad91bea57520c6c89</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fhep.27492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27492%26sid%3Dliteratum%253Aachs%26aulast%3DReichl%26aufirst%3DP.%26aulast%3DDengler%26aufirst%3DM.%26aulast%3Dvan%2BZijl%26aufirst%3DF.%26aulast%3DHuber%26aufirst%3DH.%26aulast%3DF%25C3%25BChrlinger%26aufirst%3DG.%26aulast%3DReichel%26aufirst%3DC.%26aulast%3DSieghart%26aufirst%3DW.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DGrubinger%26aufirst%3DM.%26aulast%3DMikulits%26aufirst%3DW.%26atitle%3DAxl%2520activates%2520autocrine%2520transforming%2520growth%2520factor-beta%2520signaling%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D930%26epage%3D941%26doi%3D10.1002%2Fhep.27492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koorstra, J.-B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karikari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal-Rojas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offerhaus, G. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span> <span> </span><span class="NLM_article-title">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.4161/cbt.8.7.7923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.4161%2Fcbt.8.7.7923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=19252414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=618-626&author=J.-B.+M.+Koorstraauthor=C.+Karikariauthor=G.+Feldmannauthor=S.+Bishtauthor=P.+Leal-Rojasauthor=G.+J.+A.+Offerhausauthor=H.+Alvarezauthor=A.+Maitra&title=The+Axl+receptor+tyrosine+kinase+confers+an+adverse+prognostic+influence+in+pancreatic+cancer+and+represents+a+new+therapeutic+target&doi=10.4161%2Fcbt.8.7.7923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span></div><div class="casAuthors">Koorstra, Jan-Bart M.; Karikari, Collins A.; Feldmann, Georg; Bisht, Savita; Rojas, Pamela Leal; Offerhaus, G. Johan A.; Alvarez, Hector; Maitra, Anirban</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-626</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Background: Pancreatic cancer is a near uniformly lethal disease and a better understanding of the mol. basis of this malignancy may lead to improved therapeutics.  The Axl receptor tyrosine kinase is implicated in cellular transformation and tumor progression, although its role in pancreatic cancer has not been previously documented.  Results: Axl labeling was present in 54 of 99 (55%), and was absent in 45 of 99 (45%) cases, resp.  Axl expression in pancreatic cancer was significantly assocd. with lymph node metastases (p < 0.01), and a shorter median survival (12 vs. 18 mo, p < 0.01), than in tumors with neg. labeling.  Stable knockdown of Axl resulted in significant redn. in cell viability (p < 0.001), anchorage independent growth (p = 0.0031), as well as attenuation of migratory (p < 0.001) and invasive properties (p < 0.005), compared to vector-transfected cells.  Profound inhibition of p42/p44 MAP kinase and PI-3kinase/Akt effector pathways was obsd. in MIAPaCa-2 cells with loss of Axl function.  The redn. in invasion and migration upon Axl knockdown was mirrored by a decrease in the amts. of activated (GTP-bound) GTPase proteins Rho and Rac, significant downregulation in transcript levels of the epithelial mesenchymal transition (EMT)-assocd. transcription factors slug, snail and twist, and significant decrease in matrix metalloproteinase MMP-9 mRNA levels.  Materials: The immunohistochem. expression of Axl protein was assessed in a panel of 99 archival pancreatic cancers.  Endogenous Axl expression was stably downregulated by lentiviral short hairpin shRNA directed against AXL mRNA in MIAPaCa-2 cells, and the effects on cell viability, anchorage independent growth, invasion, migration and intracellular effector pathways was assessed, by comparing to lentiviral vector-transfected cells.  Conclusion: Expression of Axl tyrosine kinase in pancreatic cancers confers an adverse prognostic influence, and represents a new therapeutic target in this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVcT_EyeJ5LVg90H21EOLACvtfcHk0lj5GmIAQO02Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D&md5=36b9836411f2b315629eb951b8765a72</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4161%2Fcbt.8.7.7923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.8.7.7923%26sid%3Dliteratum%253Aachs%26aulast%3DKoorstra%26aufirst%3DJ.-B.%2BM.%26aulast%3DKarikari%26aufirst%3DC.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DBisht%26aufirst%3DS.%26aulast%3DLeal-Rojas%26aufirst%3DP.%26aulast%3DOfferhaus%26aufirst%3DG.%2BJ.%2BA.%26aulast%3DAlvarez%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DA.%26atitle%3DThe%2520Axl%2520receptor%2520tyrosine%2520kinase%2520confers%2520an%2520adverse%2520prognostic%2520influence%2520in%2520pancreatic%2520cancer%2520and%2520represents%2520a%2520new%2520therapeutic%2520target%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D618%26epage%3D626%26doi%3D10.4161%2Fcbt.8.7.7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, H.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasnoperov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bove, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buscarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretiakova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P. S.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1038%2Fbjc.2015.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26180925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=616-625&author=H.+Yuauthor=R.+Liuauthor=B.+Maauthor=X.+Liauthor=H.-y.+Yenauthor=Y.+Zhouauthor=V.+Krasnoperovauthor=Z.+Xiaauthor=X.+Zhangauthor=A.+M.+Boveauthor=M.+Buscariniauthor=D.+Parekhauthor=I.+S.+Gillauthor=Q.+Liaoauthor=M.+Tretiakovaauthor=D.+Quinnauthor=J.+Zhaoauthor=P.+S.+Gill&title=Axl+receptor+tyrosine+kinase+is+a+potential+therapeutic+target+in+renal+cell+carcinoma&doi=10.1038%2Fbjc.2015.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span></div><div class="casAuthors">Yu, H.; Liu, R.; Ma, B.; Li, X.; Yen, H.-Y.; Zhou, Y.; Krasnoperov, V.; Xia, Z.; Zhang, X.; Bove, A. M.; Buscarini, M.; Parekh, D.; Gill, I. S.; Liao, Q.; Tretiakova, M.; Quinn, D.; Zhao, J.; Gill, P. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">616-625</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Axl plays multiple roles in tumorigenesis in several cancers.  Here we evaluated the expression and biol. function of Axl in renal cell carcinoma (RCC).  Methods: Axl expression was analyzed in a tissue microarray of 174 RCC samples by immunostaining and a panel of 11 normal tumor pairs of human RCC tissues by western blot, as well as in RCC cell lines by both western blot and quant. PCR.  The effects of Axl knockdown in RCC cells on cell growth and signalling were investigated.  The efficacy of a humanized Axl targeting monoclonal antibody hMAb173 was tested in histoculture and tumor xenograft.  Results: We have detd. by immunohistochem. (IHC) that Axl is expressed in 59% of RCC array samples with moderate to high in 20% but not expressed in normal kidney tissue.  Western blot anal. of 11 pairs of tumor and adjacent normal tissue show high Axl expression in 73% of the tumors but not normal tissue.  Axl is also expressed in RCC cell lines in which Axl knockdown reduces cell viability and PI3K/Akt signalling.  The Axl antibody hMAb173 significantly induced RCC cell apoptosis in histoculture and inhibited the growth of RCC tumor in vivo by 78%.  The hMAb173-treated tumors also had significantly reduced Axl protein levels, inhibited PI3K signalling, decreased proliferation, and induced apoptosis.  Conclusions: Axl is highly expressed in RCC and crit. for RCC cell survival.  Targeting Axl is a potential approach for RCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKf4yyaQhWrVg90H21EOLACvtfcHk0lj5GmIAQO02Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO&md5=3f916c7beaa150038cbc5ed35594be29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.237%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYen%26aufirst%3DH.-y.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKrasnoperov%26aufirst%3DV.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBove%26aufirst%3DA.%2BM.%26aulast%3DBuscarini%26aufirst%3DM.%26aulast%3DParekh%26aufirst%3DD.%26aulast%3DGill%26aufirst%3DI.%2BS.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DTretiakova%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGill%26aufirst%3DP.%2BS.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520potential%2520therapeutic%2520target%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D616%26epage%3D625%26doi%3D10.1038%2Fbjc.2015.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longacre, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccia, A. J.</span></span> <span> </span><span class="NLM_article-title">Axl is an essential factor and therapeutic target for metastatic ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">7570</span>– <span class="NLM_lpage">7579</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-1267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-10-1267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=20858715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7570-7579&author=E.+B.+Rankinauthor=K.+C.+Fuhauthor=T.+E.+Taylorauthor=A.+J.+Kriegauthor=M.+Musserauthor=J.+Yuanauthor=K.+Weiauthor=C.+J.+Kuoauthor=T.+A.+Longacreauthor=A.+J.+Giaccia&title=Axl+is+an+essential+factor+and+therapeutic+target+for+metastatic+ovarian+cancer&doi=10.1158%2F0008-5472.can-10-1267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AXL is an essential factor and therapeutic target for metastatic ovarian cancer</span></div><div class="casAuthors">Rankin, Erinn B.; Fuh, Katherine C.; Taylor, Tiffany E.; Krieg, Adam J.; Musser, Margaret; Yuan, Jenny; Wei, Kevin; Kuo, Calvin J.; Longacre, Teri A.; Giaccia, Amato J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7570-7579</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease.  In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer.  AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium.  Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo.  Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity.  Most importantly, sol. human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity.  These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of metastatic tumor progression in vivo.  Furthermore, this study defines the sol. AXL receptor as a therapeutic candidate agent for treatment of metastatic ovarian cancer, for which current therapies are ineffective.  Cancer Res; 70(19); 7570-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPykmi9dwSQrVg90H21EOLACvtfcHk0liHpwxcMG5b7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akt7bN&md5=a8ff92ad8562bf72dc6defe54cc8cdfe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1267%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DFuh%26aufirst%3DK.%2BC.%26aulast%3DTaylor%26aufirst%3DT.%2BE.%26aulast%3DKrieg%26aufirst%3DA.%2BJ.%26aulast%3DMusser%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DKuo%26aufirst%3DC.%2BJ.%26aulast%3DLongacre%26aufirst%3DT.%2BA.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DAxl%2520is%2520an%2520essential%2520factor%2520and%2520therapeutic%2520target%2520for%2520metastatic%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7570%26epage%3D7579%26doi%3D10.1158%2F0008-5472.can-10-1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span> <span> </span><span class="NLM_article-title">The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.2147/ott.s150952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.2147%2FOTT.S150952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29416351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1MvovFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=509-519&author=S.+Zhangauthor=X.+S.+Xuauthor=J.+X.+Yangauthor=J.+H.+Guoauthor=T.+F.+Chaoauthor=Y.+Tong&title=The+prognostic+role+of+Gas6%2FAxl+axis+in+solid+malignancies%3A+a+meta-analysis+and+literature+review&doi=10.2147%2Fott.s150952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review</span></div><div class="casAuthors">Zhang Sheng; Xu Xiang Shang; Yang Jie Xi; Guo Jian Hui; Tong YiXin; Chao Teng Fei</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">509-519</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">Background:  Axl is a receptor tyrosine kinase that is involved in many pathological conditions and carcinogenesis.  Gas6 is the major ligand of Axl.  Activation of Gas6/Axl pathway is essential for cancer development.  However, its prognostic significance in solid tumors remains unclear.  Therefore, we performed this meta-analysis to elucidate the prognostic impact of Axl.  Methods:  Published studies on Axl or Gas6 expression and overall survival (OS) and/or disease-free survival (DFS) were searched from databases.  The outcome measurement is hazard ratio (HR) for OS or DFS related to Axl/Gas6 expression.  Meta-analysis was performed using RevMan.  The pooled HR was calculated by fixed-/random-effect models.  Results:  A total of 3,344 patients from 25 studies were included.  The results of meta-analysis showed that Axl overexpression was correlated with shorter OS (HR: 2.03, p<0.0001) and DFS (HR: 1.85, p<0.0001).  In subgroup analysis, Axl expression was significantly correlated with poor prognosis in hepatocellular, esophageal and lung cancer.  Axl expression was associated with differentiation grade, TNM stage, lymph node and distant metastasis.  Conclusion:  These results suggest that Axl overexpression is correlated with poor prognosis in solid tumors.  This correlation varies among different types of cancers.  More studies are needed to further investigate the prognostic value of Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6pIjsaYw3_f9pSBfyDvp7fW6udTcc2eZb94q61R9F-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvovFWqug%253D%253D&md5=b6c21c011378bfcbd50af1cdc6b92a42</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2147%2FOTT.S150952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S150952%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BX.%26aulast%3DGuo%26aufirst%3DJ.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BF.%26aulast%3DTong%26aufirst%3DY.%26atitle%3DThe%2520prognostic%2520role%2520of%2520Gas6%252FAxl%2520axis%2520in%2520solid%2520malignancies%253A%2520a%2520meta-analysis%2520and%2520literature%2520review%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D509%26epage%3D519%26doi%3D10.2147%2Fott.s150952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrigan, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braverman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toulany, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimple, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, D. L.</span></span> <span> </span><span class="NLM_article-title">Axl mediates resistance to cetuximab therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5164</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-14-0294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-14-0294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=25136066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFChtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5152-5164&author=T.+M.+Brandauthor=M.+Iidaauthor=A.+P.+Steinauthor=K.+L.+Corriganauthor=C.+M.+Bravermanauthor=N.+Lutharauthor=M.+Toulanyauthor=P.+S.+Gillauthor=R.+Salgiaauthor=R.+J.+Kimpleauthor=D.+L.+Wheeler&title=Axl+mediates+resistance+to+cetuximab+therapy&doi=10.1158%2F0008-5472.can-14-0294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Mediates Resistance to Cetuximab Therapy</span></div><div class="casAuthors">Brand, Toni M.; Iida, Mari; Stein, Andrew P.; Corrigan, Kelsey L.; Braverman, Cara M.; Luthar, Neha; Toulany, Mahmoud; Gill, Parkash S.; Salgia, Ravi; Kimple, Randall J.; Wheeler, Deric L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5152-5164</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clin. outcome.  In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL was overexpressed, activated, and tightly assocd. with EGFR expression in cells resistant to cetuximab (CtR cells).  Using RNAi methods and novel AXL-targeting agents, we found that AXL activation stimulated cell proliferation, EGFR activation, and MAPK signaling in CtxR cells.  Notably, EGFR directly regulated the expression of AXL mRNA through MAPK signaling and the transcription factor c-Jun in CtxR cells, creating a pos. feedback loop that maintained EGFR activation by AXL.  Cetuximab-sensitive parental cells were rendered resistant to cetuximab by stable overexpression of AXL or stimulation with EGFR ligands, the latter of which increased AXL activity and assocn. with the EGFR.  In tumor xenograft models, the development of resistance following prolonged treatment with cetuximab was assocd. with AXL hyperactivation and EGFR assocn.  Furthermore, in an examn. of patient-derived xenografts established from surgically resected HNSCCs, AXL was overexpressed and activated in tumors that displayed intrinsic resistance to cetuximab.  Collectively, our results identify AXL as a key mediator of cetuximab resistance, providing a rationale for clin. evaluation of AXL-targeting drugs to treat cetuximab- resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN2dPn1qh9vLVg90H21EOLACvtfcHk0liHpwxcMG5b7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFChtbfO&md5=7ecf9686e615d247f010b59f480699f6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0294%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DT.%2BM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DStein%26aufirst%3DA.%2BP.%26aulast%3DCorrigan%26aufirst%3DK.%2BL.%26aulast%3DBraverman%26aufirst%3DC.%2BM.%26aulast%3DLuthar%26aufirst%3DN.%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DP.%2BS.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DKimple%26aufirst%3DR.%2BJ.%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26atitle%3DAxl%2520mediates%2520resistance%2520to%2520cetuximab%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5152%26epage%3D5164%26doi%3D10.1158%2F0008-5472.can-14-0294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkabets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazarentzos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelossof, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzaken, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixidó, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Axl mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.ccell.2015.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=25873175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=533-546&author=M.+Elkabetsauthor=E.+Pazarentzosauthor=D.+Juricauthor=Q.+Shengauthor=R.+A.+Pelossofauthor=S.+Brookauthor=A.+O.+Benzakenauthor=J.+Rodonauthor=N.+Morseauthor=J.+J.+Yanauthor=M.+Liuauthor=R.+Dasauthor=Y.+Chenauthor=A.+Tamauthor=H.+Wangauthor=J.+Liangauthor=J.+M.+Gurskiauthor=D.+A.+Kerrauthor=R.+Rosellauthor=C.+Teixid%C3%B3author=A.+Huangauthor=R.+A.+Ghosseinauthor=N.+Rosenauthor=T.+G.+Bivonaauthor=M.+Scaltritiauthor=J.+Baselga&title=Axl+mediates+resistance+to+PI3Kalpha+inhibition+by+activating+the+EGFR%2FPKC%2FmTOR+axis+in+head+and+neck+and+esophageal+squamous+cell+carcinomas&doi=10.1016%2Fj.ccell.2015.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span></div><div class="casAuthors">Elkabets, Moshe; Pazarentzos, Evangelos; Juric, Dejan; Sheng, Qing; Pelossof, Raphael A.; Brook, Samuel; Benzaken, Ana Oaknin; Rodon, Jordi; Morse, Natasha; Yan, Jenny Jiacheng; Liu, Manway; Das, Rita; Chen, Yan; Tam, Angela; Wang, Huiqin; Liang, Jinsheng; Gurski, Joseph M.; Kerr, Darcy A.; Rosell, Rafael; Teixido, Cristina; Huang, Alan; Ghossein, Ronald A.; Rosen, Neal; Bivona, Trever G.; Scaltriti, Maurizio; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-546</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clin. activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification.  Studying models of therapeutic resistance, we have obsd. that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR).  This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL.  AXL is overexpressed in resistant tumors from both lab. models and patients treated with the PI3Kα inhibitor BYL719.  AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR.  Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkH5_tNi2YrVg90H21EOLACvtfcHk0lgCxw7C6XNEaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D&md5=55b0362b0e32f0c305c5257aa66ecdc5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DElkabets%26aufirst%3DM.%26aulast%3DPazarentzos%26aufirst%3DE.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DPelossof%26aufirst%3DR.%2BA.%26aulast%3DBrook%26aufirst%3DS.%26aulast%3DBenzaken%26aufirst%3DA.%2BO.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DMorse%26aufirst%3DN.%26aulast%3DYan%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DGurski%26aufirst%3DJ.%2BM.%26aulast%3DKerr%26aufirst%3DD.%2BA.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DGhossein%26aufirst%3DR.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DAxl%2520mediates%2520resistance%2520to%2520PI3Kalpha%2520inhibition%2520by%2520activating%2520the%2520EGFR%252FPKC%252FmTOR%2520axis%2520in%2520head%2520and%2520neck%2520and%2520esophageal%2520squamous%2520cell%2520carcinomas%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D533%26epage%3D546%26doi%3D10.1016%2Fj.ccell.2015.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaola, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. R.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">15321</span>– <span class="NLM_lpage">15331</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.18632%2Foncotarget.4148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26036314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=15321-15331&author=N.+Bansalauthor=P.+J.+Mishraauthor=M.+Steinauthor=R.+S.+DiPaolaauthor=J.+R.+Bertino&title=Axl+receptor+tyrosine+kinase+is+up-regulated+in+metformin+resistant+prostate+cancer+cells&doi=10.18632%2Foncotarget.4148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span></div><div class="casAuthors">Bansal Nitu; Stein Mark; DiPaola Robert S; Bertino Joseph R; Mishra Prasun J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">15321-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent epidemiological studies showed that metformin, a widely used anti-diabetic drug might prevent certain cancers.  Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress.  However, all cancer types do not respond to metformin with the same effectiveness or acquire resistance.  To understand the mechanism of acquired resistance and possibly its mechanism of action as an anti-proliferative agent, we developed metformin resistant LNCaP prostate cancer cells.  Metformin resistant LNCaP cells had an increased proliferation rate, increased migration and invasion ability as compared to the parental cells, and expressed markers of epithelial-mesenchymal transition (EMT).  A detailed gene expression microarray comparing the resistant cells to the wild type cells revealed that Edil2, Ereg, Axl, Anax2, CD44 and Anax3 were the top up-regulated genes and calbindin 2 and TPTE (transmembrane phosphatase with tensin homology) and IGF1R were down regulated.  We focused on Axl, a receptor tyrosine kinase that has been shown to be up regulated in several drug resistance cancers.  Here, we show that the metformin resistant cell line as well as castrate resistant cell lines that over express Axl were more resistant to metformin, as well as to taxotere compared to androgen sensitive LNCaP and CWR22 cells that do not overexpress Axl.  Forced overexpression of Axl in LNCaP cells decreased metformin and taxotere sensitivity and knockdown of Axl in resistant cells increased sensitivity to these drugs.  Inhibition of Axl activity by R428, a small molecule Axl kinase inhibitor, sensitized metformin resistant cells that overexpressed Axl to metformin.  Inhibitors of Axl may enhance tumor responses to metformin and other chemotherapy in cancers that over express Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzxVEroSz9hdj_Vg2vObihfW6udTcc2eYd6Bv7aXyqY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D&md5=6dea3f587be6fb98b50e817d3735e7ef</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4148%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DP.%2BJ.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DDiPaola%26aufirst%3DR.%2BS.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520up-regulated%2520in%2520metformin%2520resistant%2520prostate%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D15321%26epage%3D15331%26doi%3D10.18632%2Foncotarget.4148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.-G.</span></span> <span> </span><span class="NLM_article-title">Targeting Axl overcomes resistance to docetaxel therapy in advanced prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">41064</span>– <span class="NLM_lpage">41077</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.18632%2Foncotarget.17026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28455956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1crisVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=41064-41077&author=J.-Z.+Linauthor=Z.-J.+Wangauthor=W.+Deauthor=M.+Zhengauthor=W.-Z.+Xuauthor=H.-F.+Wuauthor=A.+Armstrongauthor=J.-G.+Zhu&title=Targeting+Axl+overcomes+resistance+to+docetaxel+therapy+in+advanced+prostate+cancer&doi=10.18632%2Foncotarget.17026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer</span></div><div class="casAuthors">Lin Jian-Zhong; Wu Hong-Fei; Wang Zeng-Jun; Zheng Ming; De Wei; Xu Wei-Zhang; Armstrong Alex; Zhu Jia-Geng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">41064-41077</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resistance to docetaxel is a major clinical problem in advanced prostate cancer.  The overexpression of AXL receptor tyrosine kinase (AXL) has been correlated with chemotherapeutic drug resistance.  However, the role of AXL expression in docetaxel resistance in prostate cancer is yet unclear.  In this study, we demonstrate that AXL is overexpressed and activated independent of Gas6 in docetaxel-resistant prostate cancer cells (PC3-DR and DU145-DR).  Moreover, we show that forced overexpression of AXL in PC3 and DU145 cells is sufficient to induce resistance to docetaxel in these cell lines.  Notably, genetic or pharmacologic inhibition of AXL in the resistant models suppressed cell proliferation, migration, invasion, and tumor growth, and these effects were significantly augmented when AXL inhibition was combined with docetaxel treatment.  Mechanistically, we found that AXL inhibition led to reversion of the epithelial-mesenchymal transition (EMT) phenotype and decreased the expression of ATP-binding cassette B1 (ABCB1).  Overall, our results identify AXL as an important mediator of docetaxel resistance in prostate cancer.  We propose that AXL-targeted therapy, in combination with docetaxel, has the potential to improve the response to docetaxel therapy and reduce resistance induced by prolonged docetaxel therapy in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStOUb0jAA20IvKgEt20y1XfW6udTcc2eYd6Bv7aXyqY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crisVKjsw%253D%253D&md5=bacbf1956d79c39e8c71f49d82157036</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17026%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.-Z.%26aulast%3DWang%26aufirst%3DZ.-J.%26aulast%3DDe%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DW.-Z.%26aulast%3DWu%26aufirst%3DH.-F.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DJ.-G.%26atitle%3DTargeting%2520Axl%2520overcomes%2520resistance%2520to%2520docetaxel%2520therapy%2520in%2520advanced%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D41064%26epage%3D41077%26doi%3D10.18632%2Foncotarget.17026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaretsky, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu-Lieskovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berent-Maoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seja, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomeli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.02.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.cell.2016.02.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26997480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVKrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=35-44&author=W.+Hugoauthor=J.+M.+Zaretskyauthor=L.+Sunauthor=C.+Songauthor=B.+H.+Morenoauthor=S.+Hu-Lieskovanauthor=B.+Berent-Maozauthor=J.+Pangauthor=B.+Chmielowskiauthor=G.+Cherryauthor=E.+Sejaauthor=S.+Lomeliauthor=X.+Kongauthor=M.+C.+Kelleyauthor=J.+A.+Sosmanauthor=D.+B.+Johnsonauthor=A.+Ribasauthor=R.+S.+Lo&title=Genomic+and+transcriptomic+features+of+response+to+anti-PD-1+therapy+in+metastatic+melanoma&doi=10.1016%2Fj.cell.2016.02.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma</span></div><div class="casAuthors">Hugo, Willy; Zaretsky, Jesse M.; Sun, Lu; Song, Chunying; Moreno, Blanca Homet; Hu-Lieskovan, Siwen; Berent-Maoz, Beata; Pang, Jia; Chmielowski, Bartosz; Cherry, Grace; Seja, Elizabeth; Lomeli, Shirley; Kong, Xiangju; Kelley, Mark C.; Sosman, Jeffrey A.; Johnson, Douglas B.; Ribas, Antoni; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1 immune checkpoint blockade provides significant clin. benefits for melanoma patients.  We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy.  We find that overall high mutational loads assoc. with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2.  Innately resistant tumors display a transcriptional signature (referred to as the IPRES, or innate anti-PD-1 resistance), indicating concurrent up-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing.  Notably, mitogen-activated protein kinase (MAPK)-targeted therapy (MAPK inhibitor) induces similar signatures in melanoma, suggesting that a non-genomic form of MAPK inhibitor resistance mediates cross-resistance to anti-PD-1 therapy.  Validation of the IPRES in other independent tumor cohorts defines a transcriptomic subset across distinct types of advanced cancer.  These findings suggest that attenuating the biol. processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqG8tlIw784rVg90H21EOLACvtfcHk0liAtGJE6Vx2zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVKrsbw%253D&md5=6dc9125a9b933c81f63678c093d9c45f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.02.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.02.065%26sid%3Dliteratum%253Aachs%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DZaretsky%26aufirst%3DJ.%2BM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DB.%2BH.%26aulast%3DHu-Lieskovan%26aufirst%3DS.%26aulast%3DBerent-Maoz%26aufirst%3DB.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DCherry%26aufirst%3DG.%26aulast%3DSeja%26aufirst%3DE.%26aulast%3DLomeli%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DGenomic%2520and%2520transcriptomic%2520features%2520of%2520response%2520to%2520anti-PD-1%2520therapy%2520in%2520metastatic%2520melanoma%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D35%26epage%3D44%26doi%3D10.1016%2Fj.cell.2016.02.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristova, K.</span></span> <span> </span><span class="NLM_article-title">The RTK interactome: overview and perspective on RTK heterointeractions</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">5881</span>– <span class="NLM_lpage">5921</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=5881-5921&author=M.+D.+Paulauthor=K.+Hristova&title=The+RTK+interactome%3A+overview+and+perspective+on+RTK+heterointeractions&doi=10.1021%2Facs.chemrev.8b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The RTK interactome: Overview and perspective on RTK heterointeractions</span></div><div class="casAuthors">Paul, Michael D.; Hristova, Kalina</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5881-5921</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) play important roles in cell growth, motility, differentiation, and survival.  These single-pass membrane proteins are grouped into subfamilies based on the similarity of their extracellular domains.  They are generally thought to be activated by ligand binding, which promotes homodimerization and then autophosphorylation in trans.  However, RTK interactions are more complicated, as RTKs can interact in the absence of ligand and heterodimerize within and across subfamilies.  Here, we review the known cross-subfamily RTK heterointeractions and their possible biol. implications, as well as the methodologies which have been used to study them.  Moreover, we demonstrate how thermodn. models can be used to study RTKs and to explain many of the complicated biol. effects which have been described in the literature.  Finally, we discuss the concept of the RTK interactome: a putative, extensive network of interactions between the RTKs.  This RTK interactome can produce unique signaling outputs; can amplify, inhibit, and modify signaling; and can allow for signaling backups.  The existence of the RTK interactome could provide an explanation for the irreproducibility of exptl. data from different studies and for the failure of some RTK inhibitors to produce the desired therapeutic effects.  We argue that a deeper knowledge of RTK interactome thermodn. can lead to a better understanding of fundamental RTK signaling processes in health and disease.  We further argue that there is a need for quant., thermodn. studies that probe the strengths of the interactions between RTKs and their ligands and between different RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdTycRThC6O7Vg90H21EOLACvtfcHk0liAtGJE6Vx2zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bK&md5=5948f386d74206ef230e2dc0522fd0ee</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00467%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DM.%2BD.%26aulast%3DHristova%26aufirst%3DK.%26atitle%3DThe%2520RTK%2520interactome%253A%2520overview%2520and%2520perspective%2520on%2520RTK%2520heterointeractions%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D5881%26epage%3D5921%26doi%3D10.1021%2Facs.chemrev.8b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salian-Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierman, M. E.</span></span> <span> </span><span class="NLM_article-title">Axl and Met crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.mce.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23648337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2013&pages=92-100&author=S.+Salian-Mehtaauthor=M.+Xuauthor=M.+E.+Wierman&title=Axl+and+Met+crosstalk+to+promote+gonadotropin+releasing+hormone+%28GnRH%29+neuronal+cell+migration+and+survival&doi=10.1016%2Fj.mce.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span></div><div class="casAuthors">Salian-Mehta, Smita; Xu, Mei; Wierman, Margaret E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">92-100</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The membrane tyrosine kinase receptors, AXL and MET, are implicated in GnRH neuron migration and/or survival.  We hypothesized that the receptors with their ligands, GAS6 and HGF, resp. may cross-talk in GnRH neuronal function.  In NLT GnRH neuronal cells, MET co-immunopptd. with AXL, although HGF or GAS6 did not transphosphorylate AXL or MET, resp.  Co-expression of a kinase dead AXL blocked HGF activation of MET and indirectly AKT and p38MAPK.  Silencing of AXL decreased HGF's ability to phosphorylate MET and activate AXL's downstream effectors, p38MAPK and AKT.  HGF/MET signaling modulated neuron migration dependent and independent of AXL co-expression and p38MAPK.  Conversely, AXL's control of GnRH neuronal survival was dependent on HGF/MET signaling.  Together, these data support that the importance of membrane tyrosine kinase receptor crosstalk to regulate neuronal cell-specific developmental functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFg8H1UC0HerVg90H21EOLACvtfcHk0liAtGJE6Vx2zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D&md5=de528dce1d3a19fe4392b25017d3cbb0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DSalian-Mehta%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWierman%26aufirst%3DM.%2BE.%26atitle%3DAxl%2520and%2520Met%2520crosstalk%2520to%2520promote%2520gonadotropin%2520releasing%2520hormone%2520%2528GnRH%2529%2520neuronal%2520cell%2520migration%2520and%2520survival%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D374%26spage%3D92%26epage%3D100%26doi%3D10.1016%2Fj.mce.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belfiore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabras, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guaglio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deraco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span> <span> </span><span class="NLM_article-title">Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.3390/ijms20225817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.3390%2Fijms20225817" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=13&author=A.+Belfioreauthor=A.+Busicoauthor=F.+Bozziauthor=S.+Brichauthor=E.+Dalleraauthor=E.+Concaauthor=I.+Caponeauthor=A.+Gloghiniauthor=C.+C.+Volpiauthor=A.+D.+Cabrasauthor=S.+Pilottiauthor=D.+Barattiauthor=M.+Guaglioauthor=M.+Deracoauthor=S.+Kusamuraauthor=F.+Perrone&title=Molecular+signatures+for+combined+targeted+treatments+in+diffuse+malignant+peritoneal+mesothelioma&doi=10.3390%2Fijms20225817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3390%2Fijms20225817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20225817%26sid%3Dliteratum%253Aachs%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DBusico%26aufirst%3DA.%26aulast%3DBozzi%26aufirst%3DF.%26aulast%3DBrich%26aufirst%3DS.%26aulast%3DDallera%26aufirst%3DE.%26aulast%3DConca%26aufirst%3DE.%26aulast%3DCapone%26aufirst%3DI.%26aulast%3DGloghini%26aufirst%3DA.%26aulast%3DVolpi%26aufirst%3DC.%2BC.%26aulast%3DCabras%26aufirst%3DA.%2BD.%26aulast%3DPilotti%26aufirst%3DS.%26aulast%3DBaratti%26aufirst%3DD.%26aulast%3DGuaglio%26aufirst%3DM.%26aulast%3DDeraco%26aufirst%3DM.%26aulast%3DKusamura%26aufirst%3DS.%26aulast%3DPerrone%26aufirst%3DF.%26atitle%3DMolecular%2520signatures%2520for%2520combined%2520targeted%2520treatments%2520in%2520diffuse%2520malignant%2520peritoneal%2520mesothelioma%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D13%26doi%3D10.3390%2Fijms20225817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardnell, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoulidis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-15-0876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F1078-0432.CCR-15-0876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26420858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFeru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=609-620&author=M.+P.+Makauthor=P.+Tongauthor=L.+Diaoauthor=R.+J.+Cardnellauthor=D.+L.+Gibbonsauthor=W.+N.+Williamauthor=F.+Skoulidisauthor=E.+R.+Parraauthor=J.+Rodriguez-Canalesauthor=I.+I.+Wistubaauthor=J.+V.+Heymachauthor=J.+N.+Weinsteinauthor=K.+R.+Coombesauthor=J.+Wangauthor=L.+A.+Byers&title=A+patient-derived%2C+pan-cancer+EMT+signature+identifies+global+molecular+alterations+and+immune+target+enrichment+following+epithelial-to-mesenchymal+transition&doi=10.1158%2F1078-0432.ccr-15-0876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition</span></div><div class="casAuthors">Mak, Milena P.; Tong, Pan; Diao, Lixia; Cardnell, Robert J.; Gibbons, Don L.; William, William N.; Skoulidis, Ferdinandos; Parra, Edwin R.; Rodriguez-Canales, Jaime; Wistuba, Ignacio I.; Heymach, John V.; Weinstein, John N.; Coombes, Kevin R.; Wang, Jing; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">609-620</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We previously demonstrated the assocn. between epithelial-to-mesenchymal transition (EMT) and drug response in lung cancer using an EMT signature derived in cancer cell lines.  Given the contribution of tumor microenvironments to EMT, we extended our investigation of EMT to patient tumors from 11 cancer types to develop a pan-cancer EMT signature.  Using the pan-cancer EMT signature, we conducted an integrated, global anal. of genomic and proteomic profiles assocd. with EMT across 1,934 tumors including breast, lung, colon, ovarian, and bladder cancers.  Differences in outcome and in vitro drug response corresponding to expression of the pan-cancer EMT signature were also investigated.  Compared with the lung cancer EMT signature, the patient-derived, pan-cancer EMT signature encompasses a set of core EMT genes that correlate even more strongly with known EMT markers across diverse tumor types and identifies differences in drug sensitivity and global mol. alterations at the DNA, RNA, and protein levels.  Among those changes assocd. with EMT, pathway anal. revealed a strong correlation between EMT and immune activation.  Further supervised anal. demonstrated high expression of immune checkpoints and other druggable immune targets, such as PD1, PD-L1, CTLA4, OX40L, and PD-L2, in tumors with the most mesenchymal EMT scores.  Elevated PD-L1 protein expression in mesenchymal tumors was confirmed by IHC in an independent lung cancer cohort.  This new signature provides a novel, patient-based, histol.-independent tool for the investigation of EMT and offers insights into potential novel therapeutic targets for mesenchymal tumors, independent of cancer type, including immune checkpoints.  Clin Cancer Res; 22(3); 609-20. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCJX6douXHMbVg90H21EOLACvtfcHk0lhFG1CfbDfqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFeru7c%253D&md5=28dea196f02aa0f7410140a1f89d13e3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0876%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DM.%2BP.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DWilliam%26aufirst%3DW.%2BN.%26aulast%3DSkoulidis%26aufirst%3DF.%26aulast%3DParra%26aufirst%3DE.%2BR.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DA%2520patient-derived%252C%2520pan-cancer%2520EMT%2520signature%2520identifies%2520global%2520molecular%2520alterations%2520and%2520immune%2520target%2520enrichment%2520following%2520epithelial-to-mesenchymal%2520transition%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D609%26epage%3D620%26doi%3D10.1158%2F1078-0432.ccr-15-0876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saintigny, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giri, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumula, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudikote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardnell, R. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulks, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-12-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F1078-0432.CCR-12-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23091115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=279-290&author=L.+A.+Byersauthor=L.+Diaoauthor=J.+Wangauthor=P.+Saintignyauthor=L.+Girardauthor=M.+Peytonauthor=L.+Shenauthor=Y.+Fanauthor=U.+Giriauthor=P.+K.+Tumulaauthor=M.+B.+Nilssonauthor=J.+Gudikoteauthor=H.+Tranauthor=R.+J.+G.+Cardnellauthor=D.+J.+Bearssauthor=S.+L.+Warnerauthor=J.+M.+Foulksauthor=S.+B.+Kannerauthor=V.+Gandhiauthor=N.+Krettauthor=S.+T.+Rosenauthor=E.+S.+Kimauthor=R.+S.+Herbstauthor=G.+R.+Blumenscheinauthor=J.+J.+Leeauthor=S.+M.+Lippmanauthor=K.+K.+Angauthor=G.+B.+Millsauthor=W.+K.+Hongauthor=J.+N.+Weinsteinauthor=I.+I.+Wistubaauthor=K.+R.+Coombesauthor=J.+D.+Minnaauthor=J.+V.+Heymach&title=An+epithelial-mesenchymal+transition+gene+signature+predicts+resistance+to+EGFR+and+PI3K+inhibitors+and+identifies+Axl+as+a+therapeutic+target+for+overcoming+EGFR+inhibitor+resistance&doi=10.1158%2F1078-0432.ccr-12-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance</span></div><div class="casAuthors">Byers, Lauren Averett; Diao, Lixia; Wang, Jing; Saintigny, Pierre; Girard, Luc; Peyton, Michael; Shen, Li; Fan, Youhong; Giri, Uma; Tumula, Praveen K.; Nilsson, Monique B.; Gudikote, Jayanthi; Tran, Hai; Cardnell, Robert J. G.; Bearss, David J.; Warner, Steven L.; Foulks, Jason M.; Kanner, Steven B.; Gandhi, Varsha; Krett, Nancy; Rosen, Steven T.; Kim, Edward S.; Herbst, Roy S.; Blumenschein, George R.; Lee, J. Jack; Lippman, Scott M.; Ang, K. Kian; Mills, Gordon B.; Hong, Waun K.; Weinstein, John N.; Wistuba, Ignacio I.; Coombes, Kevin R.; Minna, John D.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Epithelial-mesenchymal transition (EMT) has been assocd. with metastatic spread and EGF receptor (EGFR) inhibitor resistance.  We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.  Exptl. Design: We conducted an integrated gene expression, proteomic, and drug response anal. using cell lines and tumors from patients with NSCLC.  A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms of NSCLC cell lines and patients treated in the BATTLE study, and potential therapeutic targets assocd. with EMT were identified.  Results: Compared with epithelial cells, mesenchymal cells showed significantly greater resistance to EGFR and PI3K/Akt pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies.  Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.  In patients with NSCLC, the EMT signature predicted 8-wk disease control in patients receiving erlotinib but not other therapies.  Conclusion: We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance assocd. with the mesenchymal phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwav-PXLuwi7Vg90H21EOLACvtfcHk0lhFG1CfbDfqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D&md5=d02e08e505b8487a48874abdb8a553a9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1558%26sid%3Dliteratum%253Aachs%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGiri%26aufirst%3DU.%26aulast%3DTumula%26aufirst%3DP.%2BK.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DGudikote%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%2BG.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DFoulks%26aufirst%3DJ.%2BM.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DKrett%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DAn%2520epithelial-mesenchymal%2520transition%2520gene%2520signature%2520predicts%2520resistance%2520to%2520EGFR%2520and%2520PI3K%2520inhibitors%2520and%2520identifies%2520Axl%2520as%2520a%2520therapeutic%2520target%2520for%2520overcoming%2520EGFR%2520inhibitor%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D279%26epage%3D290%26doi%3D10.1158%2F1078-0432.ccr-12-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamichi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyanaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, A.</span></span> <span> </span><span class="NLM_article-title">Overcoming drug-tolerant cancer cell subpopulations showing Axl activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">27242</span>– <span class="NLM_lpage">27255</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.18632%2Foncotarget.25531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29930762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fgs1ersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=27242-27255&author=S.+Nakamichiauthor=M.+Seikeauthor=A.+Miyanagaauthor=M.+Chibaauthor=F.+Zouauthor=A.+Takahashiauthor=A.+Ishikawaauthor=S.+Kunugiauthor=R.+Noroauthor=K.+Kubotaauthor=A.+Gemma&title=Overcoming+drug-tolerant+cancer+cell+subpopulations+showing+Axl+activation+and+epithelial-mesenchymal+transition+is+critical+in+conquering+ALK-positive+lung+cancer&doi=10.18632%2Foncotarget.25531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer</span></div><div class="casAuthors">Nakamichi Shinji; Seike Masahiro; Miyanaga Akihiko; Chiba Mika; Zou Fenfei; Takahashi Akiko; Noro Rintaro; Kubota Kaoru; Gemma Akihiko; Ishikawa Arimi; Kunugi Shinobu</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">27242-27255</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) induce a dramatic response in non-small cell lung cancer (NSCLC) patients with the ALK fusion gene.  However, acquired resistance to ALK-TKIs remains an inevitable problem.  In this study, we aimed to discover novel therapeutic targets to conquer ALK-positive lung cancer.  We established three types of ALK-TKI (crizotinib, alectinib and ceritinib)-resistant H2228 NSCLC cell lines by high exposure and stepwise methods.  We found these cells showed a loss of ALK signaling, overexpressed AXL with epithelial-mesenchymal transition (EMT), and had cancer stem cell-like (CSC) properties, suggesting drug-tolerant cancer cell subpopulations.  Similarly, we demonstrated that TGF-β1 treated H2228 cells also showed AXL overexpression with EMT features and ALK-TKI resistance.  The AXL inhibitor, R428, or HSP90 inhibitor, ganetespib, were effective in reversing ALK-TKI resistance and EMT changes in both ALK-TKI-resistant and TGF-β1-exposed H2228 cells.  Tumor volumes of xenograft mice implanted with established H2228-ceritinib-resistant (H2228-CER) cells were significantly reduced after treatment with ganetespib, or ganetespib in combination with ceritinib.  Some ALK-positive NSCLC patients with AXL overexpression showed a poorer response to crizotinib therapy than patients with a low expression of AXL.  ALK signaling-independent AXL overexpressed in drug-tolerant cancer cell subpopulations with EMT and CSC features may be commonly involved commonly involved in intrinsic and acquired resistance to ALK-TKIs.  This suggests AXL and HSP90 inhibitors may be promising therapeutic drugs to overcome drug-tolerant cancer cell subpopulations in ALK-positive NSCLC patients for the reason that ALK-positive NSCLC cells do not live through ALK-TKI therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd9KJdxsHx--Lt9HypzAgQfW6udTcc2eZFB9BBb0jpmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fgs1ersw%253D%253D&md5=25a466edcea1dd1f44195e587626d57e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25531%26sid%3Dliteratum%253Aachs%26aulast%3DNakamichi%26aufirst%3DS.%26aulast%3DSeike%26aufirst%3DM.%26aulast%3DMiyanaga%26aufirst%3DA.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DA.%26aulast%3DKunugi%26aufirst%3DS.%26aulast%3DNoro%26aufirst%3DR.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DGemma%26aufirst%3DA.%26atitle%3DOvercoming%2520drug-tolerant%2520cancer%2520cell%2520subpopulations%2520showing%2520Axl%2520activation%2520and%2520epithelial-mesenchymal%2520transition%2520is%2520critical%2520in%2520conquering%2520ALK-positive%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D27242%26epage%3D27255%26doi%3D10.18632%2Foncotarget.25531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemann, D. W.</span></span> <span> </span><span class="NLM_article-title">Gas6/Axl signaling pathway in the tumor immune microenvironment</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1850</span>, <span class="refDoi"> DOI: 10.3390/cancers12071850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.3390%2Fcancers12071850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKnur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1850&author=M.+Tanakaauthor=D.+W.+Siemann&title=Gas6%2FAxl+signaling+pathway+in+the+tumor+immune+microenvironment&doi=10.3390%2Fcancers12071850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6/Axl signaling pathway in the tumor immune microenvironment</span></div><div class="casAuthors">Tanaka, Mai; Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1850</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases have been shown to dysregulate a no. of pathways assocd. with tumor development, progression, and metastasis.  Axl is a receptor tyrosine kinase expressed in many cancer types and has been assocd. with therapy resistance and poor clin. prognosis and outcomes.  In addn., Axl and its ligand growth arrest specific 6 (Gas6) protein are expressed by a no. of host cells.  The Gas6/Axl signaling pathway has been implicated in the promotion of tumor cell proliferation, survival, migration, invasion, angiogenesis, and immune evasion.  As a result, Axl is an attractive, novel therapeutic target to impair multiple stages of tumor progression from both neoplastic and host cell axes.  This review focuses on the role of the Gas6/Axl signaling pathway in promoting the immunosuppressive tumor microenvironment, as immune evasion is considered one of the hallmarks of cancer.  The review discusses the structure and activation of the Gas6/Axl signaling pathway, GAS6 and AXL expression patterns in the tumor microenvironment, mechanisms of Axl-mediated tumor immune response, and the role of Gas6/Axl signaling in immune cell recruitment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYxCwzKOzcbVg90H21EOLACvtfcHk0lgP-k-M4mT6Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKnur7L&md5=cba755674ebeeeac3b16c9718afb6340</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3390%2Fcancers12071850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12071850%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DGas6%252FAxl%2520signaling%2520pathway%2520in%2520the%2520tumor%2520immune%2520microenvironment%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1850%26doi%3D10.3390%2Fcancers12071850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span> <span> </span><span class="NLM_article-title">Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β-catenin signaling</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.7150/thno.15083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.7150%2Fthno.15083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=27279912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFersrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1205-1219&author=C.+Wangauthor=H.+Jinauthor=N.+Wangauthor=S.+Fanauthor=Y.+Wangauthor=Y.+Zhangauthor=L.+Weiauthor=X.+Taoauthor=D.+Guauthor=F.+Zhaoauthor=J.+Fangauthor=M.+Yaoauthor=W.+Qin&title=Gas6%2FAxl+axis+contributes+to+chemoresistance+and+metastasis+in+breast+cancer+through+Akt%2FGSK-3%CE%B2%2F%CE%B2-catenin+signaling&doi=10.7150%2Fthno.15083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β-catenin signaling</span></div><div class="casAuthors">Wang, Cun; Jin, Haojie; Wang, Ning; Fan, Shaohua; Wang, Yanyan; Zhang, Yurong; Wei, Lin; Tao, Xuemei; Gu, Dishui; Zhao, Fangyu; Fang, Jingyuan; Yao, Ming; Qin, Wenxin</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1205-1219</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Chemoresistance in breast cancer has been of great interest in past studies.  However, the development of rational therapeutic strategies targeting chemoresistant cells is still a challenge in clin. oncol.  By integrating data from global differences of gene expression and phospho-receptor tyrosine kinases between sensitive parental cells (MCF-7) and doxorubicin-resistant cells (MCF-7/ADR), we identified Axl as a potential target for chemoresistance and metastasis in multidrug resistant breast cancer cells.  We analyzed Axl expression in 57 breast cancer cell lines and detected a dramatic increase in its expression level in mesenchymal breast cancer cell lines.  Axl silencing suppressed invasive and metastatic potentials of chemoresistant breast cancer cells as well as increased elimination of cancer cells when combined with doxorubicin.  Furthermore, in preclin. assays, an Axl inhibitor R428 showed increased cell death upon doxorubicin treatment.  Addnl., using phospho-kinase array based proteomic anal., we identified that Akt/GSK-3β/β-catenin cascade was responsible for Axl-induced cell invasion.  Nuclear translocation of β-catenin then induced transcriptional upregulation of ZEB1, which in turn regulated DNA damage repair and doxorubicin-resistance in breast cancer cells.  Most importantly, Axl was correlated with its downstream targets in tumor samples and was assocd. with poor prognosis in breast cancer patients.  These results demonstrate that Gas6/Axl axis confers aggressiveness in breast cancer and may represent a therapeutic target for chemoresistance and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNND2-ZStJbVg90H21EOLACvtfcHk0lgP-k-M4mT6Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFersrfN&md5=d4bd2d77b51e9397587f45519a36dbe6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.7150%2Fthno.15083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15083%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DW.%26atitle%3DGas6%252FAxl%2520axis%2520contributes%2520to%2520chemoresistance%2520and%2520metastasis%2520in%2520breast%2520cancer%2520through%2520Akt%252FGSK-3%25CE%25B2%252F%25CE%25B2-catenin%2520signaling%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D1205%26epage%3D1219%26doi%3D10.7150%2Fthno.15083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aguilera, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shehade, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariolis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Eyben, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellies, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koong, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccia, A. J.</span></span> <span> </span><span class="NLM_article-title">Reprogramming the immunological microenvironment through radiation and targeting Axl</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13898</span>, <span class="refDoi"> DOI: 10.1038/ncomms13898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1038%2Fncomms13898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28008921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGit7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13898&author=T.+A.+Aguileraauthor=M.+Rafatauthor=L.+Castelliniauthor=H.+Shehadeauthor=M.+S.+Kariolisauthor=A.+B.-Y.+Huiauthor=H.+Stehrauthor=R.+von+Eybenauthor=D.+Jiangauthor=L.+G.+Elliesauthor=A.+C.+Koongauthor=M.+Diehnauthor=E.+B.+Rankinauthor=E.+E.+Gravesauthor=A.+J.+Giaccia&title=Reprogramming+the+immunological+microenvironment+through+radiation+and+targeting+Axl&doi=10.1038%2Fncomms13898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Reprogramming the immunological microenvironment through radiation and targeting Axl</span></div><div class="casAuthors">Aguilera, Todd A.; Rafat, Marjan; Castellini, Laura; Shehade, Hussein; Kariolis, Mihalis S.; Hui, Angela Bik-Yu; Stehr, Henning; von Eyben, Rie; Jiang, Dadi; Ellies, Lesley G.; Koong, Albert C.; Diehn, Maximilian; Rankin, Erinn B.; Graves, Edward E.; Giaccia, Amato J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13898</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Increasing evidence suggests that ionizing radiation therapy (RT) in combination with checkpoint immunotherapy is highly effective in treating a subset of cancers.  To better understand the limited responses to this combination we analyzed the genetic, microenvironmental, and immune factors in tumors derived from a transgenic breast cancer model.  We identified two tumors with similar growth characteristics but different RT responses primarily due to an antitumor immune response.  The combination of RT and checkpoint immunotherapy resulted in cures in the responsive but not the unresponsive tumors.  Profiling the tumors revealed that the Axl receptor tyrosine kinase is overexpressed in the unresponsive tumors, and Axl knockout resulted in slower growth and increased radiosensitivity.  These changes were assocd. with a CD8+ T-cell response, which was improved in combination with checkpoint immunotherapy.  These results suggest a novel role for Axl in suppressing antigen presentation through MHCI, and enhancing cytokine release, which promotes a suppressive myeloid microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU9gnrG_aWe7Vg90H21EOLACvtfcHk0lj6V9JSWGdmBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGit7%252FE&md5=c4d5abf03674d5d3b8a12f0b66444a5f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fncomms13898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13898%26sid%3Dliteratum%253Aachs%26aulast%3DAguilera%26aufirst%3DT.%2BA.%26aulast%3DRafat%26aufirst%3DM.%26aulast%3DCastellini%26aufirst%3DL.%26aulast%3DShehade%26aufirst%3DH.%26aulast%3DKariolis%26aufirst%3DM.%2BS.%26aulast%3DHui%26aufirst%3DA.%2BB.-Y.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3Dvon%2BEyben%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DEllies%26aufirst%3DL.%2BG.%26aulast%3DKoong%26aufirst%3DA.%2BC.%26aulast%3DDiehn%26aufirst%3DM.%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DGraves%26aufirst%3DE.%2BE.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DReprogramming%2520the%2520immunological%2520microenvironment%2520through%2520radiation%2520and%2520targeting%2520Axl%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13898%26doi%3D10.1038%2Fncomms13898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">ASP2215, a novel FLT3/Axl inhibitor: preclinical evaluation in acute myeloid leukemia (AML)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">7070</span>, <span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.7070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1200%2Fjco.2014.32.15_suppl.7070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7070&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=R.+Tanakaauthor=K.+Choauthor=R.+Saitoauthor=Y.+Kondohauthor=I.+Shimadaauthor=S.+Kuromitsu&title=ASP2215%2C+a+novel+FLT3%2FAxl+inhibitor%3A+preclinical+evaluation+in+acute+myeloid+leukemia+%28AML%29&doi=10.1200%2Fjco.2014.32.15_suppl.7070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.7070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.7070%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DASP2215%252C%2520a%2520novel%2520FLT3%252FAxl%2520inhibitor%253A%2520preclinical%2520evaluation%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D7070%26doi%3D10.1200%2Fjco.2014.32.15_suppl.7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torneros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckrodt, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apatira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitoshi, Y.</span></span> <span> </span><span class="NLM_article-title">R428, a selective small molecule inhibitor of axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-09-2997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-09-2997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=20145120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFaksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1544-1554&author=S.+J.+Hollandauthor=A.+Panauthor=C.+Franciauthor=Y.+Huauthor=B.+Changauthor=W.+Liauthor=M.+Duanauthor=A.+Tornerosauthor=J.+Yuauthor=T.+J.+Heckrodtauthor=J.+Zhangauthor=P.+Dingauthor=A.+Apatiraauthor=J.+Chuaauthor=R.+Brandtauthor=P.+Pineauthor=D.+Goffauthor=R.+Singhauthor=D.+G.+Payanauthor=Y.+Hitoshi&title=R428%2C+a+selective+small+molecule+inhibitor+of+axl+kinase%2C+blocks+tumor+spread+and+prolongs+survival+in+models+of+metastatic+breast+cancer&doi=10.1158%2F0008-5472.can-09-2997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer</span></div><div class="casAuthors">Holland, Sacha J.; Pan, Alison; Franci, Christian; Hu, Yuanming; Chang, Betty; Li, Weiqun; Duan, Matt; Torneros, Allan; Yu, Jiaxin; Heckrodt, Thilo J.; Zhang, Jing; Ding, Pingyu; Apatira, Ayodele; Chua, Joanne; Brandt, Ralf; Pine, Polly; Goff, Dane; Singh, Rajinder; Payan, Donald G.; Hitoshi, Yasumichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1544-1554</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Accumulating evidence suggests important roles for the receptor tyrosine kinase Axl in cancer progression, invasion, metastasis, drug resistance, and patient mortality, highlighting Axl as an attractive target for therapeutic development.  We have generated and characterized a potent and selective small-mol. inhibitor, R428, that blocks the catalytic and procancerous activities of Axl.  R428 inhibits Axl with low nanomolar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine prodn.  Pharmacol. investigations revealed favorable exposure after oral administration such that R428-treated tumors displayed a dose-dependent redn. in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail.  In support of an earlier study, R428 inhibited angiogenesis in corneal micropocket and tumor models.  R428 administration reduced metastatic burden and extended survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis.  Addnl., R428 synergized with cisplatin to enhance suppression of liver micrometastasis.  Our results show that Axl signaling regulates breast cancer metastasis at multiple levels in tumor cells and tumor stromal cells and that selective Axl blockade confers therapeutic value in prolonging survival of animals bearing metastatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DJ8WI7aob7Vg90H21EOLACvtfcHk0lj6V9JSWGdmBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFaksb0%253D&md5=66e88d0864e22d737d5fb540c9982d15</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2997%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DM.%26aulast%3DTorneros%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHeckrodt%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DApatira%26aufirst%3DA.%26aulast%3DChua%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DHitoshi%26aufirst%3DY.%26atitle%3DR428%252C%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520axl%2520kinase%252C%2520blocks%2520tumor%2520spread%2520and%2520prolongs%2520survival%2520in%2520models%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1544%26epage%3D1554%26doi%3D10.1158%2F0008-5472.can-09-2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boer, R. H.</span></span> <span> </span><span class="NLM_article-title">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.2147/OTT.S27671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.2147%2FOTT.S27671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23319867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1-7&author=C.+D.+Hartauthor=R.+H.+De+Boer&title=Profile+of+cabozantinib+and+its+potential+in+the+treatment+of+advanced+medullary+thyroid+cancer&doi=10.2147%2FOTT.S27671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span></div><div class="casAuthors">Hart, Christopher D.; De Boer, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed.  It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development.  Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients.  Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdeH_ML0s97Vg90H21EOLACvtfcHk0ljG7ReBJ-ojaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D&md5=048635660f5262d406ec13baef91bc78</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2147%2FOTT.S27671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S27671%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DC.%2BD.%26aulast%3DDe%2BBoer%26aufirst%3DR.%2BH.%26atitle%3DProfile%2520of%2520cabozantinib%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.2147%2FOTT.S27671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcón, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D. M.</span></span> <span> </span><span class="NLM_article-title">VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4758</span>– <span class="NLM_lpage">4768</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-10-2527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=21613405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFarsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4758-4768&author=W.-K.+Youauthor=B.+Senninoauthor=C.+W.+Williamsonauthor=B.+Falc%C3%B3nauthor=H.+Hashizumeauthor=L.-C.+Yaoauthor=D.+T.+Aftabauthor=D.+M.+McDonald&title=VEGF+and+c-Met+blockade+amplify+angiogenesis+inhibition+in+pancreatic+islet+cancer&doi=10.1158%2F0008-5472.can-10-2527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer</span></div><div class="casAuthors">You, Weon-Kyoo; Sennino, Barbara; Williamson, Casey W.; Falcon, Beverly; Hashizume, Hiroya; Yao, Li-Chin; Aftab, Dana T.; McDonald, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4758-4768</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the disease progresses.  Multiple strategies are being explored to improve efficacy by concurrent inhibition of other functionally relevant receptor tyrosine kinases (RTK).  XL880 (foretinib, GSK1363089) and XL184 (cabozantinib) are small-mol. inhibitors that potently block multiple RTKs, including VEGFR and the receptor of hepatocyte growth factor c-Met, which can drive tumor invasion and metastasis.  This study compared the cellular effects of XL880 and XL184 with those of an RTK inhibitor (XL999) that blocks VEGFR but not c-Met.  Treatment of RIP-Tag2 mice with XL999 resulted in 43% redn. in vascularity of spontaneous pancreatic islet tumors over 7 days, but treatment with XL880 or XL184 eliminated approx. 80% of the tumor vasculature, reduced pericytes and empty basement membrane sleeves, caused widespread intratumoral hypoxia and tumor cell apoptosis, and slowed regrowth of the tumor vasculature after drug withdrawal.  Importantly, XL880 and XL184 also decreased invasiveness of primary tumors and reduced metastasis.  Overall, these findings indicate that inhibition of c-Met and functionally related kinases amplifies the effects of VEGFR blockade and leads to rapid, robust, and progressive regression of tumor vasculature, increased intratumoral hypoxia and apoptosis, and reduced tumor invasiveness and metastasis.  Cancer Res; 71(14); 4758-68.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-APd9r4wTwLVg90H21EOLACvtfcHk0ljG7ReBJ-ojaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFarsLY%253D&md5=b0328a10c02cde5f8ced211d82e1b45f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2527%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DW.-K.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BW.%26aulast%3DFalc%25C3%25B3n%26aufirst%3DB.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DL.-C.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DVEGF%2520and%2520c-Met%2520blockade%2520amplify%2520angiogenesis%2520inhibition%2520in%2520pancreatic%2520islet%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4758%26epage%3D4768%26doi%3D10.1158%2F0008-5472.can-10-2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, K.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greshock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, A. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">8009</span>– <span class="NLM_lpage">8016</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.-A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases&doi=10.1158%2F0008-5472.can-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0ljG7ReBJ-ojaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.-A.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.can-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, N.</span></span> <span> </span><span class="NLM_article-title">Substituted quinoline compounds and methods of use</span>. U.S. Patent <span class="NLM_patent">20,120,219,522 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Xi&title=Substituted+quinoline+compounds+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DN.%26atitle%3DSubstituted%2520quinoline%2520compounds%2520and%2520methods%2520of%2520use%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peek, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajamie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konicek, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, R. A.</span></span> <span> </span><span class="NLM_article-title">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against Met, Mst1r, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1007%2Fs10637-012-9912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23275061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=833-844&author=S.+B.+Yanauthor=V.+L.+Peekauthor=R.+Ajamieauthor=S.+G.+Buchananauthor=J.+R.+Graffauthor=S.+A.+Heidlerauthor=Y.-H.+Huiauthor=K.+L.+Hussauthor=B.+W.+Konicekauthor=J.+R.+Manroauthor=C.+Shihauthor=J.+A.+Stewartauthor=T.+R.+Stewartauthor=S.+L.+Stoutauthor=M.+T.+Uhlikauthor=S.+L.+Umauthor=Y.+Wangauthor=W.+Wuauthor=L.+Yanauthor=W.+J.+Yangauthor=B.+Zhongauthor=R.+A.+Walgren&title=LY2801653+is+an+orally+bioavailable+multi-kinase+inhibitor+with+potent+activity+against+Met%2C+Mst1r%2C+and+other+oncoproteins%2C+and+displays+anti-tumor+activities+in+mouse+xenograft+models&doi=10.1007%2Fs10637-012-9912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span></div><div class="casAuthors">Yan, S. Betty; Peek, Victoria L.; Ajamie, Rose; Buchanan, Sean G.; Graff, Jeremy R.; Heidler, Steven A.; Hui, Yu-Hua; Huss, Karen L.; Konicek, Bruce W.; Manro, Jason R.; Shih, Chuan; Stewart, Julie A.; Stewart, Trent R.; Stout, Stephanie L.; Uhlik, Mark T.; Um, Suzane L.; Wang, Yong; Wu, Wenjuan; Yan, Lei; Yang, Wei J.; Zhong, Boyu; Walgren, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis.  MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand prodn., and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are assocd. with poor prognostic outcome.  We report here preclin. development of a potent, orally bioavailable, small-mol. inhibitor LY2801653 targeting MET kinase.  LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissocn. const. (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min.  LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects.  LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation.  In subsequent nonclin. characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.  The potential value of MET and other inhibited targets within a no. of malignancies (such as colon, bile ducts, and lung) is discussed.  LY2801653 is currently in phase 1 clin. testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04limPWxrHLVg90H21EOLACvtfcHk0liST5yZNhc7Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE&md5=9d80bcdb04ebec24e2516dcf26821ad3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9912-9%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%2BB.%26aulast%3DPeek%26aufirst%3DV.%2BL.%26aulast%3DAjamie%26aufirst%3DR.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DHeidler%26aufirst%3DS.%2BA.%26aulast%3DHui%26aufirst%3DY.-H.%26aulast%3DHuss%26aufirst%3DK.%2BL.%26aulast%3DKonicek%26aufirst%3DB.%2BW.%26aulast%3DManro%26aufirst%3DJ.%2BR.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DT.%2BR.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DUm%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DWalgren%26aufirst%3DR.%2BA.%26atitle%3DLY2801653%2520is%2520an%2520orally%2520bioavailable%2520multi-kinase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520Met%252C%2520Mst1r%252C%2520and%2520other%2520oncoproteins%252C%2520and%2520displays%2520anti-tumor%2520activities%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D833%26epage%3D844%26doi%3D10.1007%2Fs10637-012-9912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span>; <span class="NLM_string-name">Ator, M. A.</span>; <span class="NLM_string-name">Cheng, M. M.</span>; <span class="NLM_string-name">Dorsey, B.</span>; <span class="NLM_string-name">Hudkins, R. L.</span>; <span class="NLM_string-name">Ruggeri, B. A.</span></span> <span> </span><span class="NLM_article-title">Methods of treating various cancers using an Axl/cMet inhibitor alone or in combination with other agents</span>. <span class="NLM_patent">WO 2015017607 A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+S.+Angeles&author=M.+A.+Ator&author=M.+M.+Cheng&author=B.+Dorsey&author=R.+L.+Hudkins&author=B.+A.+Ruggeri&title=Methods+of+treating+various+cancers+using+an+Axl%2FcMet+inhibitor+alone+or+in+combination+with+other+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26atitle%3DMethods%2520of%2520treating%2520various%2520cancers%2520using%2520an%2520Axl%252FcMet%2520inhibitor%2520alone%2520or%2520in%2520combination%2520with%2520other%2520agents%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6807</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6807-6825&author=L.+Tanauthor=Z.+Zhangauthor=D.+Gaoauthor=J.+Luoauthor=Z.-C.+Tuauthor=Z.+Liauthor=L.+Pengauthor=X.+Renauthor=K.+Ding&title=4-oxo-1%2C4-dihydroquinoline-3-carboxamide+derivatives+as+new+Axl+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.6b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Zhang, Zhang; Gao, Donglin; Luo, Jinfeng; Tu, Zheng-Chao; Li, Zhengqiu; Peng, Lijie; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6807-6825</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Axl is a new potential target for anticancer drug discovery.  A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides I (9a-u, 9ha-9hh, 9ia-9ic; R1 = H, Cl, F, Br, CF3, Me, Et, cyclopropyl, iPr, isopropenyl, OMe, CO2Me; R2, R3 = H, Me, Et, n-Pr, Bu, Ph; R4 = F, H, Me) and II [9id-9im; Z = CH, N; X = H, Cl; Y = H, NH2; X-Y = CPh:CHO, CPh:CHNH, CH:C(OMe)C(OMe):CH] were designed and synthesized as highly potent Axl kinase inhibitors.  One of the most promising compds., 9im [shown as II, X-Y = CH:C(OMe)C(OMe):CH], tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, resp., while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concn.  The compd. dose-dependently inhibited the TGF-β1-induced epithelial-mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells.  In addn., 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells.  Compd. 9im may serve as a lead compd. for new anticancer drug discovery and a valuable research probe for further biol. investigation on Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtSA_rcxZaeLVg90H21EOLACvtfcHk0liST5yZNhc7Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO&md5=2b737ed5ab9349788d82c0d1ec81b914</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D4-oxo-1%252C4-dihydroquinoline-3-carboxamide%2520derivatives%2520as%2520new%2520Axl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6807%26epage%3D6825%26doi%3D10.1021%2Facs.jmedchem.6b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Cell- and tissue-based proteome profiling and bioimaging with probes derived from a potent Axl kinase inhibitor</span>. <i>Chem.–Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2605</span>, <span class="refDoi"> DOI: 10.1002/asia.201800605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1002%2Fasia.201800605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29939481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2601-2605&author=B.+Zhengauthor=H.+Guoauthor=N.+Maauthor=Y.+Niauthor=J.+Xuauthor=L.+Liauthor=P.+Haoauthor=K.+Dingauthor=Z.+Li&title=Cell-+and+tissue-based+proteome+profiling+and+bioimaging+with+probes+derived+from+a+potent+Axl+kinase+inhibitor&doi=10.1002%2Fasia.201800605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor</span></div><div class="casAuthors">Zheng, Binbin; Guo, Haijun; Ma, Nan; Ni, Yun; Xu, Jiaqian; Li, Lin; Hao, Piliang; Ding, Ke; Li, Zhengqiu</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2601-2605</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">AXL has been defined as a novel target for cancer therapeutics.  However, only a few potent and selective inhibitors targeting AXL are available to date.  Recently, our group has developed a lead compd., 9i.m., capable of displaying potent and specific inhibition of AXL.  To further identify the cellular on/off targets, in this study, competitive affinity-based proteome profiling was carried out, leading to the discovery of several unknown cellular targets such as BCAP31, LPCAT3, POR, TM9SF3, SCCPDH and CANX.  In addn., trans-cyclooctene (TCO) and acedan-contg. probes were developed to image the binding between 9i.m. and its target proteins inside live cells and tumor tissues.  These probes would be useful tools in the detection of AXL in various biosystems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogjbWcokDOWrVg90H21EOLACvtfcHk0liST5yZNhc7Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKrtr%252FN&md5=99af1417a3b3ebf0868b9f366081215f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fasia.201800605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.201800605%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DCell-%2520and%2520tissue-based%2520proteome%2520profiling%2520and%2520bioimaging%2520with%2520probes%2520derived%2520from%2520a%2520potent%2520Axl%2520kinase%2520inhibitor%26jtitle%3DChem.%25E2%2580%2593Asian%2520J.%26date%3D2018%26volume%3D13%26spage%3D2601%26epage%3D2605%26doi%3D10.1002%2Fasia.201800605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(5’-Substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6690</span>– <span class="NLM_lpage">6708</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKisb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6690-6708&author=W.+Yanauthor=X.+Wangauthor=Y.+Daiauthor=B.+Zhaoauthor=X.+Yangauthor=J.+Fanauthor=Y.+Gaoauthor=F.+Mengauthor=Y.+Wangauthor=C.+Luoauthor=J.+Aiauthor=M.+Gengauthor=W.+Duan&title=Discovery+of+3-%285%E2%80%99-Substituted%29-benzimidazole-5-%281-%283%2C5-dichloropyridin-4-yl%29ethoxy%29-1H-indazoles+as+potent+fibroblast+growth+factor+receptor+inhibitors%3A+design%2C+synthesis%2C+and+biological+evaluation&doi=10.1021%2Facs.jmedchem.6b00056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Yan, Wei; Wang, Xinyi; Dai, Yang; Zhao, Bin; Yang, Xinying; Fan, Jun; Gao, Yinglei; Meng, Fanwang; Wang, Yuming; Luo, Cheng; Ai, Jing; Geng, Meiyu; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6690-6708</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) represents an attractive oncol. target for cancer therapy in view of its crit. role in promoting cancer formation and progression, as well as causing resistance to approved therapies.  In this article, the authors describe the identification of the potent pan-FGFR inhibitor (R)-21c (FGFR1-4 IC50 values of 0.9, 2.0, 2.0, and 6.1 nM, resp.).  Compd. (R)-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazole ((R)-21c) exhibited excellent in vitro inhibitory activity against a panel of FGFR-amplified cell lines.  Western blot anal. demonstrated that (R)-21c suppressed FGF/FGFR and downstream signaling pathways at nanomolar concns.  Moreover, (R)-21c provided nearly complete inhibition of tumor growth (96.9% TGI) in NCI-H1581 (FGFR1-amplified) xenograft mice model at the dose of 10 mg/kg/qd via oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBssqm8VpRHrVg90H21EOLACvtfcHk0lh123EQpyHtZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKisb7E&md5=a7ce472feea2293d28c57f1609d8c941</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00056%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25203-%25285%25E2%2580%2599-Substituted%2529-benzimidazole-5-%25281-%25283%252C5-dichloropyridin-4-yl%2529ethoxy%2529-1H-indazoles%2520as%2520potent%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6690%26epage%3D6708%26doi%3D10.1021%2Facs.jmedchem.6b00056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/Axl inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAxl+inhibitor%2C+shows+antileukemic+activity+in+mouse+models+of+FLT3+mutated+acute+myeloid+leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0lh123EQpyHtZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAxl%2520inhibitor%252C%2520shows%2520antileukemic%2520activity%2520in%2520mouse%2520models%2520of%2520FLT3%2520mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span>; <span class="NLM_string-name">Klebl, B.</span>; <span class="NLM_string-name">Choidas, A.</span>; <span class="NLM_string-name">Koch, U.</span>; <span class="NLM_string-name">Eickhoff, J.</span>; <span class="NLM_string-name">Wolf, A.</span>; <span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of quinoline carboxamide compounds as Axl inhibitors</span>. <span class="NLM_patent">WO 2012028332 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Schultz-Fademrecht&author=B.+Klebl&author=A.+Choidas&author=U.+Koch&author=J.+Eickhoff&author=A.+Wolf&author=A.+Ullrich&title=Preparation+of+quinoline+carboxamide+compounds+as+Axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520quinoline%2520carboxamide%2520compounds%2520as%2520Axl%2520inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span> <span> </span><span class="NLM_article-title">1-oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2903</span>– <span class="NLM_lpage">2908</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(97)10110-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2FS0960-894X%2897%2910110-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK2sXnvV2mt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=2903-2908&author=M.+R.+Barvianauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+J.+Krakerauthor=A.+Amarauthor=B.+Hartlauthor=J.+M.+Hambyauthor=H.+D.+H.+Showalter&title=1-oxo-3-aryl-1H-indene-2-carboxylic+acid+derivatives+as+selective+inhibitors+of+fibroblast+growth+factor+receptor-1+tyrosine+kinase&doi=10.1016%2Fs0960-894x%2897%2910110-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">1-oxo-3-Aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase</span></div><div class="casAuthors">Barvian, M. R.; Panek, R. L.; Lu, G. H.; Kraker, A. J.; Amar, A.; Hartl, B.; Hamby, J. M.; Showalter, H. D. H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2903-2908</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFr) mediated signal transduction is implicated in vascular proliferative diseases and some cancers.  Thus, Me 1-oxo-3-phenyl-1H-indene-2-carboxylic ester was identified as a small mol. inhibitor of the tyrosine kinase activity of FGFr-1, (IC50 = 5.1 μM).  The synthesis and structure-activity studies about this template core were reported.  N example compd. thus prepd. was N-methyl-1-oxo-3-phenyl-1H-Indene-2-carboxamide.  Addnl., screening of this series against a panel of tyrosine kinases shows selective inhibition of FGFr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKzkITINbR7Vg90H21EOLACvtfcHk0lgvK0wpXI1RjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvV2mt7k%253D&md5=e7e782dc4426cbefc45babeb38c4c03c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2910110-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252910110-X%26sid%3Dliteratum%253Aachs%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DAmar%26aufirst%3DA.%26aulast%3DHartl%26aufirst%3DB.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26atitle%3D1-oxo-3-aryl-1H-indene-2-carboxylic%2520acid%2520derivatives%2520as%2520selective%2520inhibitors%2520of%2520fibroblast%2520growth%2520factor%2520receptor-1%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D2903%26epage%3D2908%26doi%3D10.1016%2Fs0960-894x%2897%2910110-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, P. R.</span>; <span class="NLM_string-name">Patel, K. M.</span>; <span class="NLM_string-name">Selby, T. P.</span>; <span class="NLM_string-name">Smith, B. T.</span>; <span class="NLM_string-name">Taggi, A. E.</span></span> <span> </span><span class="NLM_article-title">Herbicidal pyrimidone derivatives</span>. <span class="NLM_patent">WO 2011031658 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+R.+Kovacs&author=K.+M.+Patel&author=T.+P.+Selby&author=B.+T.+Smith&author=A.+E.+Taggi&title=Herbicidal+pyrimidone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKovacs%26aufirst%3DP.%2BR.%26atitle%3DHerbicidal%2520pyrimidone%2520derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inukai, T.</span>; <span class="NLM_string-name">Takeuchi, J.</span>; <span class="NLM_string-name">Yasuhiro, T.</span></span> <span> </span><span class="NLM_article-title">Quinoline derivatives</span>. <span class="NLM_patent">WO 2016104617 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Inukai&author=J.+Takeuchi&author=T.+Yasuhiro&title=Quinoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInukai%26aufirst%3DT.%26atitle%3DQuinoline%2520derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inukai, T.</span>; <span class="NLM_string-name">Takeuchi, J.</span>; <span class="NLM_string-name">Yasuhiro, T.</span></span> <span> </span><span class="NLM_article-title">Quinoline derivative</span>. <span class="NLM_patent">WO 2015012298 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+Inukai&author=J.+Takeuchi&author=T.+Yasuhiro&title=Quinoline+derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInukai%26aufirst%3DT.%26atitle%3DQuinoline%2520derivative%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.ejmech.2018.08.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=30216852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWisrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=201-213&author=Q.+Tangauthor=Y.+Duanauthor=H.+Xiongauthor=T.+Chenauthor=Z.+Xiaoauthor=L.+Wangauthor=Y.+Xiaoauthor=S.+Huangauthor=Y.+Xiongauthor=W.+Zhuauthor=P.+Gongauthor=P.+Zheng&title=Synthesis+and+antiproliferative+activity+of+6%2C7-disubstituted-4-phenoxyquinoline+derivatives+bearing+the+1%2C8-naphthyridin-2-one+moiety&doi=10.1016%2Fj.ejmech.2018.08.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety</span></div><div class="casAuthors">Tang, Qidong; Duan, Yongli; Xiong, Hehua; Chen, Ting; Xiao, Zhen; Wang, Linxiao; Xiao, Yueyue; Huang, Shunmin; Xiong, Yinhua; Zhu, Wufu; Gong, Ping; Zheng, Pengwu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">201-213</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 6,7-disubstituted-4-phenoxyquinoline derivs. bearing the 1,8-naphthyridin-2-one moiety were designed, synthesized and evaluated for their biol. activities.  The target compds. exhibited moderate to high antiproliferative activity against three cancer cell lines (A549, HepG2 and MCF-7) and several compds. were evaluated for the activity against c-Met kinase.  The most promising compd. I (IC50 c-Met = 2.36 nM) showed excellent activity against A549, HepG2 and MCF-7 cell lines with IC50 values of 0.23 μM, 0.42 μM and 0.21 μM, resp., which was 1.5-2.1 times of the pos. control.  Furthermore, compd. I was evaluated for the activity against Flt3, PDGFR-α, PDGFR-β, c-Kit, Flt4, ALK and EGFR kinase.  Structure activity relationship studies indicated that mono-EWGs, such as fluorine at 4-position of moiety C was a key factor in improving the antitumor activity.  In addn., further research on compd. I was mainly including concn. dependence, apoptosis (acridine orange staining), apoptosis result analyzing and mol. docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-OR3VdwSo7Vg90H21EOLACvtfcHk0lgvK0wpXI1RjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWisrfJ&md5=66e989df578414d1451612d54614574d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.066%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%25206%252C7-disubstituted-4-phenoxyquinoline%2520derivatives%2520bearing%2520the%25201%252C8-naphthyridin-2-one%2520moiety%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D201%26epage%3D213%26doi%3D10.1016%2Fj.ejmech.2018.08.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dandu, R.</span>; <span class="NLM_string-name">Hudkins, R. L.</span>; <span class="NLM_string-name">Josef, K. A.</span>; <span class="NLM_string-name">Prouty, C. P.</span>; <span class="NLM_string-name">Tripathy, R.</span></span> <span> </span><span class="NLM_article-title">Uracil derivatives as axl and c-met kinase inhibitors</span>. <span class="NLM_patent">WO2013074633A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Dandu&author=R.+L.+Hudkins&author=K.+A.+Josef&author=C.+P.+Prouty&author=R.+Tripathy&title=Uracil+derivatives+as+axl+and+c-met+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDandu%26aufirst%3DR.%26atitle%3DUracil%2520derivatives%2520as%2520axl%2520and%2520c-met%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manne, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppenheimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wautlet, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1021/jm801586s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.-W.+Caiauthor=X.-T.+Chenauthor=C.+Clarkauthor=L.+A.+M.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+Met+kinase+superfamily&doi=10.1021%2Fjm801586s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily</span></div><div class="casAuthors">Schroeder, Gretchen M.; An, Yongmi; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors.  Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aq. soly. and kinase selectivity.  Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration.  Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHEvJXf0Fq7Vg90H21EOLACvtfcHk0lgvK0wpXI1RjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D&md5=784623be820fcc8b931200ced3a476df</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.-W.%26aulast%3DChen%26aufirst%3DX.-T.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520Met%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254%26doi%3D10.1021%2Fjm801586s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Chemical mechanisms of catalysis by cytochromes P-450: a unified view</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/ar00097a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00097a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaL2cXkslCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=9-16&author=F.+P.+Guengerichauthor=T.+L.+Macdonald&title=Chemical+mechanisms+of+catalysis+by+cytochromes+P-450%3A+a+unified+view&doi=10.1021%2Far00097a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical mechanisms of catalysis by cytochromes P-450:  a unified view</span></div><div class="casAuthors">Guengerich, F. Peter; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-16</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with 96 refs. on the mechanism of enzymic O transfer catalyzed by cytochrome P 450-contg. mixed-function oxidases (monooxygenases).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwCjg9zCGUobVg90H21EOLACvtfcHk0lj6FPluWgNOWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkslCgug%253D%253D&md5=65f638decb81e414a80468c33f62a325</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Far00097a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00097a002%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DChemical%2520mechanisms%2520of%2520catalysis%2520by%2520cytochromes%2520P-450%253A%2520a%2520unified%2520view%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1984%26volume%3D17%26spage%3D9%26epage%3D16%26doi%3D10.1021%2Far00097a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.can-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lj6FPluWgNOWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.can-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumienny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beer, T. A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rempfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwede, T.</span></span> <span> </span><span class="NLM_article-title">SWISS-MODEL: homology modelling of protein structures and complexes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">W296</span>– <span class="NLM_lpage">W303</span>, <span class="refDoi"> DOI: 10.1093/nar/gky427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1093%2Fnar%2Fgky427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29788355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVyru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=W296-W303&author=A.+Waterhouseauthor=M.+Bertoniauthor=S.+Bienertauthor=G.+Studerauthor=G.+Taurielloauthor=R.+Gumiennyauthor=F.+T.+Heerauthor=T.+A.+P.+de+Beerauthor=C.+Rempferauthor=L.+Bordoliauthor=R.+Leporeauthor=T.+Schwede&title=SWISS-MODEL%3A+homology+modelling+of+protein+structures+and+complexes&doi=10.1093%2Fnar%2Fgky427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SWISS-MODEL: homology modelling of protein structures and complexes</span></div><div class="casAuthors">Waterhouse, Andrew; Bertoni, Martino; Bienert, Stefan; Studer, Gabriel; Tauriello, Gerardo; Gumienny, Rafal; Heer, Florian T.; de Beer, Tjaart A. P.; Rempfer, Christine; Bordoli, Lorenza; Lepore, Rosalba; Schwede, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W296-W303</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Homol. modeling has matured into an important technique in structural biol., significantly contributing to narrowing the gap between known protein sequences and exptl. detd. structures.  Fully automated workflows and servers simplify and streamline the homol. modeling process, also allowing users without a specific computational expertise to generate reliable protein models and have easy access to modeling results, their visualization and interpretation.  Here, we present an update to the SWISS-MODEL server, which pioneered the field of automated modeling 25 years ago and been continuously further developed.  Recently, its functionality has been extended to the modeling of homo- and heteromeric complexes.  Starting from the amino acid sequences of the interacting proteins, both the stoichiometry and the overall structure of the complex are inferred by homol. modeling.  Other major improvements include the implementation of a new modeling engine, ProMod3 and the introduction a new local model quality estn. method, QMEANDisCo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9ZhQAzPVe7Vg90H21EOLACvtfcHk0ljQQYTqxGS_KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVyru70%253D&md5=651b55ade2d4f354f5d6699f318424d0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky427%26sid%3Dliteratum%253Aachs%26aulast%3DWaterhouse%26aufirst%3DA.%26aulast%3DBertoni%26aufirst%3DM.%26aulast%3DBienert%26aufirst%3DS.%26aulast%3DStuder%26aufirst%3DG.%26aulast%3DTauriello%26aufirst%3DG.%26aulast%3DGumienny%26aufirst%3DR.%26aulast%3DHeer%26aufirst%3DF.%2BT.%26aulast%3Dde%2BBeer%26aufirst%3DT.%2BA.%2BP.%26aulast%3DRempfer%26aufirst%3DC.%26aulast%3DBordoli%26aufirst%3DL.%26aulast%3DLepore%26aufirst%3DR.%26aulast%3DSchwede%26aufirst%3DT.%26atitle%3DSWISS-MODEL%253A%2520homology%2520modelling%2520of%2520protein%2520structures%2520and%2520complexes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DW296%26epage%3DW303%26doi%3D10.1093%2Fnar%2Fgky427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0ljQQYTqxGS_KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative Axl inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Analysis of the structural features of the type II Axl inhibitor from the cocrystal structure of Met in complex with the Axl inhibitor <b>4</b>: (A) binding mode of Met with the representative type II Axl inhibitor <b>4</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a>). (B) Compound <b>4</b> was used to display the structural features of classic type II Axl inhibitors. (C) Sequence alignment of Axl and Met kinase domains, where the identical residues are colored in red and the binding pocket residues of the Met DFG-out conformation are boxed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structure of compound <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic illustration of the proposed binding mode of <b>10g</b> with the Axl DFG-out homology model (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82">3F82</a>): (A) Type II binding model of compound 1<b>0g</b>. (B) Compound <b>10g</b> with the hinge region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Schematic illustration of the proposed binding mode of <b>13c</b> with the Axl DFG-out homology model (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82">3F82</a>): (A) Type II binding model of compound <b>13c</b>. (B) Compound <b>13c</b> with the hinge region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>13c</b> suppressed Axl/Met phosphorylation and downstream signaling in BaF3/TEL-AXL cells (A), NCI-H1299 cells (B), MKN45 cells (C), and EBC-1 cells (D). BaF3/TEL-AXL, MKN45, and EBC-1 cells were treated with compounds at different concentrations for 2 h; NCI-H1299 cells were serum-deprived for 24 h prior to 2 h of treatment with compounds and then stimulated with Gas6 for 15 min. Then, the cells were lysed and subjected to western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>13c</b> inhibited Axl-dependent neoplastic phenotypes of metastasis: (A) Compound <b>13c</b> suppressed Gas6-induced NCI-H1299 cell migration. (B) Compound <b>13c</b> inhibited Gas6-induced SNU449 cell invasion. Representative images are shown (scale bars, 10 μm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>13c</b> significantly inhibited Axl/Met-mediated tumor growth in vivo: (A) Tumor growth was inhibited after <b>13c</b> treatment in BaF3/TEL-AXL xenografts. (B) Tumor growth was inhibited after <b>13c</b> treatment in U87MG xenografts. The tumor volumes are expressed as the mean ± SEM. Significant differences from the vehicle group were determined using a <i>t</i>-test, ***<i>P</i> < 0.001 and **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of <b>9</b> and <b>10a–n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminophenol, potassium <i>tert</i>-butoxide, dimethylacetamide (DMA), room temperature (RT) to 85 °C; (b) 1-methyl-4-pyrazole boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane/water, 90 °C; and (c) <i>O</i>-(7-aza-1<i>H</i>-benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetramethyluronium hexafluorophosphate (HATU), triethylamine (TEA), <i>N</i>,<i>N</i>-dimethylformamide (DMF), RT.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of <b>11a–g</b>, <b>11i</b>, and <b>12a–e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate 4-aminophenol, potassium <i>tert</i>-butoxide, DMA, RT to 85 °C; (b) 1-methyl-4-pyrazole boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane/water, 90 °C; and (c) acid <b>17h</b>, HATU, TEA, DMF, RT.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>11h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, 1,2,4-trifluoro-5-nitrobenzene, DMF, RT; (b) SnCl<sub>2</sub>, EtOH, 80 °C; (c) 1-methyl-4-pyrazole boronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane/water, 90 °C; and (d) acid <b>17h</b>, HATU, TEA, DMF, RT.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of <b>13a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate acid chloride, TEA, dichloromethane, 0 °C to RT; (b) 2-fluoro-4-nitrophenol, chlorobenzene, 140 °C; (c) iron powder, acetic acid, ethyl acetate, 80 °C; and (d) acid <b>17h</b>, HATU, TEA, DMF, RT.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/medium/jm0c02093_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Syntheses of <b>13d–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02093/20210331/images/large/jm0c02093_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02093&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-amino-2-fluorophenol, potassium <i>tert</i>-butoxide, dimethyl sulfoxide (DMSO), RT to 80 °C; (b) acid <b>17h</b>, HATU, TEA, DMF, RT; (c) iodobenzene diacetate, ethyl acetate/acetonitrile/water, 0 °C to RT; (d) cyclobutane carboxylic acid, HATU, TEA, DMF, RT; and (e) appropriate amine, phenyl chloroformate, TEA, tetrahydrofuran (THF), 0 °C to RT.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 54 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varnum, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartley, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clogston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toso, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagihara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merewether, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H. K.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase stimulated by the vitamin-K-dependent protein encoded by growth-arrest-specific gene 6</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/373623a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1038%2F373623a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=7854420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=623-626&author=B.+C.+Varnumauthor=C.+Youngauthor=G.+Elliottauthor=A.+Garciaauthor=T.+D.+Bartleyauthor=Y.-W.+Fridellauthor=R.+W.+Huntauthor=G.+Trailauthor=C.+Clogstonauthor=R.+J.+Tosoauthor=D.+Yanagiharaauthor=L.+Bennettauthor=M.+Sylberauthor=L.+A.+Merewetherauthor=A.+Tsengauthor=E.+Escobarauthor=E.+T.+Liuauthor=H.+K.+Yamane&title=Axl+receptor+tyrosine+kinase+stimulated+by+the+vitamin-K-dependent+protein+encoded+by+growth-arrest-specific+gene+6&doi=10.1038%2F373623a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ax1 receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</span></div><div class="casAuthors">Varnum, Brian C.; Young, Cynthia; Elliott, Gary; Garcia, Andy; Bartley, Timothy D.; Fridell, Yih-Woei; Hunt, Robert W.; Trail, Geraldine; Clogston, Chris; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">6515</span>),
    <span class="NLM_cas:pages">623-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukemia cells by DNA-mediated transformation of NIH 3T3 cells.  Ax1 is the founding member of a family of related receptors that includes Eyk, encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer, encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines.  The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation.  The function of Ax1 in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor.  We report here the purifn. of an Ax1 stimulatory factor, and its identification as the product of growth-arrest-specific gene 6.  This is, to our knowledge, the first description of a ligand for the Ax1 family of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-4cxnEY4sPbVg90H21EOLACvtfcHk0li-gbT7-QwQXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D&md5=0d8ecf55926f43384ca646ffa3692529</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F373623a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F373623a0%26sid%3Dliteratum%253Aachs%26aulast%3DVarnum%26aufirst%3DB.%2BC.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DBartley%26aufirst%3DT.%2BD.%26aulast%3DFridell%26aufirst%3DY.-W.%26aulast%3DHunt%26aufirst%3DR.%2BW.%26aulast%3DTrail%26aufirst%3DG.%26aulast%3DClogston%26aufirst%3DC.%26aulast%3DToso%26aufirst%3DR.%2BJ.%26aulast%3DYanagihara%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DL.%26aulast%3DSylber%26aufirst%3DM.%26aulast%3DMerewether%26aufirst%3DL.%2BA.%26aulast%3DTseng%26aufirst%3DA.%26aulast%3DEscobar%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DYamane%26aufirst%3DH.%2BK.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520stimulated%2520by%2520the%2520vitamin-K-dependent%2520protein%2520encoded%2520by%2520growth-arrest-specific%2520gene%25206%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D623%26epage%3D626%26doi%3D10.1038%2F373623a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quilliam, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCloskey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spizz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span> <span> </span><span class="NLM_article-title">Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1128/mcb.16.1.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1128%2FMCB.16.1.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=8524290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK28XhtVGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=135-145&author=Y.+W.+Fridellauthor=Y.+Jinauthor=L.+A.+Quilliamauthor=A.+Burchertauthor=P.+McCloskeyauthor=G.+Spizzauthor=B.+Varnumauthor=C.+Derauthor=E.+T.+Liu&title=Differential+activation+of+the+Ras%2Fextracellular-signal-regulated+protein+kinase+pathway+is+responsible+for+the+biological+consequences+induced+by+the+Axl+receptor+tyrosine+kinase&doi=10.1128%2Fmcb.16.1.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase</span></div><div class="casAuthors">Fridell, Yih-Woei C.; Jin, Yan; Quilliam, Lawrence A.; Burchert, Andreas; McCloskey, Patrick; Spizz, Gwendolyn; Varnum, Brian; Der, Channing; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-45</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">To understand the mechanism of Axl signaling, we have initiated studies to delineate downstream components in interleukin-3-dependent 32D cells by using a chimeric receptor contg. the recombinant epidermal growth factor (EGF) receptor extracellular and transmembrane domains and the Axl kinase domain (EAK [for EGF receptor-Axl kinase]).  We have previously shown that upon exogenous EGF stimulation, 32D-EAK cells are capable of proliferation in the absence of interleukin-3.  With this system, we detd. that EAK-induced cell survival and mitogenesis are dependent upon the Ras/extracellular-signal-regulated protein kinase (ERK) cascade.  Although the phosphatidylinositol-3 kinase pathway is activated upon EAK signaling, it appears to be dispensable for the biol. actions of the Axl kinase.  Furthermore, we demonstrated that different threshold levels of Ras/ERK activation are needed to induce a block to apoptosis or proliferation in 32D cells.  Recently, we have identified an Axl ligand, GAS6.  Surprisingly, GAS6-stimulated 32D-Axl cells exhibited no blockage to apoptosis or mitogenic response which is correlated with the absence of Ras/ERK activation.  Taken together, these data suggest that different extracellular domains dramatically alter the intracellular response of the Axl kinase.  Furthermore, our data suggest that the GAS6-Axl interaction does not induce mitogenesis and that its exact role remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCI2en51B0vLVg90H21EOLACvtfcHk0li-gbT7-QwQXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtVGqsQ%253D%253D&md5=c7523c9c82a2e9f7010c9a4000e82b8a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.1.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.1.135%26sid%3Dliteratum%253Aachs%26aulast%3DFridell%26aufirst%3DY.%2BW.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DQuilliam%26aufirst%3DL.%2BA.%26aulast%3DBurchert%26aufirst%3DA.%26aulast%3DMcCloskey%26aufirst%3DP.%26aulast%3DSpizz%26aufirst%3DG.%26aulast%3DVarnum%26aufirst%3DB.%26aulast%3DDer%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DDifferential%2520activation%2520of%2520the%2520Ras%252Fextracellular-signal-regulated%2520protein%2520kinase%2520pathway%2520is%2520responsible%2520for%2520the%2520biological%2520consequences%2520induced%2520by%2520the%2520Axl%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D135%26epage%3D145%26doi%3D10.1128%2Fmcb.16.1.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Axl and mTOR pathway overcomes primary and acquired resistance to Wee1 inhibition in small-cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6239</span>– <span class="NLM_lpage">6253</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-17-1284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F1078-0432.CCR-17-1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28698200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6239-6253&author=T.+Senauthor=P.+Tongauthor=L.+Diaoauthor=L.+Liauthor=Y.+Fanauthor=J.+Hoffauthor=J.+V.+Heymachauthor=J.+Wangauthor=L.+A.+Byers&title=Targeting+Axl+and+mTOR+pathway+overcomes+primary+and+acquired+resistance+to+Wee1+inhibition+in+small-cell+lung+cancer&doi=10.1158%2F1078-0432.ccr-17-1284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer</span></div><div class="casAuthors">Sen, Triparna; Tong, Pan; Diao, Lixia; Li, Lerong; Fan, Youhong; Hoff, Jennifer; Heymach, John V.; Wang, Jing; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6239-6253</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Drugs targeting DNA repair and cell-cycle checkpoints have emerged as promising therapies for small-cell lung cancer (SCLC).  Among these, the WEE1 inhibitor AZD1775 has shown clin. activity in a subset of SCLC patients, but resistance is common.  Understanding primary and acquired resistance mechanisms will be crit. for developing effective WEE1 inhibitor combinations.  AZD1775 sensitivity in SCLC cell lines was correlated with baseline expression level of 200 total or phosphorylated proteins measured by reverse-phase protein array (RPPA) to identify predictive markers of primary resistance.  We further established AZD1775 acquired resistance models to identify mechanism of acquired resistance.  Combination regimens were tested to overcome primary and acquired resistance to AZD1775 in in vitro and in vivo SCLC models.  High-throughput proteomic profiling demonstrate that SCLC models with primary resistance to AZD1775 express high levels of AXL and phosphorylated S6 and that WEE1/AXL or WEE1/mTOR inhibitor combinations overcome resistance in vitro and in vivo.  Furthermore, AXL, independently and via mTOR, activates the ERK pathway, leading to recruitment and activation of another G2-checkpoint protein, CHK1.  AZD1775 acquired resistance models demonstrated upregulation of AXL, pS6, and MET, and resistance was overcome with the addn. of AXL (TP0903), dual-AXL/MET (cabozantinib), or mTOR (RAD001) inhibitors.  AXL promotes resistance to WEE1 inhibition via downstream mTOR signaling and resulting activation of a parallel DNA damage repair pathway, CHK1.  These findings suggest rational combinations to enhance the clin. efficacy of AZD1775, which is currently in clin. trials for SCLC and other malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXHr15nrmjyrVg90H21EOLACvtfcHk0lhR_O_CreYb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrbK&md5=4206192309431713c6877b7ee8958ee7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1284%26sid%3Dliteratum%253Aachs%26aulast%3DSen%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DHoff%26aufirst%3DJ.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DTargeting%2520Axl%2520and%2520mTOR%2520pathway%2520overcomes%2520primary%2520and%2520acquired%2520resistance%2520to%2520Wee1%2520inhibition%2520in%2520small-cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D6239%26epage%3D6253%26doi%3D10.1158%2F1078-0432.ccr-17-1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linger, R. M. A.</span>; <span class="NLM_string-name">Keating, A. K.</span>; <span class="NLM_string-name">Earp, H. S.</span>; <span class="NLM_string-name">Graham, D. K.</span></span> <span> </span><span class="NLM_article-title">TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer</span>. In  <i>Advances in Cancer Research, Vol. 100</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">VandeWoude, G. F.</span>, <span class="NLM_string-name">Klein, G.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier Academic Press Inc.</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2008</span>; Vol.  <span class="NLM_volume">100</span>, pp  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">83</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2FS0065-230X%2808%2900002-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=35-83&author=R.+M.+A.+Linger&author=A.+K.+Keating&author=H.+S.+Earp&author=D.+K.+Grahamauthor=G.+F.+VandeWoude&author=G.+Klein&title=Advances+in+Cancer+Research%2C+Vol.+100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2808%2900002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0065-230X%252808%252900002-X%26sid%3Dliteratum%253Aachs%26aulast%3DLinger%26aufirst%3DR.%2BM.%2BA.%26atitle%3DTAM%2520receptor%2520tyrosine%2520kinases%253A%2520biologic%2520functions%252C%2520signaling%252C%2520and%2520potential%2520therapeutic%2520targeting%2520in%2520human%2520cancer%26btitle%3DAdvances%2520in%2520Cancer%2520Research%252C%2520Vol.%2520100%26aulast%3DVandeWoude%26aufirst%3DG.%2BF.%26pub%3DElsevier%2520Academic%2520Press%2520Inc%26date%3D2008%26volume%3D100%26spage%3D35%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X. W.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">153</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-1090-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1186%2Fs12943-019-1090-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=31684958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BB3MjkvFyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=153&author=C.+J.+Zhuauthor=Y.+Q.+Weiauthor=X.+W.+Wei&title=Axl+receptor+tyrosine+kinase+as+a+promising+anti-cancer+approach%3A+functions%2C+molecular+mechanisms+and+clinical+applications&doi=10.1186%2Fs12943-019-1090-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications</span></div><div class="casAuthors">Zhu Chenjing; Wei Yuquan; Wei Xiawei; Zhu Chenjing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular targeted therapy for cancer has been a research hotspot for decades.  AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6).  The Gas6/AXL signalling pathway is associated with tumour cell growth, metastasis, invasion, epithelial-mesenchymal transition (EMT), angiogenesis, drug resistance, immune regulation and stem cell maintenance.  Different therapeutic agents targeting AXL have been developed, typically including small molecule inhibitors, monoclonal antibodies (mAbs), nucleotide aptamers, soluble receptors, and several natural compounds.  In this review, we first provide a comprehensive discussion of the structure, function, regulation, and signalling pathways of AXL.  Then, we highlight recent strategies for targeting AXL in the treatment of cancer.AXL-targeted drugs, either as single agents or in combination with conventional chemotherapy or other small molecule inhibitors, are likely to improve the survival of many patients.  However, future investigations into AXL molecular signalling networks and robust predictive biomarkers are warranted to select patients who could receive clinical benefit and to avoid potential toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWZj0ShdbIUTjk2McQZ6XmfW6udTcc2eYl2cv_7cvBNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjkvFyhsA%253D%253D&md5=7fc0485d2e05aab8ccca4577280f3988</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1090-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1090-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DC.%2BJ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DWei%26aufirst%3DX.%2BW.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520anti-cancer%2520approach%253A%2520functions%252C%2520molecular%2520mechanisms%2520and%2520clinical%2520applications%26jtitle%3DMol.%2520Cancer%26date%3D2019%26volume%3D18%26spage%3D153%26doi%3D10.1186%2Fs12943-019-1090-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinato, D. J.</span></span> <span> </span><span class="NLM_article-title">Gene of the month: Axl</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1136/jclinpath-2016-203629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1136%2Fjclinpath-2016-203629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26951083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVyktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=391-397&author=M.+Brownauthor=J.+R.+M.+Blackauthor=R.+Sharmaauthor=J.+Stebbingauthor=D.+J.+Pinato&title=Gene+of+the+month%3A+Axl&doi=10.1136%2Fjclinpath-2016-203629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Gene of the month: axl</span></div><div class="casAuthors">Brown, Matthew; Black, James R. M.; Sharma, Rohini; Stebbing, Justin; Pinato, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">391-397</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">The interaction between Axl receptor tyrosine kinase and its main ligand Gas6 has been implicated in the progression of a wide no. of malignancies.  More recently, overexpression of Axl has emerged as a key mol. determinant underlying the development of acquired resistance to targeted anticancer agents.  The activation of Axl is overexpression-dependent and controls a no. of hallmarks of cancer progression including proliferation, migration, resistance to apoptosis and survival through a complex network of intracellular second messengers.  Axl has been noted to influence clin. meaningful end points including metastatic recurrence and survival in the vast majority of tumor types.  With Axl inhibitors having gained momentum as novel anticancer therapies, we provide an overview of the biol. and clin. relevance of this mol. pathway, outlining the main directions of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMgYKvX3NBebVg90H21EOLACvtfcHk0lhR_O_CreYb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVyktLw%253D&md5=0711fa811911dc6a383b48c1ce7ed3a9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2016-203629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2016-203629%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DBlack%26aufirst%3DJ.%2BR.%2BM.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DPinato%26aufirst%3DD.%2BJ.%26atitle%3DGene%2520of%2520the%2520month%253A%2520Axl%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2016%26volume%3D69%26spage%3D391%26epage%3D397%26doi%3D10.1136%2Fjclinpath-2016-203629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramjiawan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffioen, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, D. G.</span></span> <span> </span><span class="NLM_article-title">Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?</span>. <i>Angiogenesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1007/s10456-017-9552-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1007%2Fs10456-017-9552-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28361267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1cvjtVWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=185-204&author=R.+R.+Ramjiawanauthor=A.+W.+Griffioenauthor=D.+G.+Duda&title=Anti-angiogenesis+for+cancer+revisited%3A+is+there+a+role+for+combinations+with+immunotherapy%3F&doi=10.1007%2Fs10456-017-9552-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?</span></div><div class="casAuthors">Ramjiawan Rakesh R; Duda Dan G; Ramjiawan Rakesh R; Griffioen Arjan W</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-204</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and has been characterized as an essential process for tumor cell proliferation and viability.  This has led to the development of pharmacological agents for anti-angiogenesis to disrupt the vascular supply and starve tumor of nutrients and oxygen, primarily through blockade of VEGF/VEGFR signaling.  This effort has resulted in 11 anti-VEGF drugs approved for certain advanced cancers, alone or in combination with chemotherapy or other targeted therapies.  But this success had only limited impact on overall survival of cancer patients and rarely resulted in durable responses.  Given the recent success of immunotherapies, combinations of anti-angiogenics with immune checkpoint blockers have become an attractive strategy.  However, implementing such combinations will require a better mechanistic understanding of their interaction.  Due to overexpression of pro-angiogenic factors in tumors, their vasculature is often tortuous and disorganized, with excessively branched leaky vessels.  This enhances vascular permeability, which in turn is associated with high interstitial fluid pressure, and a reduction in blood perfusion and oxygenation.  Judicious dosing of anti-angiogenic treatment can transiently normalize the tumor vasculature by decreasing vascular permeability and improving tumor perfusion and blood flow, and synergize with immunotherapy in this time window.  However, anti-angiogenics may also excessively prune tumor vessels in a dose and time-dependent manner, which induces hypoxia and immunosuppression, including increased expression of the immune checkpoint programmed death receptor ligand (PD-L1).  This review focuses on revisiting the concept of anti-angiogenesis in combination with immunotherapy as a strategy for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa4t3uAUqTpoYPsCkJIw00fW6udTcc2ebs4W86He1yiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvjtVWgug%253D%253D&md5=6ecf5a8cbecdf525a7d132d5211d7096</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs10456-017-9552-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-017-9552-y%26sid%3Dliteratum%253Aachs%26aulast%3DRamjiawan%26aufirst%3DR.%2BR.%26aulast%3DGriffioen%26aufirst%3DA.%2BW.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26atitle%3DAnti-angiogenesis%2520for%2520cancer%2520revisited%253A%2520is%2520there%2520a%2520role%2520for%2520combinations%2520with%2520immunotherapy%253F%26jtitle%3DAngiogenesis%26date%3D2017%26volume%3D20%26spage%3D185%26epage%3D204%26doi%3D10.1007%2Fs10456-017-9552-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’bryan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebeau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. T.</span></span> <span> </span><span class="NLM_article-title">Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5016</span>– <span class="NLM_lpage">5031</span>, <span class="refDoi"> DOI: 10.1128/mcb.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Lebeauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=Axl%2C+a+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2Fmcb.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0ljAbOS0DpyLuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLebeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DAxl%252C%2520a%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2Fmcb.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Axl Inhibitors in cancer: a medicinal chemistry perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3593</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3593-3608&author=S.+H.+Myersauthor=V.+G.+Bruntonauthor=A.+Unciti-Broceta&title=Axl+Inhibitors+in+cancer%3A+a+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.5b01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Myers, Samuel H.; Brunton, Valerie G.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of the AXL receptor tyrosine kinase has been assocd. with many types of cancer.  It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance.  The entry of the first AXL-branded inhibitor in clin. trials in 2013 marked an important milestone for the clin. validation of AXL as an anticancer target.  Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clin. development have AXL as either a prominent secondary or even the primary target.  Through this review, the chem. and biol. properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7-ZTTNRD9LLVg90H21EOLACvtfcHk0ljAbOS0DpyLuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI&md5=4643d9d9950251a14c3991c306c4cec0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DAxl%2520Inhibitors%2520in%2520cancer%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.5b01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gjerdrum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoiby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklem, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glackin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorens, J. B.</span></span> <span> </span><span class="NLM_article-title">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1073/pnas.0909333107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1073%2Fpnas.0909333107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=20080645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1124-1129&author=C.+Gjerdrumauthor=C.+Tironauthor=T.+Hoibyauthor=I.+Stefanssonauthor=H.+Haugenauthor=T.+Sandalauthor=K.+Collettauthor=S.+Liauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=D.+R.+Micklemauthor=L.+A.+Akslenauthor=C.+Glackinauthor=J.+B.+Lorens&title=Axl+is+an+essential+epithelial-to-mesenchymal+transition-induced+regulator+of+breast+cancer+metastasis+and+patient+survival&doi=10.1073%2Fpnas.0909333107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span></div><div class="casAuthors">Gjerdrum, Christine; Tiron, Crina; Hoeiby, Torill; Stefansson, Ingunn; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet; Gjertsen, Bjoern Tore; Micklem, David R.; Akslen, Lars A.; Glackin, Carlotta; Lorens, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129, S1124/1-S1124/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Metastasis underlies the majority of cancer-related deaths.  Thus, furthering our understanding of the mol. mechanisms that enable tumor cell dissemination is a vital health issue.  Epithelial-to-mesenchymal transitions (EMTs) endow carcinoma cells with enhanced migratory and survival attributes that facilitate malignant progression.  Characterization of EMT effectors is likely to yield new insights into metastasis and novel avenues for treatment.  We show that the presence of the receptor tyrosine kinase Axl in primary breast cancers independently predicts strongly reduced overall patient survival, and that matched patient metastatic lesions show enhanced Axl expression.  We demonstrate that Axl is strongly induced by EMT in immortalized mammary epithelial cells that establishes an autocrine signaling loop with its ligand, Gas6.  Epiallelic RNA interference anal. in metastatic breast cancer cells delineated a distinct threshold of Axl expression for mesenchymal-like in vitro cell invasiveness and formation of tumors in foreign and tissue-engineered micro-environments in vivo.  Importantly, in two different optical imaging-based exptl. breast cancer models, Axl knockdown completely prevented the spread of highly metastatic breast carcinoma cells from the mammary gland to lymph nodes and several major organs and increased overall survival.  These findings suggest that Axl represents a downstream effector of the tumor cell EMT that is required for breast cancer metastasis.  Thus, the detection and targeted treatment of Axl-expressing tumors represents an important new therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPiST_cnXhqrVg90H21EOLACvtfcHk0lgduaAGwQ14EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D&md5=dbd7113028010a800e22ff1f206b9337</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909333107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909333107%26sid%3Dliteratum%253Aachs%26aulast%3DGjerdrum%26aufirst%3DC.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DHoiby%26aufirst%3DT.%26aulast%3DStefansson%26aufirst%3DI.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DCollett%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGlackin%26aufirst%3DC.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DAxl%2520is%2520an%2520essential%2520epithelial-to-mesenchymal%2520transition-induced%2520regulator%2520of%2520breast%2520cancer%2520metastasis%2520and%2520patient%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D1124%26epage%3D1129%26doi%3D10.1073%2Fpnas.0909333107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase as a therapeutic target in NSCLC</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S60438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.2147%2FLCTT.S60438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28210148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1c3nvVyqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=27-34&author=R.+A.+Okimotoauthor=T.+G.+Bivona&title=Axl+receptor+tyrosine+kinase+as+a+therapeutic+target+in+NSCLC&doi=10.2147%2FLCTT.S60438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor tyrosine kinase as a therapeutic target in NSCLC</span></div><div class="casAuthors">Okimoto Ross A; Bivona Trever G</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer (Auckland, N.Z.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-34</span>
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    </div><div class="casAbstract">The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial-mesenchymal transition-associated drug resistance.  Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models.  These findings implicate AXL as a promising therapeutic target in lung cancer.  In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHsEgSYJcabOLt9HypzAgQfW6udTcc2eYIhDnCvrVuWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3nvVyqsQ%253D%253D&md5=60fcef522f3feebeb40f86ef7880e90f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S60438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S60438%26sid%3Dliteratum%253Aachs%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520NSCLC%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D6%26spage%3D27%26epage%3D34%26doi%3D10.2147%2FLCTT.S60438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reichl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zijl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Führlinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieghart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck-Radosavljevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulits, W.</span></span> <span> </span><span class="NLM_article-title">Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1002/hep.27492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1002%2Fhep.27492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=25251599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=930-941&author=P.+Reichlauthor=M.+Denglerauthor=F.+van+Zijlauthor=H.+Huberauthor=G.+F%C3%BChrlingerauthor=C.+Reichelauthor=W.+Sieghartauthor=M.+Peck-Radosavljevicauthor=M.+Grubingerauthor=W.+Mikulits&title=Axl+activates+autocrine+transforming+growth+factor-beta+signaling+in+hepatocellular+carcinoma&doi=10.1002%2Fhep.27492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma</span></div><div class="casAuthors">Reichl, Patrick; Dengler, Mirko; van Zijl, Franziska; Huber, Heidemarie; Fuehrlinger, Gerhard; Reichel, Christian; Sieghart, Wolfgang; Peck-Radosavljevic, Markus; Grubinger, Markus; Mikulits, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">930-941</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epithelial to mesenchymal transition (EMT) of malignant hepatocytes.  Several mechanisms have been identified to be essentially involved in hepatocellular EMT, among them transforming growth factor (TGF)-β signaling.  Here we show the up-regulation and activation of the receptor tyrosine kinase Axl in EMT-transformed hepatoma cells.  Knockdown of Axl expression resulted in abrogation of invasive and transendothelial migratory abilities of mesenchymal HCC cells in vitro and Axl overexpression-induced metastatic colonization of epithelial hepatoma cells in vivo.  Importantly, Axl knockdown severely impaired resistance to TGF-β-mediated growth inhibition.  Anal. of the Axl interactome revealed binding of Axl to 14-3-3ζ, which is essentially required for Axl-mediated cell invasion, transendothelial migration, and resistance against TGF-β.  Axl/14-3-3ζ signaling caused phosphorylation of Smad3 linker region (Smad3L) at Ser213, resulting in the up-regulation of tumor-progressive TGF-β target genes such as PAI1, MMP9, and Snail as well as augmented TGF-β1 secretion in mesenchymal HCC cells.  Accordingly, high Axl expression in HCC patient samples correlated with elevated vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong phosphorylation of Smad3L, and lower survival.  In addn., elevated expression of both Axl and 14-3-3ζ showed strongly reduced survival of HCC patients.  Conclusion: Our data suggest that Axl/14-3-3ζ signaling is central for TGF-β-mediated HCC progression and a promising target for HCC therapy. (Hepatol. 2015;61:930-941).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYINc0VpFLaLVg90H21EOLACvtfcHk0lgduaAGwQ14EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D&md5=9a7978862c05e63ad91bea57520c6c89</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fhep.27492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27492%26sid%3Dliteratum%253Aachs%26aulast%3DReichl%26aufirst%3DP.%26aulast%3DDengler%26aufirst%3DM.%26aulast%3Dvan%2BZijl%26aufirst%3DF.%26aulast%3DHuber%26aufirst%3DH.%26aulast%3DF%25C3%25BChrlinger%26aufirst%3DG.%26aulast%3DReichel%26aufirst%3DC.%26aulast%3DSieghart%26aufirst%3DW.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DGrubinger%26aufirst%3DM.%26aulast%3DMikulits%26aufirst%3DW.%26atitle%3DAxl%2520activates%2520autocrine%2520transforming%2520growth%2520factor-beta%2520signaling%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D930%26epage%3D941%26doi%3D10.1002%2Fhep.27492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koorstra, J.-B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karikari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal-Rojas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offerhaus, G. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span> <span> </span><span class="NLM_article-title">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.4161/cbt.8.7.7923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.4161%2Fcbt.8.7.7923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=19252414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=618-626&author=J.-B.+M.+Koorstraauthor=C.+Karikariauthor=G.+Feldmannauthor=S.+Bishtauthor=P.+Leal-Rojasauthor=G.+J.+A.+Offerhausauthor=H.+Alvarezauthor=A.+Maitra&title=The+Axl+receptor+tyrosine+kinase+confers+an+adverse+prognostic+influence+in+pancreatic+cancer+and+represents+a+new+therapeutic+target&doi=10.4161%2Fcbt.8.7.7923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span></div><div class="casAuthors">Koorstra, Jan-Bart M.; Karikari, Collins A.; Feldmann, Georg; Bisht, Savita; Rojas, Pamela Leal; Offerhaus, G. Johan A.; Alvarez, Hector; Maitra, Anirban</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-626</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Background: Pancreatic cancer is a near uniformly lethal disease and a better understanding of the mol. basis of this malignancy may lead to improved therapeutics.  The Axl receptor tyrosine kinase is implicated in cellular transformation and tumor progression, although its role in pancreatic cancer has not been previously documented.  Results: Axl labeling was present in 54 of 99 (55%), and was absent in 45 of 99 (45%) cases, resp.  Axl expression in pancreatic cancer was significantly assocd. with lymph node metastases (p < 0.01), and a shorter median survival (12 vs. 18 mo, p < 0.01), than in tumors with neg. labeling.  Stable knockdown of Axl resulted in significant redn. in cell viability (p < 0.001), anchorage independent growth (p = 0.0031), as well as attenuation of migratory (p < 0.001) and invasive properties (p < 0.005), compared to vector-transfected cells.  Profound inhibition of p42/p44 MAP kinase and PI-3kinase/Akt effector pathways was obsd. in MIAPaCa-2 cells with loss of Axl function.  The redn. in invasion and migration upon Axl knockdown was mirrored by a decrease in the amts. of activated (GTP-bound) GTPase proteins Rho and Rac, significant downregulation in transcript levels of the epithelial mesenchymal transition (EMT)-assocd. transcription factors slug, snail and twist, and significant decrease in matrix metalloproteinase MMP-9 mRNA levels.  Materials: The immunohistochem. expression of Axl protein was assessed in a panel of 99 archival pancreatic cancers.  Endogenous Axl expression was stably downregulated by lentiviral short hairpin shRNA directed against AXL mRNA in MIAPaCa-2 cells, and the effects on cell viability, anchorage independent growth, invasion, migration and intracellular effector pathways was assessed, by comparing to lentiviral vector-transfected cells.  Conclusion: Expression of Axl tyrosine kinase in pancreatic cancers confers an adverse prognostic influence, and represents a new therapeutic target in this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVcT_EyeJ5LVg90H21EOLACvtfcHk0ljBmtzGgaq-nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D&md5=36b9836411f2b315629eb951b8765a72</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4161%2Fcbt.8.7.7923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.8.7.7923%26sid%3Dliteratum%253Aachs%26aulast%3DKoorstra%26aufirst%3DJ.-B.%2BM.%26aulast%3DKarikari%26aufirst%3DC.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DBisht%26aufirst%3DS.%26aulast%3DLeal-Rojas%26aufirst%3DP.%26aulast%3DOfferhaus%26aufirst%3DG.%2BJ.%2BA.%26aulast%3DAlvarez%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DA.%26atitle%3DThe%2520Axl%2520receptor%2520tyrosine%2520kinase%2520confers%2520an%2520adverse%2520prognostic%2520influence%2520in%2520pancreatic%2520cancer%2520and%2520represents%2520a%2520new%2520therapeutic%2520target%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D618%26epage%3D626%26doi%3D10.4161%2Fcbt.8.7.7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, H.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasnoperov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bove, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buscarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretiakova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P. S.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1038%2Fbjc.2015.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26180925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=616-625&author=H.+Yuauthor=R.+Liuauthor=B.+Maauthor=X.+Liauthor=H.-y.+Yenauthor=Y.+Zhouauthor=V.+Krasnoperovauthor=Z.+Xiaauthor=X.+Zhangauthor=A.+M.+Boveauthor=M.+Buscariniauthor=D.+Parekhauthor=I.+S.+Gillauthor=Q.+Liaoauthor=M.+Tretiakovaauthor=D.+Quinnauthor=J.+Zhaoauthor=P.+S.+Gill&title=Axl+receptor+tyrosine+kinase+is+a+potential+therapeutic+target+in+renal+cell+carcinoma&doi=10.1038%2Fbjc.2015.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span></div><div class="casAuthors">Yu, H.; Liu, R.; Ma, B.; Li, X.; Yen, H.-Y.; Zhou, Y.; Krasnoperov, V.; Xia, Z.; Zhang, X.; Bove, A. M.; Buscarini, M.; Parekh, D.; Gill, I. S.; Liao, Q.; Tretiakova, M.; Quinn, D.; Zhao, J.; Gill, P. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">616-625</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Axl plays multiple roles in tumorigenesis in several cancers.  Here we evaluated the expression and biol. function of Axl in renal cell carcinoma (RCC).  Methods: Axl expression was analyzed in a tissue microarray of 174 RCC samples by immunostaining and a panel of 11 normal tumor pairs of human RCC tissues by western blot, as well as in RCC cell lines by both western blot and quant. PCR.  The effects of Axl knockdown in RCC cells on cell growth and signalling were investigated.  The efficacy of a humanized Axl targeting monoclonal antibody hMAb173 was tested in histoculture and tumor xenograft.  Results: We have detd. by immunohistochem. (IHC) that Axl is expressed in 59% of RCC array samples with moderate to high in 20% but not expressed in normal kidney tissue.  Western blot anal. of 11 pairs of tumor and adjacent normal tissue show high Axl expression in 73% of the tumors but not normal tissue.  Axl is also expressed in RCC cell lines in which Axl knockdown reduces cell viability and PI3K/Akt signalling.  The Axl antibody hMAb173 significantly induced RCC cell apoptosis in histoculture and inhibited the growth of RCC tumor in vivo by 78%.  The hMAb173-treated tumors also had significantly reduced Axl protein levels, inhibited PI3K signalling, decreased proliferation, and induced apoptosis.  Conclusions: Axl is highly expressed in RCC and crit. for RCC cell survival.  Targeting Axl is a potential approach for RCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKf4yyaQhWrVg90H21EOLACvtfcHk0ljBmtzGgaq-nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO&md5=3f916c7beaa150038cbc5ed35594be29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.237%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYen%26aufirst%3DH.-y.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKrasnoperov%26aufirst%3DV.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBove%26aufirst%3DA.%2BM.%26aulast%3DBuscarini%26aufirst%3DM.%26aulast%3DParekh%26aufirst%3DD.%26aulast%3DGill%26aufirst%3DI.%2BS.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DTretiakova%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGill%26aufirst%3DP.%2BS.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520potential%2520therapeutic%2520target%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D616%26epage%3D625%26doi%3D10.1038%2Fbjc.2015.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longacre, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccia, A. J.</span></span> <span> </span><span class="NLM_article-title">Axl is an essential factor and therapeutic target for metastatic ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">7570</span>– <span class="NLM_lpage">7579</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-1267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-10-1267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=20858715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7570-7579&author=E.+B.+Rankinauthor=K.+C.+Fuhauthor=T.+E.+Taylorauthor=A.+J.+Kriegauthor=M.+Musserauthor=J.+Yuanauthor=K.+Weiauthor=C.+J.+Kuoauthor=T.+A.+Longacreauthor=A.+J.+Giaccia&title=Axl+is+an+essential+factor+and+therapeutic+target+for+metastatic+ovarian+cancer&doi=10.1158%2F0008-5472.can-10-1267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AXL is an essential factor and therapeutic target for metastatic ovarian cancer</span></div><div class="casAuthors">Rankin, Erinn B.; Fuh, Katherine C.; Taylor, Tiffany E.; Krieg, Adam J.; Musser, Margaret; Yuan, Jenny; Wei, Kevin; Kuo, Calvin J.; Longacre, Teri A.; Giaccia, Amato J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7570-7579</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease.  In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer.  AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium.  Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo.  Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity.  Most importantly, sol. human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity.  These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of metastatic tumor progression in vivo.  Furthermore, this study defines the sol. AXL receptor as a therapeutic candidate agent for treatment of metastatic ovarian cancer, for which current therapies are ineffective.  Cancer Res; 70(19); 7570-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPykmi9dwSQrVg90H21EOLACvtfcHk0ljBmtzGgaq-nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akt7bN&md5=a8ff92ad8562bf72dc6defe54cc8cdfe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1267%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DFuh%26aufirst%3DK.%2BC.%26aulast%3DTaylor%26aufirst%3DT.%2BE.%26aulast%3DKrieg%26aufirst%3DA.%2BJ.%26aulast%3DMusser%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DKuo%26aufirst%3DC.%2BJ.%26aulast%3DLongacre%26aufirst%3DT.%2BA.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DAxl%2520is%2520an%2520essential%2520factor%2520and%2520therapeutic%2520target%2520for%2520metastatic%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7570%26epage%3D7579%26doi%3D10.1158%2F0008-5472.can-10-1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span> <span> </span><span class="NLM_article-title">The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.2147/ott.s150952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.2147%2FOTT.S150952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29416351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1MvovFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=509-519&author=S.+Zhangauthor=X.+S.+Xuauthor=J.+X.+Yangauthor=J.+H.+Guoauthor=T.+F.+Chaoauthor=Y.+Tong&title=The+prognostic+role+of+Gas6%2FAxl+axis+in+solid+malignancies%3A+a+meta-analysis+and+literature+review&doi=10.2147%2Fott.s150952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review</span></div><div class="casAuthors">Zhang Sheng; Xu Xiang Shang; Yang Jie Xi; Guo Jian Hui; Tong YiXin; Chao Teng Fei</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">509-519</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">Background:  Axl is a receptor tyrosine kinase that is involved in many pathological conditions and carcinogenesis.  Gas6 is the major ligand of Axl.  Activation of Gas6/Axl pathway is essential for cancer development.  However, its prognostic significance in solid tumors remains unclear.  Therefore, we performed this meta-analysis to elucidate the prognostic impact of Axl.  Methods:  Published studies on Axl or Gas6 expression and overall survival (OS) and/or disease-free survival (DFS) were searched from databases.  The outcome measurement is hazard ratio (HR) for OS or DFS related to Axl/Gas6 expression.  Meta-analysis was performed using RevMan.  The pooled HR was calculated by fixed-/random-effect models.  Results:  A total of 3,344 patients from 25 studies were included.  The results of meta-analysis showed that Axl overexpression was correlated with shorter OS (HR: 2.03, p<0.0001) and DFS (HR: 1.85, p<0.0001).  In subgroup analysis, Axl expression was significantly correlated with poor prognosis in hepatocellular, esophageal and lung cancer.  Axl expression was associated with differentiation grade, TNM stage, lymph node and distant metastasis.  Conclusion:  These results suggest that Axl overexpression is correlated with poor prognosis in solid tumors.  This correlation varies among different types of cancers.  More studies are needed to further investigate the prognostic value of Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6pIjsaYw3_f9pSBfyDvp7fW6udTcc2eY7gmlTy_PEQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvovFWqug%253D%253D&md5=b6c21c011378bfcbd50af1cdc6b92a42</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2147%2FOTT.S150952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S150952%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BX.%26aulast%3DGuo%26aufirst%3DJ.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BF.%26aulast%3DTong%26aufirst%3DY.%26atitle%3DThe%2520prognostic%2520role%2520of%2520Gas6%252FAxl%2520axis%2520in%2520solid%2520malignancies%253A%2520a%2520meta-analysis%2520and%2520literature%2520review%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D509%26epage%3D519%26doi%3D10.2147%2Fott.s150952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrigan, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braverman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toulany, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimple, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, D. L.</span></span> <span> </span><span class="NLM_article-title">Axl mediates resistance to cetuximab therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5164</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-14-0294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-14-0294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=25136066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFChtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5152-5164&author=T.+M.+Brandauthor=M.+Iidaauthor=A.+P.+Steinauthor=K.+L.+Corriganauthor=C.+M.+Bravermanauthor=N.+Lutharauthor=M.+Toulanyauthor=P.+S.+Gillauthor=R.+Salgiaauthor=R.+J.+Kimpleauthor=D.+L.+Wheeler&title=Axl+mediates+resistance+to+cetuximab+therapy&doi=10.1158%2F0008-5472.can-14-0294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Mediates Resistance to Cetuximab Therapy</span></div><div class="casAuthors">Brand, Toni M.; Iida, Mari; Stein, Andrew P.; Corrigan, Kelsey L.; Braverman, Cara M.; Luthar, Neha; Toulany, Mahmoud; Gill, Parkash S.; Salgia, Ravi; Kimple, Randall J.; Wheeler, Deric L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5152-5164</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clin. outcome.  In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL was overexpressed, activated, and tightly assocd. with EGFR expression in cells resistant to cetuximab (CtR cells).  Using RNAi methods and novel AXL-targeting agents, we found that AXL activation stimulated cell proliferation, EGFR activation, and MAPK signaling in CtxR cells.  Notably, EGFR directly regulated the expression of AXL mRNA through MAPK signaling and the transcription factor c-Jun in CtxR cells, creating a pos. feedback loop that maintained EGFR activation by AXL.  Cetuximab-sensitive parental cells were rendered resistant to cetuximab by stable overexpression of AXL or stimulation with EGFR ligands, the latter of which increased AXL activity and assocn. with the EGFR.  In tumor xenograft models, the development of resistance following prolonged treatment with cetuximab was assocd. with AXL hyperactivation and EGFR assocn.  Furthermore, in an examn. of patient-derived xenografts established from surgically resected HNSCCs, AXL was overexpressed and activated in tumors that displayed intrinsic resistance to cetuximab.  Collectively, our results identify AXL as a key mediator of cetuximab resistance, providing a rationale for clin. evaluation of AXL-targeting drugs to treat cetuximab- resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN2dPn1qh9vLVg90H21EOLACvtfcHk0lhM-JrdQAOe_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFChtbfO&md5=7ecf9686e615d247f010b59f480699f6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0294%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DT.%2BM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DStein%26aufirst%3DA.%2BP.%26aulast%3DCorrigan%26aufirst%3DK.%2BL.%26aulast%3DBraverman%26aufirst%3DC.%2BM.%26aulast%3DLuthar%26aufirst%3DN.%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DP.%2BS.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DKimple%26aufirst%3DR.%2BJ.%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26atitle%3DAxl%2520mediates%2520resistance%2520to%2520cetuximab%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5152%26epage%3D5164%26doi%3D10.1158%2F0008-5472.can-14-0294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkabets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazarentzos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelossof, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzaken, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixidó, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Axl mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.ccell.2015.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=25873175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=533-546&author=M.+Elkabetsauthor=E.+Pazarentzosauthor=D.+Juricauthor=Q.+Shengauthor=R.+A.+Pelossofauthor=S.+Brookauthor=A.+O.+Benzakenauthor=J.+Rodonauthor=N.+Morseauthor=J.+J.+Yanauthor=M.+Liuauthor=R.+Dasauthor=Y.+Chenauthor=A.+Tamauthor=H.+Wangauthor=J.+Liangauthor=J.+M.+Gurskiauthor=D.+A.+Kerrauthor=R.+Rosellauthor=C.+Teixid%C3%B3author=A.+Huangauthor=R.+A.+Ghosseinauthor=N.+Rosenauthor=T.+G.+Bivonaauthor=M.+Scaltritiauthor=J.+Baselga&title=Axl+mediates+resistance+to+PI3Kalpha+inhibition+by+activating+the+EGFR%2FPKC%2FmTOR+axis+in+head+and+neck+and+esophageal+squamous+cell+carcinomas&doi=10.1016%2Fj.ccell.2015.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span></div><div class="casAuthors">Elkabets, Moshe; Pazarentzos, Evangelos; Juric, Dejan; Sheng, Qing; Pelossof, Raphael A.; Brook, Samuel; Benzaken, Ana Oaknin; Rodon, Jordi; Morse, Natasha; Yan, Jenny Jiacheng; Liu, Manway; Das, Rita; Chen, Yan; Tam, Angela; Wang, Huiqin; Liang, Jinsheng; Gurski, Joseph M.; Kerr, Darcy A.; Rosell, Rafael; Teixido, Cristina; Huang, Alan; Ghossein, Ronald A.; Rosen, Neal; Bivona, Trever G.; Scaltriti, Maurizio; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-546</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clin. activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification.  Studying models of therapeutic resistance, we have obsd. that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR).  This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL.  AXL is overexpressed in resistant tumors from both lab. models and patients treated with the PI3Kα inhibitor BYL719.  AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR.  Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkH5_tNi2YrVg90H21EOLACvtfcHk0lhM-JrdQAOe_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D&md5=55b0362b0e32f0c305c5257aa66ecdc5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DElkabets%26aufirst%3DM.%26aulast%3DPazarentzos%26aufirst%3DE.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DPelossof%26aufirst%3DR.%2BA.%26aulast%3DBrook%26aufirst%3DS.%26aulast%3DBenzaken%26aufirst%3DA.%2BO.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DMorse%26aufirst%3DN.%26aulast%3DYan%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DGurski%26aufirst%3DJ.%2BM.%26aulast%3DKerr%26aufirst%3DD.%2BA.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DGhossein%26aufirst%3DR.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DAxl%2520mediates%2520resistance%2520to%2520PI3Kalpha%2520inhibition%2520by%2520activating%2520the%2520EGFR%252FPKC%252FmTOR%2520axis%2520in%2520head%2520and%2520neck%2520and%2520esophageal%2520squamous%2520cell%2520carcinomas%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D533%26epage%3D546%26doi%3D10.1016%2Fj.ccell.2015.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaola, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. R.</span></span> <span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">15321</span>– <span class="NLM_lpage">15331</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.18632%2Foncotarget.4148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26036314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=15321-15331&author=N.+Bansalauthor=P.+J.+Mishraauthor=M.+Steinauthor=R.+S.+DiPaolaauthor=J.+R.+Bertino&title=Axl+receptor+tyrosine+kinase+is+up-regulated+in+metformin+resistant+prostate+cancer+cells&doi=10.18632%2Foncotarget.4148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span></div><div class="casAuthors">Bansal Nitu; Stein Mark; DiPaola Robert S; Bertino Joseph R; Mishra Prasun J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">15321-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent epidemiological studies showed that metformin, a widely used anti-diabetic drug might prevent certain cancers.  Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress.  However, all cancer types do not respond to metformin with the same effectiveness or acquire resistance.  To understand the mechanism of acquired resistance and possibly its mechanism of action as an anti-proliferative agent, we developed metformin resistant LNCaP prostate cancer cells.  Metformin resistant LNCaP cells had an increased proliferation rate, increased migration and invasion ability as compared to the parental cells, and expressed markers of epithelial-mesenchymal transition (EMT).  A detailed gene expression microarray comparing the resistant cells to the wild type cells revealed that Edil2, Ereg, Axl, Anax2, CD44 and Anax3 were the top up-regulated genes and calbindin 2 and TPTE (transmembrane phosphatase with tensin homology) and IGF1R were down regulated.  We focused on Axl, a receptor tyrosine kinase that has been shown to be up regulated in several drug resistance cancers.  Here, we show that the metformin resistant cell line as well as castrate resistant cell lines that over express Axl were more resistant to metformin, as well as to taxotere compared to androgen sensitive LNCaP and CWR22 cells that do not overexpress Axl.  Forced overexpression of Axl in LNCaP cells decreased metformin and taxotere sensitivity and knockdown of Axl in resistant cells increased sensitivity to these drugs.  Inhibition of Axl activity by R428, a small molecule Axl kinase inhibitor, sensitized metformin resistant cells that overexpressed Axl to metformin.  Inhibitors of Axl may enhance tumor responses to metformin and other chemotherapy in cancers that over express Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzxVEroSz9hdj_Vg2vObihfW6udTcc2ebYNq6QRQto4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D&md5=6dea3f587be6fb98b50e817d3735e7ef</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4148%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DP.%2BJ.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DDiPaola%26aufirst%3DR.%2BS.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520up-regulated%2520in%2520metformin%2520resistant%2520prostate%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D15321%26epage%3D15331%26doi%3D10.18632%2Foncotarget.4148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.-G.</span></span> <span> </span><span class="NLM_article-title">Targeting Axl overcomes resistance to docetaxel therapy in advanced prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">41064</span>– <span class="NLM_lpage">41077</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.18632%2Foncotarget.17026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28455956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BC1crisVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=41064-41077&author=J.-Z.+Linauthor=Z.-J.+Wangauthor=W.+Deauthor=M.+Zhengauthor=W.-Z.+Xuauthor=H.-F.+Wuauthor=A.+Armstrongauthor=J.-G.+Zhu&title=Targeting+Axl+overcomes+resistance+to+docetaxel+therapy+in+advanced+prostate+cancer&doi=10.18632%2Foncotarget.17026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer</span></div><div class="casAuthors">Lin Jian-Zhong; Wu Hong-Fei; Wang Zeng-Jun; Zheng Ming; De Wei; Xu Wei-Zhang; Armstrong Alex; Zhu Jia-Geng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">41064-41077</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resistance to docetaxel is a major clinical problem in advanced prostate cancer.  The overexpression of AXL receptor tyrosine kinase (AXL) has been correlated with chemotherapeutic drug resistance.  However, the role of AXL expression in docetaxel resistance in prostate cancer is yet unclear.  In this study, we demonstrate that AXL is overexpressed and activated independent of Gas6 in docetaxel-resistant prostate cancer cells (PC3-DR and DU145-DR).  Moreover, we show that forced overexpression of AXL in PC3 and DU145 cells is sufficient to induce resistance to docetaxel in these cell lines.  Notably, genetic or pharmacologic inhibition of AXL in the resistant models suppressed cell proliferation, migration, invasion, and tumor growth, and these effects were significantly augmented when AXL inhibition was combined with docetaxel treatment.  Mechanistically, we found that AXL inhibition led to reversion of the epithelial-mesenchymal transition (EMT) phenotype and decreased the expression of ATP-binding cassette B1 (ABCB1).  Overall, our results identify AXL as an important mediator of docetaxel resistance in prostate cancer.  We propose that AXL-targeted therapy, in combination with docetaxel, has the potential to improve the response to docetaxel therapy and reduce resistance induced by prolonged docetaxel therapy in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStOUb0jAA20IvKgEt20y1XfW6udTcc2ebYNq6QRQto4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crisVKjsw%253D%253D&md5=bacbf1956d79c39e8c71f49d82157036</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17026%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.-Z.%26aulast%3DWang%26aufirst%3DZ.-J.%26aulast%3DDe%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DW.-Z.%26aulast%3DWu%26aufirst%3DH.-F.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DJ.-G.%26atitle%3DTargeting%2520Axl%2520overcomes%2520resistance%2520to%2520docetaxel%2520therapy%2520in%2520advanced%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D41064%26epage%3D41077%26doi%3D10.18632%2Foncotarget.17026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaretsky, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu-Lieskovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berent-Maoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seja, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomeli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.02.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.cell.2016.02.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26997480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVKrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=35-44&author=W.+Hugoauthor=J.+M.+Zaretskyauthor=L.+Sunauthor=C.+Songauthor=B.+H.+Morenoauthor=S.+Hu-Lieskovanauthor=B.+Berent-Maozauthor=J.+Pangauthor=B.+Chmielowskiauthor=G.+Cherryauthor=E.+Sejaauthor=S.+Lomeliauthor=X.+Kongauthor=M.+C.+Kelleyauthor=J.+A.+Sosmanauthor=D.+B.+Johnsonauthor=A.+Ribasauthor=R.+S.+Lo&title=Genomic+and+transcriptomic+features+of+response+to+anti-PD-1+therapy+in+metastatic+melanoma&doi=10.1016%2Fj.cell.2016.02.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma</span></div><div class="casAuthors">Hugo, Willy; Zaretsky, Jesse M.; Sun, Lu; Song, Chunying; Moreno, Blanca Homet; Hu-Lieskovan, Siwen; Berent-Maoz, Beata; Pang, Jia; Chmielowski, Bartosz; Cherry, Grace; Seja, Elizabeth; Lomeli, Shirley; Kong, Xiangju; Kelley, Mark C.; Sosman, Jeffrey A.; Johnson, Douglas B.; Ribas, Antoni; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1 immune checkpoint blockade provides significant clin. benefits for melanoma patients.  We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy.  We find that overall high mutational loads assoc. with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2.  Innately resistant tumors display a transcriptional signature (referred to as the IPRES, or innate anti-PD-1 resistance), indicating concurrent up-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing.  Notably, mitogen-activated protein kinase (MAPK)-targeted therapy (MAPK inhibitor) induces similar signatures in melanoma, suggesting that a non-genomic form of MAPK inhibitor resistance mediates cross-resistance to anti-PD-1 therapy.  Validation of the IPRES in other independent tumor cohorts defines a transcriptomic subset across distinct types of advanced cancer.  These findings suggest that attenuating the biol. processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqG8tlIw784rVg90H21EOLACvtfcHk0linKlxk0rhpsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVKrsbw%253D&md5=6dc9125a9b933c81f63678c093d9c45f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.02.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.02.065%26sid%3Dliteratum%253Aachs%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DZaretsky%26aufirst%3DJ.%2BM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DB.%2BH.%26aulast%3DHu-Lieskovan%26aufirst%3DS.%26aulast%3DBerent-Maoz%26aufirst%3DB.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DCherry%26aufirst%3DG.%26aulast%3DSeja%26aufirst%3DE.%26aulast%3DLomeli%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DGenomic%2520and%2520transcriptomic%2520features%2520of%2520response%2520to%2520anti-PD-1%2520therapy%2520in%2520metastatic%2520melanoma%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D35%26epage%3D44%26doi%3D10.1016%2Fj.cell.2016.02.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristova, K.</span></span> <span> </span><span class="NLM_article-title">The RTK interactome: overview and perspective on RTK heterointeractions</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">5881</span>– <span class="NLM_lpage">5921</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=5881-5921&author=M.+D.+Paulauthor=K.+Hristova&title=The+RTK+interactome%3A+overview+and+perspective+on+RTK+heterointeractions&doi=10.1021%2Facs.chemrev.8b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The RTK interactome: Overview and perspective on RTK heterointeractions</span></div><div class="casAuthors">Paul, Michael D.; Hristova, Kalina</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5881-5921</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) play important roles in cell growth, motility, differentiation, and survival.  These single-pass membrane proteins are grouped into subfamilies based on the similarity of their extracellular domains.  They are generally thought to be activated by ligand binding, which promotes homodimerization and then autophosphorylation in trans.  However, RTK interactions are more complicated, as RTKs can interact in the absence of ligand and heterodimerize within and across subfamilies.  Here, we review the known cross-subfamily RTK heterointeractions and their possible biol. implications, as well as the methodologies which have been used to study them.  Moreover, we demonstrate how thermodn. models can be used to study RTKs and to explain many of the complicated biol. effects which have been described in the literature.  Finally, we discuss the concept of the RTK interactome: a putative, extensive network of interactions between the RTKs.  This RTK interactome can produce unique signaling outputs; can amplify, inhibit, and modify signaling; and can allow for signaling backups.  The existence of the RTK interactome could provide an explanation for the irreproducibility of exptl. data from different studies and for the failure of some RTK inhibitors to produce the desired therapeutic effects.  We argue that a deeper knowledge of RTK interactome thermodn. can lead to a better understanding of fundamental RTK signaling processes in health and disease.  We further argue that there is a need for quant., thermodn. studies that probe the strengths of the interactions between RTKs and their ligands and between different RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdTycRThC6O7Vg90H21EOLACvtfcHk0linKlxk0rhpsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bK&md5=5948f386d74206ef230e2dc0522fd0ee</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00467%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DM.%2BD.%26aulast%3DHristova%26aufirst%3DK.%26atitle%3DThe%2520RTK%2520interactome%253A%2520overview%2520and%2520perspective%2520on%2520RTK%2520heterointeractions%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D5881%26epage%3D5921%26doi%3D10.1021%2Facs.chemrev.8b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salian-Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierman, M. E.</span></span> <span> </span><span class="NLM_article-title">Axl and Met crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.mce.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23648337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2013&pages=92-100&author=S.+Salian-Mehtaauthor=M.+Xuauthor=M.+E.+Wierman&title=Axl+and+Met+crosstalk+to+promote+gonadotropin+releasing+hormone+%28GnRH%29+neuronal+cell+migration+and+survival&doi=10.1016%2Fj.mce.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span></div><div class="casAuthors">Salian-Mehta, Smita; Xu, Mei; Wierman, Margaret E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">92-100</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The membrane tyrosine kinase receptors, AXL and MET, are implicated in GnRH neuron migration and/or survival.  We hypothesized that the receptors with their ligands, GAS6 and HGF, resp. may cross-talk in GnRH neuronal function.  In NLT GnRH neuronal cells, MET co-immunopptd. with AXL, although HGF or GAS6 did not transphosphorylate AXL or MET, resp.  Co-expression of a kinase dead AXL blocked HGF activation of MET and indirectly AKT and p38MAPK.  Silencing of AXL decreased HGF's ability to phosphorylate MET and activate AXL's downstream effectors, p38MAPK and AKT.  HGF/MET signaling modulated neuron migration dependent and independent of AXL co-expression and p38MAPK.  Conversely, AXL's control of GnRH neuronal survival was dependent on HGF/MET signaling.  Together, these data support that the importance of membrane tyrosine kinase receptor crosstalk to regulate neuronal cell-specific developmental functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFg8H1UC0HerVg90H21EOLACvtfcHk0linKlxk0rhpsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D&md5=de528dce1d3a19fe4392b25017d3cbb0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DSalian-Mehta%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWierman%26aufirst%3DM.%2BE.%26atitle%3DAxl%2520and%2520Met%2520crosstalk%2520to%2520promote%2520gonadotropin%2520releasing%2520hormone%2520%2528GnRH%2529%2520neuronal%2520cell%2520migration%2520and%2520survival%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D374%26spage%3D92%26epage%3D100%26doi%3D10.1016%2Fj.mce.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belfiore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabras, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guaglio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deraco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span> <span> </span><span class="NLM_article-title">Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.3390/ijms20225817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.3390%2Fijms20225817" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=13&author=A.+Belfioreauthor=A.+Busicoauthor=F.+Bozziauthor=S.+Brichauthor=E.+Dalleraauthor=E.+Concaauthor=I.+Caponeauthor=A.+Gloghiniauthor=C.+C.+Volpiauthor=A.+D.+Cabrasauthor=S.+Pilottiauthor=D.+Barattiauthor=M.+Guaglioauthor=M.+Deracoauthor=S.+Kusamuraauthor=F.+Perrone&title=Molecular+signatures+for+combined+targeted+treatments+in+diffuse+malignant+peritoneal+mesothelioma&doi=10.3390%2Fijms20225817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3390%2Fijms20225817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20225817%26sid%3Dliteratum%253Aachs%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DBusico%26aufirst%3DA.%26aulast%3DBozzi%26aufirst%3DF.%26aulast%3DBrich%26aufirst%3DS.%26aulast%3DDallera%26aufirst%3DE.%26aulast%3DConca%26aufirst%3DE.%26aulast%3DCapone%26aufirst%3DI.%26aulast%3DGloghini%26aufirst%3DA.%26aulast%3DVolpi%26aufirst%3DC.%2BC.%26aulast%3DCabras%26aufirst%3DA.%2BD.%26aulast%3DPilotti%26aufirst%3DS.%26aulast%3DBaratti%26aufirst%3DD.%26aulast%3DGuaglio%26aufirst%3DM.%26aulast%3DDeraco%26aufirst%3DM.%26aulast%3DKusamura%26aufirst%3DS.%26aulast%3DPerrone%26aufirst%3DF.%26atitle%3DMolecular%2520signatures%2520for%2520combined%2520targeted%2520treatments%2520in%2520diffuse%2520malignant%2520peritoneal%2520mesothelioma%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D13%26doi%3D10.3390%2Fijms20225817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardnell, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoulidis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-15-0876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F1078-0432.CCR-15-0876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=26420858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFeru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=609-620&author=M.+P.+Makauthor=P.+Tongauthor=L.+Diaoauthor=R.+J.+Cardnellauthor=D.+L.+Gibbonsauthor=W.+N.+Williamauthor=F.+Skoulidisauthor=E.+R.+Parraauthor=J.+Rodriguez-Canalesauthor=I.+I.+Wistubaauthor=J.+V.+Heymachauthor=J.+N.+Weinsteinauthor=K.+R.+Coombesauthor=J.+Wangauthor=L.+A.+Byers&title=A+patient-derived%2C+pan-cancer+EMT+signature+identifies+global+molecular+alterations+and+immune+target+enrichment+following+epithelial-to-mesenchymal+transition&doi=10.1158%2F1078-0432.ccr-15-0876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition</span></div><div class="casAuthors">Mak, Milena P.; Tong, Pan; Diao, Lixia; Cardnell, Robert J.; Gibbons, Don L.; William, William N.; Skoulidis, Ferdinandos; Parra, Edwin R.; Rodriguez-Canales, Jaime; Wistuba, Ignacio I.; Heymach, John V.; Weinstein, John N.; Coombes, Kevin R.; Wang, Jing; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">609-620</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We previously demonstrated the assocn. between epithelial-to-mesenchymal transition (EMT) and drug response in lung cancer using an EMT signature derived in cancer cell lines.  Given the contribution of tumor microenvironments to EMT, we extended our investigation of EMT to patient tumors from 11 cancer types to develop a pan-cancer EMT signature.  Using the pan-cancer EMT signature, we conducted an integrated, global anal. of genomic and proteomic profiles assocd. with EMT across 1,934 tumors including breast, lung, colon, ovarian, and bladder cancers.  Differences in outcome and in vitro drug response corresponding to expression of the pan-cancer EMT signature were also investigated.  Compared with the lung cancer EMT signature, the patient-derived, pan-cancer EMT signature encompasses a set of core EMT genes that correlate even more strongly with known EMT markers across diverse tumor types and identifies differences in drug sensitivity and global mol. alterations at the DNA, RNA, and protein levels.  Among those changes assocd. with EMT, pathway anal. revealed a strong correlation between EMT and immune activation.  Further supervised anal. demonstrated high expression of immune checkpoints and other druggable immune targets, such as PD1, PD-L1, CTLA4, OX40L, and PD-L2, in tumors with the most mesenchymal EMT scores.  Elevated PD-L1 protein expression in mesenchymal tumors was confirmed by IHC in an independent lung cancer cohort.  This new signature provides a novel, patient-based, histol.-independent tool for the investigation of EMT and offers insights into potential novel therapeutic targets for mesenchymal tumors, independent of cancer type, including immune checkpoints.  Clin Cancer Res; 22(3); 609-20. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCJX6douXHMbVg90H21EOLACvtfcHk0ljn7p7HOAtJFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFeru7c%253D&md5=28dea196f02aa0f7410140a1f89d13e3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0876%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DM.%2BP.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DWilliam%26aufirst%3DW.%2BN.%26aulast%3DSkoulidis%26aufirst%3DF.%26aulast%3DParra%26aufirst%3DE.%2BR.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DA%2520patient-derived%252C%2520pan-cancer%2520EMT%2520signature%2520identifies%2520global%2520molecular%2520alterations%2520and%2520immune%2520target%2520enrichment%2520following%2520epithelial-to-mesenchymal%2520transition%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D609%26epage%3D620%26doi%3D10.1158%2F1078-0432.ccr-15-0876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saintigny, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giri, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumula, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudikote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardnell, R. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulks, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-12-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F1078-0432.CCR-12-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23091115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=279-290&author=L.+A.+Byersauthor=L.+Diaoauthor=J.+Wangauthor=P.+Saintignyauthor=L.+Girardauthor=M.+Peytonauthor=L.+Shenauthor=Y.+Fanauthor=U.+Giriauthor=P.+K.+Tumulaauthor=M.+B.+Nilssonauthor=J.+Gudikoteauthor=H.+Tranauthor=R.+J.+G.+Cardnellauthor=D.+J.+Bearssauthor=S.+L.+Warnerauthor=J.+M.+Foulksauthor=S.+B.+Kannerauthor=V.+Gandhiauthor=N.+Krettauthor=S.+T.+Rosenauthor=E.+S.+Kimauthor=R.+S.+Herbstauthor=G.+R.+Blumenscheinauthor=J.+J.+Leeauthor=S.+M.+Lippmanauthor=K.+K.+Angauthor=G.+B.+Millsauthor=W.+K.+Hongauthor=J.+N.+Weinsteinauthor=I.+I.+Wistubaauthor=K.+R.+Coombesauthor=J.+D.+Minnaauthor=J.+V.+Heymach&title=An+epithelial-mesenchymal+transition+gene+signature+predicts+resistance+to+EGFR+and+PI3K+inhibitors+and+identifies+Axl+as+a+therapeutic+target+for+overcoming+EGFR+inhibitor+resistance&doi=10.1158%2F1078-0432.ccr-12-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance</span></div><div class="casAuthors">Byers, Lauren Averett; Diao, Lixia; Wang, Jing; Saintigny, Pierre; Girard, Luc; Peyton, Michael; Shen, Li; Fan, Youhong; Giri, Uma; Tumula, Praveen K.; Nilsson, Monique B.; Gudikote, Jayanthi; Tran, Hai; Cardnell, Robert J. G.; Bearss, David J.; Warner, Steven L.; Foulks, Jason M.; Kanner, Steven B.; Gandhi, Varsha; Krett, Nancy; Rosen, Steven T.; Kim, Edward S.; Herbst, Roy S.; Blumenschein, George R.; Lee, J. Jack; Lippman, Scott M.; Ang, K. Kian; Mills, Gordon B.; Hong, Waun K.; Weinstein, John N.; Wistuba, Ignacio I.; Coombes, Kevin R.; Minna, John D.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Epithelial-mesenchymal transition (EMT) has been assocd. with metastatic spread and EGF receptor (EGFR) inhibitor resistance.  We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.  Exptl. Design: We conducted an integrated gene expression, proteomic, and drug response anal. using cell lines and tumors from patients with NSCLC.  A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms of NSCLC cell lines and patients treated in the BATTLE study, and potential therapeutic targets assocd. with EMT were identified.  Results: Compared with epithelial cells, mesenchymal cells showed significantly greater resistance to EGFR and PI3K/Akt pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies.  Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.  In patients with NSCLC, the EMT signature predicted 8-wk disease control in patients receiving erlotinib but not other therapies.  Conclusion: We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance assocd. with the mesenchymal phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwav-PXLuwi7Vg90H21EOLACvtfcHk0ljn7p7HOAtJFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D&md5=d02e08e505b8487a48874abdb8a553a9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1558%26sid%3Dliteratum%253Aachs%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGiri%26aufirst%3DU.%26aulast%3DTumula%26aufirst%3DP.%2BK.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DGudikote%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%2BG.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DFoulks%26aufirst%3DJ.%2BM.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DKrett%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DAn%2520epithelial-mesenchymal%2520transition%2520gene%2520signature%2520predicts%2520resistance%2520to%2520EGFR%2520and%2520PI3K%2520inhibitors%2520and%2520identifies%2520Axl%2520as%2520a%2520therapeutic%2520target%2520for%2520overcoming%2520EGFR%2520inhibitor%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D279%26epage%3D290%26doi%3D10.1158%2F1078-0432.ccr-12-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamichi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyanaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, A.</span></span> <span> </span><span class="NLM_article-title">Overcoming drug-tolerant cancer cell subpopulations showing Axl activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">27242</span>– <span class="NLM_lpage">27255</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.18632%2Foncotarget.25531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29930762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fgs1ersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=27242-27255&author=S.+Nakamichiauthor=M.+Seikeauthor=A.+Miyanagaauthor=M.+Chibaauthor=F.+Zouauthor=A.+Takahashiauthor=A.+Ishikawaauthor=S.+Kunugiauthor=R.+Noroauthor=K.+Kubotaauthor=A.+Gemma&title=Overcoming+drug-tolerant+cancer+cell+subpopulations+showing+Axl+activation+and+epithelial-mesenchymal+transition+is+critical+in+conquering+ALK-positive+lung+cancer&doi=10.18632%2Foncotarget.25531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer</span></div><div class="casAuthors">Nakamichi Shinji; Seike Masahiro; Miyanaga Akihiko; Chiba Mika; Zou Fenfei; Takahashi Akiko; Noro Rintaro; Kubota Kaoru; Gemma Akihiko; Ishikawa Arimi; Kunugi Shinobu</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">27242-27255</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) induce a dramatic response in non-small cell lung cancer (NSCLC) patients with the ALK fusion gene.  However, acquired resistance to ALK-TKIs remains an inevitable problem.  In this study, we aimed to discover novel therapeutic targets to conquer ALK-positive lung cancer.  We established three types of ALK-TKI (crizotinib, alectinib and ceritinib)-resistant H2228 NSCLC cell lines by high exposure and stepwise methods.  We found these cells showed a loss of ALK signaling, overexpressed AXL with epithelial-mesenchymal transition (EMT), and had cancer stem cell-like (CSC) properties, suggesting drug-tolerant cancer cell subpopulations.  Similarly, we demonstrated that TGF-β1 treated H2228 cells also showed AXL overexpression with EMT features and ALK-TKI resistance.  The AXL inhibitor, R428, or HSP90 inhibitor, ganetespib, were effective in reversing ALK-TKI resistance and EMT changes in both ALK-TKI-resistant and TGF-β1-exposed H2228 cells.  Tumor volumes of xenograft mice implanted with established H2228-ceritinib-resistant (H2228-CER) cells were significantly reduced after treatment with ganetespib, or ganetespib in combination with ceritinib.  Some ALK-positive NSCLC patients with AXL overexpression showed a poorer response to crizotinib therapy than patients with a low expression of AXL.  ALK signaling-independent AXL overexpressed in drug-tolerant cancer cell subpopulations with EMT and CSC features may be commonly involved commonly involved in intrinsic and acquired resistance to ALK-TKIs.  This suggests AXL and HSP90 inhibitors may be promising therapeutic drugs to overcome drug-tolerant cancer cell subpopulations in ALK-positive NSCLC patients for the reason that ALK-positive NSCLC cells do not live through ALK-TKI therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd9KJdxsHx--Lt9HypzAgQfW6udTcc2eYnJZG9T_cpE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fgs1ersw%253D%253D&md5=25a466edcea1dd1f44195e587626d57e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25531%26sid%3Dliteratum%253Aachs%26aulast%3DNakamichi%26aufirst%3DS.%26aulast%3DSeike%26aufirst%3DM.%26aulast%3DMiyanaga%26aufirst%3DA.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DA.%26aulast%3DKunugi%26aufirst%3DS.%26aulast%3DNoro%26aufirst%3DR.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DGemma%26aufirst%3DA.%26atitle%3DOvercoming%2520drug-tolerant%2520cancer%2520cell%2520subpopulations%2520showing%2520Axl%2520activation%2520and%2520epithelial-mesenchymal%2520transition%2520is%2520critical%2520in%2520conquering%2520ALK-positive%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D27242%26epage%3D27255%26doi%3D10.18632%2Foncotarget.25531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemann, D. W.</span></span> <span> </span><span class="NLM_article-title">Gas6/Axl signaling pathway in the tumor immune microenvironment</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1850</span>, <span class="refDoi"> DOI: 10.3390/cancers12071850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.3390%2Fcancers12071850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKnur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1850&author=M.+Tanakaauthor=D.+W.+Siemann&title=Gas6%2FAxl+signaling+pathway+in+the+tumor+immune+microenvironment&doi=10.3390%2Fcancers12071850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6/Axl signaling pathway in the tumor immune microenvironment</span></div><div class="casAuthors">Tanaka, Mai; Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1850</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases have been shown to dysregulate a no. of pathways assocd. with tumor development, progression, and metastasis.  Axl is a receptor tyrosine kinase expressed in many cancer types and has been assocd. with therapy resistance and poor clin. prognosis and outcomes.  In addn., Axl and its ligand growth arrest specific 6 (Gas6) protein are expressed by a no. of host cells.  The Gas6/Axl signaling pathway has been implicated in the promotion of tumor cell proliferation, survival, migration, invasion, angiogenesis, and immune evasion.  As a result, Axl is an attractive, novel therapeutic target to impair multiple stages of tumor progression from both neoplastic and host cell axes.  This review focuses on the role of the Gas6/Axl signaling pathway in promoting the immunosuppressive tumor microenvironment, as immune evasion is considered one of the hallmarks of cancer.  The review discusses the structure and activation of the Gas6/Axl signaling pathway, GAS6 and AXL expression patterns in the tumor microenvironment, mechanisms of Axl-mediated tumor immune response, and the role of Gas6/Axl signaling in immune cell recruitment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYxCwzKOzcbVg90H21EOLACvtfcHk0lhKUV0Vr5mbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKnur7L&md5=cba755674ebeeeac3b16c9718afb6340</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3390%2Fcancers12071850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12071850%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DGas6%252FAxl%2520signaling%2520pathway%2520in%2520the%2520tumor%2520immune%2520microenvironment%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1850%26doi%3D10.3390%2Fcancers12071850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span> <span> </span><span class="NLM_article-title">Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β-catenin signaling</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.7150/thno.15083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.7150%2Fthno.15083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=27279912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFersrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1205-1219&author=C.+Wangauthor=H.+Jinauthor=N.+Wangauthor=S.+Fanauthor=Y.+Wangauthor=Y.+Zhangauthor=L.+Weiauthor=X.+Taoauthor=D.+Guauthor=F.+Zhaoauthor=J.+Fangauthor=M.+Yaoauthor=W.+Qin&title=Gas6%2FAxl+axis+contributes+to+chemoresistance+and+metastasis+in+breast+cancer+through+Akt%2FGSK-3%CE%B2%2F%CE%B2-catenin+signaling&doi=10.7150%2Fthno.15083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β-catenin signaling</span></div><div class="casAuthors">Wang, Cun; Jin, Haojie; Wang, Ning; Fan, Shaohua; Wang, Yanyan; Zhang, Yurong; Wei, Lin; Tao, Xuemei; Gu, Dishui; Zhao, Fangyu; Fang, Jingyuan; Yao, Ming; Qin, Wenxin</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1205-1219</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Chemoresistance in breast cancer has been of great interest in past studies.  However, the development of rational therapeutic strategies targeting chemoresistant cells is still a challenge in clin. oncol.  By integrating data from global differences of gene expression and phospho-receptor tyrosine kinases between sensitive parental cells (MCF-7) and doxorubicin-resistant cells (MCF-7/ADR), we identified Axl as a potential target for chemoresistance and metastasis in multidrug resistant breast cancer cells.  We analyzed Axl expression in 57 breast cancer cell lines and detected a dramatic increase in its expression level in mesenchymal breast cancer cell lines.  Axl silencing suppressed invasive and metastatic potentials of chemoresistant breast cancer cells as well as increased elimination of cancer cells when combined with doxorubicin.  Furthermore, in preclin. assays, an Axl inhibitor R428 showed increased cell death upon doxorubicin treatment.  Addnl., using phospho-kinase array based proteomic anal., we identified that Akt/GSK-3β/β-catenin cascade was responsible for Axl-induced cell invasion.  Nuclear translocation of β-catenin then induced transcriptional upregulation of ZEB1, which in turn regulated DNA damage repair and doxorubicin-resistance in breast cancer cells.  Most importantly, Axl was correlated with its downstream targets in tumor samples and was assocd. with poor prognosis in breast cancer patients.  These results demonstrate that Gas6/Axl axis confers aggressiveness in breast cancer and may represent a therapeutic target for chemoresistance and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNND2-ZStJbVg90H21EOLACvtfcHk0lhKUV0Vr5mbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFersrfN&md5=d4bd2d77b51e9397587f45519a36dbe6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.7150%2Fthno.15083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15083%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DW.%26atitle%3DGas6%252FAxl%2520axis%2520contributes%2520to%2520chemoresistance%2520and%2520metastasis%2520in%2520breast%2520cancer%2520through%2520Akt%252FGSK-3%25CE%25B2%252F%25CE%25B2-catenin%2520signaling%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D1205%26epage%3D1219%26doi%3D10.7150%2Fthno.15083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aguilera, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shehade, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariolis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Eyben, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellies, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koong, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccia, A. J.</span></span> <span> </span><span class="NLM_article-title">Reprogramming the immunological microenvironment through radiation and targeting Axl</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13898</span>, <span class="refDoi"> DOI: 10.1038/ncomms13898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1038%2Fncomms13898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28008921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGit7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13898&author=T.+A.+Aguileraauthor=M.+Rafatauthor=L.+Castelliniauthor=H.+Shehadeauthor=M.+S.+Kariolisauthor=A.+B.-Y.+Huiauthor=H.+Stehrauthor=R.+von+Eybenauthor=D.+Jiangauthor=L.+G.+Elliesauthor=A.+C.+Koongauthor=M.+Diehnauthor=E.+B.+Rankinauthor=E.+E.+Gravesauthor=A.+J.+Giaccia&title=Reprogramming+the+immunological+microenvironment+through+radiation+and+targeting+Axl&doi=10.1038%2Fncomms13898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Reprogramming the immunological microenvironment through radiation and targeting Axl</span></div><div class="casAuthors">Aguilera, Todd A.; Rafat, Marjan; Castellini, Laura; Shehade, Hussein; Kariolis, Mihalis S.; Hui, Angela Bik-Yu; Stehr, Henning; von Eyben, Rie; Jiang, Dadi; Ellies, Lesley G.; Koong, Albert C.; Diehn, Maximilian; Rankin, Erinn B.; Graves, Edward E.; Giaccia, Amato J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13898</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Increasing evidence suggests that ionizing radiation therapy (RT) in combination with checkpoint immunotherapy is highly effective in treating a subset of cancers.  To better understand the limited responses to this combination we analyzed the genetic, microenvironmental, and immune factors in tumors derived from a transgenic breast cancer model.  We identified two tumors with similar growth characteristics but different RT responses primarily due to an antitumor immune response.  The combination of RT and checkpoint immunotherapy resulted in cures in the responsive but not the unresponsive tumors.  Profiling the tumors revealed that the Axl receptor tyrosine kinase is overexpressed in the unresponsive tumors, and Axl knockout resulted in slower growth and increased radiosensitivity.  These changes were assocd. with a CD8+ T-cell response, which was improved in combination with checkpoint immunotherapy.  These results suggest a novel role for Axl in suppressing antigen presentation through MHCI, and enhancing cytokine release, which promotes a suppressive myeloid microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU9gnrG_aWe7Vg90H21EOLACvtfcHk0lhKUV0Vr5mbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGit7%252FE&md5=c4d5abf03674d5d3b8a12f0b66444a5f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fncomms13898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13898%26sid%3Dliteratum%253Aachs%26aulast%3DAguilera%26aufirst%3DT.%2BA.%26aulast%3DRafat%26aufirst%3DM.%26aulast%3DCastellini%26aufirst%3DL.%26aulast%3DShehade%26aufirst%3DH.%26aulast%3DKariolis%26aufirst%3DM.%2BS.%26aulast%3DHui%26aufirst%3DA.%2BB.-Y.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3Dvon%2BEyben%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DEllies%26aufirst%3DL.%2BG.%26aulast%3DKoong%26aufirst%3DA.%2BC.%26aulast%3DDiehn%26aufirst%3DM.%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DGraves%26aufirst%3DE.%2BE.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DReprogramming%2520the%2520immunological%2520microenvironment%2520through%2520radiation%2520and%2520targeting%2520Axl%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13898%26doi%3D10.1038%2Fncomms13898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">ASP2215, a novel FLT3/Axl inhibitor: preclinical evaluation in acute myeloid leukemia (AML)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">7070</span>, <span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.7070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1200%2Fjco.2014.32.15_suppl.7070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7070&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=R.+Tanakaauthor=K.+Choauthor=R.+Saitoauthor=Y.+Kondohauthor=I.+Shimadaauthor=S.+Kuromitsu&title=ASP2215%2C+a+novel+FLT3%2FAxl+inhibitor%3A+preclinical+evaluation+in+acute+myeloid+leukemia+%28AML%29&doi=10.1200%2Fjco.2014.32.15_suppl.7070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.7070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.7070%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DASP2215%252C%2520a%2520novel%2520FLT3%252FAxl%2520inhibitor%253A%2520preclinical%2520evaluation%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D7070%26doi%3D10.1200%2Fjco.2014.32.15_suppl.7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torneros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckrodt, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apatira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitoshi, Y.</span></span> <span> </span><span class="NLM_article-title">R428, a selective small molecule inhibitor of axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-09-2997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-09-2997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=20145120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFaksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1544-1554&author=S.+J.+Hollandauthor=A.+Panauthor=C.+Franciauthor=Y.+Huauthor=B.+Changauthor=W.+Liauthor=M.+Duanauthor=A.+Tornerosauthor=J.+Yuauthor=T.+J.+Heckrodtauthor=J.+Zhangauthor=P.+Dingauthor=A.+Apatiraauthor=J.+Chuaauthor=R.+Brandtauthor=P.+Pineauthor=D.+Goffauthor=R.+Singhauthor=D.+G.+Payanauthor=Y.+Hitoshi&title=R428%2C+a+selective+small+molecule+inhibitor+of+axl+kinase%2C+blocks+tumor+spread+and+prolongs+survival+in+models+of+metastatic+breast+cancer&doi=10.1158%2F0008-5472.can-09-2997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer</span></div><div class="casAuthors">Holland, Sacha J.; Pan, Alison; Franci, Christian; Hu, Yuanming; Chang, Betty; Li, Weiqun; Duan, Matt; Torneros, Allan; Yu, Jiaxin; Heckrodt, Thilo J.; Zhang, Jing; Ding, Pingyu; Apatira, Ayodele; Chua, Joanne; Brandt, Ralf; Pine, Polly; Goff, Dane; Singh, Rajinder; Payan, Donald G.; Hitoshi, Yasumichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1544-1554</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Accumulating evidence suggests important roles for the receptor tyrosine kinase Axl in cancer progression, invasion, metastasis, drug resistance, and patient mortality, highlighting Axl as an attractive target for therapeutic development.  We have generated and characterized a potent and selective small-mol. inhibitor, R428, that blocks the catalytic and procancerous activities of Axl.  R428 inhibits Axl with low nanomolar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine prodn.  Pharmacol. investigations revealed favorable exposure after oral administration such that R428-treated tumors displayed a dose-dependent redn. in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail.  In support of an earlier study, R428 inhibited angiogenesis in corneal micropocket and tumor models.  R428 administration reduced metastatic burden and extended survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis.  Addnl., R428 synergized with cisplatin to enhance suppression of liver micrometastasis.  Our results show that Axl signaling regulates breast cancer metastasis at multiple levels in tumor cells and tumor stromal cells and that selective Axl blockade confers therapeutic value in prolonging survival of animals bearing metastatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DJ8WI7aob7Vg90H21EOLACvtfcHk0ljGioGTyCYVhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFaksb0%253D&md5=66e88d0864e22d737d5fb540c9982d15</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2997%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DM.%26aulast%3DTorneros%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHeckrodt%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DApatira%26aufirst%3DA.%26aulast%3DChua%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DHitoshi%26aufirst%3DY.%26atitle%3DR428%252C%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520axl%2520kinase%252C%2520blocks%2520tumor%2520spread%2520and%2520prolongs%2520survival%2520in%2520models%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1544%26epage%3D1554%26doi%3D10.1158%2F0008-5472.can-09-2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boer, R. H.</span></span> <span> </span><span class="NLM_article-title">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.2147/OTT.S27671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.2147%2FOTT.S27671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23319867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1-7&author=C.+D.+Hartauthor=R.+H.+De+Boer&title=Profile+of+cabozantinib+and+its+potential+in+the+treatment+of+advanced+medullary+thyroid+cancer&doi=10.2147%2FOTT.S27671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span></div><div class="casAuthors">Hart, Christopher D.; De Boer, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed.  It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development.  Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients.  Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdeH_ML0s97Vg90H21EOLACvtfcHk0ljGioGTyCYVhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D&md5=048635660f5262d406ec13baef91bc78</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2147%2FOTT.S27671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S27671%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DC.%2BD.%26aulast%3DDe%2BBoer%26aufirst%3DR.%2BH.%26atitle%3DProfile%2520of%2520cabozantinib%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.2147%2FOTT.S27671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcón, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D. M.</span></span> <span> </span><span class="NLM_article-title">VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4758</span>– <span class="NLM_lpage">4768</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-10-2527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=21613405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFarsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4758-4768&author=W.-K.+Youauthor=B.+Senninoauthor=C.+W.+Williamsonauthor=B.+Falc%C3%B3nauthor=H.+Hashizumeauthor=L.-C.+Yaoauthor=D.+T.+Aftabauthor=D.+M.+McDonald&title=VEGF+and+c-Met+blockade+amplify+angiogenesis+inhibition+in+pancreatic+islet+cancer&doi=10.1158%2F0008-5472.can-10-2527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer</span></div><div class="casAuthors">You, Weon-Kyoo; Sennino, Barbara; Williamson, Casey W.; Falcon, Beverly; Hashizume, Hiroya; Yao, Li-Chin; Aftab, Dana T.; McDonald, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4758-4768</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the disease progresses.  Multiple strategies are being explored to improve efficacy by concurrent inhibition of other functionally relevant receptor tyrosine kinases (RTK).  XL880 (foretinib, GSK1363089) and XL184 (cabozantinib) are small-mol. inhibitors that potently block multiple RTKs, including VEGFR and the receptor of hepatocyte growth factor c-Met, which can drive tumor invasion and metastasis.  This study compared the cellular effects of XL880 and XL184 with those of an RTK inhibitor (XL999) that blocks VEGFR but not c-Met.  Treatment of RIP-Tag2 mice with XL999 resulted in 43% redn. in vascularity of spontaneous pancreatic islet tumors over 7 days, but treatment with XL880 or XL184 eliminated approx. 80% of the tumor vasculature, reduced pericytes and empty basement membrane sleeves, caused widespread intratumoral hypoxia and tumor cell apoptosis, and slowed regrowth of the tumor vasculature after drug withdrawal.  Importantly, XL880 and XL184 also decreased invasiveness of primary tumors and reduced metastasis.  Overall, these findings indicate that inhibition of c-Met and functionally related kinases amplifies the effects of VEGFR blockade and leads to rapid, robust, and progressive regression of tumor vasculature, increased intratumoral hypoxia and apoptosis, and reduced tumor invasiveness and metastasis.  Cancer Res; 71(14); 4758-68.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-APd9r4wTwLVg90H21EOLACvtfcHk0lggShkDg6x2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFarsLY%253D&md5=b0328a10c02cde5f8ced211d82e1b45f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2527%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DW.-K.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BW.%26aulast%3DFalc%25C3%25B3n%26aufirst%3DB.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DL.-C.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DVEGF%2520and%2520c-Met%2520blockade%2520amplify%2520angiogenesis%2520inhibition%2520in%2520pancreatic%2520islet%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4758%26epage%3D4768%26doi%3D10.1158%2F0008-5472.can-10-2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, K.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greshock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, A. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">8009</span>– <span class="NLM_lpage">8016</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.-A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases&doi=10.1158%2F0008-5472.can-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0lggShkDg6x2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.-A.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.can-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, N.</span></span> <span> </span><span class="NLM_article-title">Substituted quinoline compounds and methods of use</span>. U.S. Patent <span class="NLM_patent">20,120,219,522 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Xi&title=Substituted+quinoline+compounds+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DN.%26atitle%3DSubstituted%2520quinoline%2520compounds%2520and%2520methods%2520of%2520use%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peek, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajamie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konicek, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, R. A.</span></span> <span> </span><span class="NLM_article-title">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against Met, Mst1r, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1007%2Fs10637-012-9912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=23275061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=833-844&author=S.+B.+Yanauthor=V.+L.+Peekauthor=R.+Ajamieauthor=S.+G.+Buchananauthor=J.+R.+Graffauthor=S.+A.+Heidlerauthor=Y.-H.+Huiauthor=K.+L.+Hussauthor=B.+W.+Konicekauthor=J.+R.+Manroauthor=C.+Shihauthor=J.+A.+Stewartauthor=T.+R.+Stewartauthor=S.+L.+Stoutauthor=M.+T.+Uhlikauthor=S.+L.+Umauthor=Y.+Wangauthor=W.+Wuauthor=L.+Yanauthor=W.+J.+Yangauthor=B.+Zhongauthor=R.+A.+Walgren&title=LY2801653+is+an+orally+bioavailable+multi-kinase+inhibitor+with+potent+activity+against+Met%2C+Mst1r%2C+and+other+oncoproteins%2C+and+displays+anti-tumor+activities+in+mouse+xenograft+models&doi=10.1007%2Fs10637-012-9912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span></div><div class="casAuthors">Yan, S. Betty; Peek, Victoria L.; Ajamie, Rose; Buchanan, Sean G.; Graff, Jeremy R.; Heidler, Steven A.; Hui, Yu-Hua; Huss, Karen L.; Konicek, Bruce W.; Manro, Jason R.; Shih, Chuan; Stewart, Julie A.; Stewart, Trent R.; Stout, Stephanie L.; Uhlik, Mark T.; Um, Suzane L.; Wang, Yong; Wu, Wenjuan; Yan, Lei; Yang, Wei J.; Zhong, Boyu; Walgren, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis.  MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand prodn., and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are assocd. with poor prognostic outcome.  We report here preclin. development of a potent, orally bioavailable, small-mol. inhibitor LY2801653 targeting MET kinase.  LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissocn. const. (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min.  LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects.  LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation.  In subsequent nonclin. characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.  The potential value of MET and other inhibited targets within a no. of malignancies (such as colon, bile ducts, and lung) is discussed.  LY2801653 is currently in phase 1 clin. testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04limPWxrHLVg90H21EOLACvtfcHk0lggShkDg6x2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE&md5=9d80bcdb04ebec24e2516dcf26821ad3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9912-9%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%2BB.%26aulast%3DPeek%26aufirst%3DV.%2BL.%26aulast%3DAjamie%26aufirst%3DR.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DHeidler%26aufirst%3DS.%2BA.%26aulast%3DHui%26aufirst%3DY.-H.%26aulast%3DHuss%26aufirst%3DK.%2BL.%26aulast%3DKonicek%26aufirst%3DB.%2BW.%26aulast%3DManro%26aufirst%3DJ.%2BR.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DT.%2BR.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DUm%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DWalgren%26aufirst%3DR.%2BA.%26atitle%3DLY2801653%2520is%2520an%2520orally%2520bioavailable%2520multi-kinase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520Met%252C%2520Mst1r%252C%2520and%2520other%2520oncoproteins%252C%2520and%2520displays%2520anti-tumor%2520activities%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D833%26epage%3D844%26doi%3D10.1007%2Fs10637-012-9912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span>; <span class="NLM_string-name">Ator, M. A.</span>; <span class="NLM_string-name">Cheng, M. M.</span>; <span class="NLM_string-name">Dorsey, B.</span>; <span class="NLM_string-name">Hudkins, R. L.</span>; <span class="NLM_string-name">Ruggeri, B. A.</span></span> <span> </span><span class="NLM_article-title">Methods of treating various cancers using an Axl/cMet inhibitor alone or in combination with other agents</span>. <span class="NLM_patent">WO 2015017607 A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+S.+Angeles&author=M.+A.+Ator&author=M.+M.+Cheng&author=B.+Dorsey&author=R.+L.+Hudkins&author=B.+A.+Ruggeri&title=Methods+of+treating+various+cancers+using+an+Axl%2FcMet+inhibitor+alone+or+in+combination+with+other+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26atitle%3DMethods%2520of%2520treating%2520various%2520cancers%2520using%2520an%2520Axl%252FcMet%2520inhibitor%2520alone%2520or%2520in%2520combination%2520with%2520other%2520agents%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6807</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6807-6825&author=L.+Tanauthor=Z.+Zhangauthor=D.+Gaoauthor=J.+Luoauthor=Z.-C.+Tuauthor=Z.+Liauthor=L.+Pengauthor=X.+Renauthor=K.+Ding&title=4-oxo-1%2C4-dihydroquinoline-3-carboxamide+derivatives+as+new+Axl+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.6b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Zhang, Zhang; Gao, Donglin; Luo, Jinfeng; Tu, Zheng-Chao; Li, Zhengqiu; Peng, Lijie; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6807-6825</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Axl is a new potential target for anticancer drug discovery.  A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides I (9a-u, 9ha-9hh, 9ia-9ic; R1 = H, Cl, F, Br, CF3, Me, Et, cyclopropyl, iPr, isopropenyl, OMe, CO2Me; R2, R3 = H, Me, Et, n-Pr, Bu, Ph; R4 = F, H, Me) and II [9id-9im; Z = CH, N; X = H, Cl; Y = H, NH2; X-Y = CPh:CHO, CPh:CHNH, CH:C(OMe)C(OMe):CH] were designed and synthesized as highly potent Axl kinase inhibitors.  One of the most promising compds., 9im [shown as II, X-Y = CH:C(OMe)C(OMe):CH], tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, resp., while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concn.  The compd. dose-dependently inhibited the TGF-β1-induced epithelial-mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells.  In addn., 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells.  Compd. 9im may serve as a lead compd. for new anticancer drug discovery and a valuable research probe for further biol. investigation on Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtSA_rcxZaeLVg90H21EOLACvtfcHk0lgRtU0YBYfP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO&md5=2b737ed5ab9349788d82c0d1ec81b914</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D4-oxo-1%252C4-dihydroquinoline-3-carboxamide%2520derivatives%2520as%2520new%2520Axl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6807%26epage%3D6825%26doi%3D10.1021%2Facs.jmedchem.6b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Cell- and tissue-based proteome profiling and bioimaging with probes derived from a potent Axl kinase inhibitor</span>. <i>Chem.–Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2605</span>, <span class="refDoi"> DOI: 10.1002/asia.201800605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1002%2Fasia.201800605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29939481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2601-2605&author=B.+Zhengauthor=H.+Guoauthor=N.+Maauthor=Y.+Niauthor=J.+Xuauthor=L.+Liauthor=P.+Haoauthor=K.+Dingauthor=Z.+Li&title=Cell-+and+tissue-based+proteome+profiling+and+bioimaging+with+probes+derived+from+a+potent+Axl+kinase+inhibitor&doi=10.1002%2Fasia.201800605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor</span></div><div class="casAuthors">Zheng, Binbin; Guo, Haijun; Ma, Nan; Ni, Yun; Xu, Jiaqian; Li, Lin; Hao, Piliang; Ding, Ke; Li, Zhengqiu</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2601-2605</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">AXL has been defined as a novel target for cancer therapeutics.  However, only a few potent and selective inhibitors targeting AXL are available to date.  Recently, our group has developed a lead compd., 9i.m., capable of displaying potent and specific inhibition of AXL.  To further identify the cellular on/off targets, in this study, competitive affinity-based proteome profiling was carried out, leading to the discovery of several unknown cellular targets such as BCAP31, LPCAT3, POR, TM9SF3, SCCPDH and CANX.  In addn., trans-cyclooctene (TCO) and acedan-contg. probes were developed to image the binding between 9i.m. and its target proteins inside live cells and tumor tissues.  These probes would be useful tools in the detection of AXL in various biosystems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogjbWcokDOWrVg90H21EOLACvtfcHk0lgRtU0YBYfP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKrtr%252FN&md5=99af1417a3b3ebf0868b9f366081215f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fasia.201800605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.201800605%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DCell-%2520and%2520tissue-based%2520proteome%2520profiling%2520and%2520bioimaging%2520with%2520probes%2520derived%2520from%2520a%2520potent%2520Axl%2520kinase%2520inhibitor%26jtitle%3DChem.%25E2%2580%2593Asian%2520J.%26date%3D2018%26volume%3D13%26spage%3D2601%26epage%3D2605%26doi%3D10.1002%2Fasia.201800605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(5’-Substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6690</span>– <span class="NLM_lpage">6708</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKisb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6690-6708&author=W.+Yanauthor=X.+Wangauthor=Y.+Daiauthor=B.+Zhaoauthor=X.+Yangauthor=J.+Fanauthor=Y.+Gaoauthor=F.+Mengauthor=Y.+Wangauthor=C.+Luoauthor=J.+Aiauthor=M.+Gengauthor=W.+Duan&title=Discovery+of+3-%285%E2%80%99-Substituted%29-benzimidazole-5-%281-%283%2C5-dichloropyridin-4-yl%29ethoxy%29-1H-indazoles+as+potent+fibroblast+growth+factor+receptor+inhibitors%3A+design%2C+synthesis%2C+and+biological+evaluation&doi=10.1021%2Facs.jmedchem.6b00056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Yan, Wei; Wang, Xinyi; Dai, Yang; Zhao, Bin; Yang, Xinying; Fan, Jun; Gao, Yinglei; Meng, Fanwang; Wang, Yuming; Luo, Cheng; Ai, Jing; Geng, Meiyu; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6690-6708</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) represents an attractive oncol. target for cancer therapy in view of its crit. role in promoting cancer formation and progression, as well as causing resistance to approved therapies.  In this article, the authors describe the identification of the potent pan-FGFR inhibitor (R)-21c (FGFR1-4 IC50 values of 0.9, 2.0, 2.0, and 6.1 nM, resp.).  Compd. (R)-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazole ((R)-21c) exhibited excellent in vitro inhibitory activity against a panel of FGFR-amplified cell lines.  Western blot anal. demonstrated that (R)-21c suppressed FGF/FGFR and downstream signaling pathways at nanomolar concns.  Moreover, (R)-21c provided nearly complete inhibition of tumor growth (96.9% TGI) in NCI-H1581 (FGFR1-amplified) xenograft mice model at the dose of 10 mg/kg/qd via oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBssqm8VpRHrVg90H21EOLACvtfcHk0lgRtU0YBYfP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKisb7E&md5=a7ce472feea2293d28c57f1609d8c941</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00056%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25203-%25285%25E2%2580%2599-Substituted%2529-benzimidazole-5-%25281-%25283%252C5-dichloropyridin-4-yl%2529ethoxy%2529-1H-indazoles%2520as%2520potent%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6690%26epage%3D6708%26doi%3D10.1021%2Facs.jmedchem.6b00056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/Axl inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAxl+inhibitor%2C+shows+antileukemic+activity+in+mouse+models+of+FLT3+mutated+acute+myeloid+leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0lgr38c65ZV3BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAxl%2520inhibitor%252C%2520shows%2520antileukemic%2520activity%2520in%2520mouse%2520models%2520of%2520FLT3%2520mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span>; <span class="NLM_string-name">Klebl, B.</span>; <span class="NLM_string-name">Choidas, A.</span>; <span class="NLM_string-name">Koch, U.</span>; <span class="NLM_string-name">Eickhoff, J.</span>; <span class="NLM_string-name">Wolf, A.</span>; <span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of quinoline carboxamide compounds as Axl inhibitors</span>. <span class="NLM_patent">WO 2012028332 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Schultz-Fademrecht&author=B.+Klebl&author=A.+Choidas&author=U.+Koch&author=J.+Eickhoff&author=A.+Wolf&author=A.+Ullrich&title=Preparation+of+quinoline+carboxamide+compounds+as+Axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520quinoline%2520carboxamide%2520compounds%2520as%2520Axl%2520inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span> <span> </span><span class="NLM_article-title">1-oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2903</span>– <span class="NLM_lpage">2908</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(97)10110-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2FS0960-894X%2897%2910110-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaK2sXnvV2mt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=2903-2908&author=M.+R.+Barvianauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+J.+Krakerauthor=A.+Amarauthor=B.+Hartlauthor=J.+M.+Hambyauthor=H.+D.+H.+Showalter&title=1-oxo-3-aryl-1H-indene-2-carboxylic+acid+derivatives+as+selective+inhibitors+of+fibroblast+growth+factor+receptor-1+tyrosine+kinase&doi=10.1016%2Fs0960-894x%2897%2910110-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">1-oxo-3-Aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase</span></div><div class="casAuthors">Barvian, M. R.; Panek, R. L.; Lu, G. H.; Kraker, A. J.; Amar, A.; Hartl, B.; Hamby, J. M.; Showalter, H. D. H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2903-2908</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFr) mediated signal transduction is implicated in vascular proliferative diseases and some cancers.  Thus, Me 1-oxo-3-phenyl-1H-indene-2-carboxylic ester was identified as a small mol. inhibitor of the tyrosine kinase activity of FGFr-1, (IC50 = 5.1 μM).  The synthesis and structure-activity studies about this template core were reported.  N example compd. thus prepd. was N-methyl-1-oxo-3-phenyl-1H-Indene-2-carboxamide.  Addnl., screening of this series against a panel of tyrosine kinases shows selective inhibition of FGFr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKzkITINbR7Vg90H21EOLACvtfcHk0lgr38c65ZV3BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvV2mt7k%253D&md5=e7e782dc4426cbefc45babeb38c4c03c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2910110-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252910110-X%26sid%3Dliteratum%253Aachs%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DAmar%26aufirst%3DA.%26aulast%3DHartl%26aufirst%3DB.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26atitle%3D1-oxo-3-aryl-1H-indene-2-carboxylic%2520acid%2520derivatives%2520as%2520selective%2520inhibitors%2520of%2520fibroblast%2520growth%2520factor%2520receptor-1%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D2903%26epage%3D2908%26doi%3D10.1016%2Fs0960-894x%2897%2910110-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, P. R.</span>; <span class="NLM_string-name">Patel, K. M.</span>; <span class="NLM_string-name">Selby, T. P.</span>; <span class="NLM_string-name">Smith, B. T.</span>; <span class="NLM_string-name">Taggi, A. E.</span></span> <span> </span><span class="NLM_article-title">Herbicidal pyrimidone derivatives</span>. <span class="NLM_patent">WO 2011031658 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+R.+Kovacs&author=K.+M.+Patel&author=T.+P.+Selby&author=B.+T.+Smith&author=A.+E.+Taggi&title=Herbicidal+pyrimidone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKovacs%26aufirst%3DP.%2BR.%26atitle%3DHerbicidal%2520pyrimidone%2520derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inukai, T.</span>; <span class="NLM_string-name">Takeuchi, J.</span>; <span class="NLM_string-name">Yasuhiro, T.</span></span> <span> </span><span class="NLM_article-title">Quinoline derivatives</span>. <span class="NLM_patent">WO 2016104617 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Inukai&author=J.+Takeuchi&author=T.+Yasuhiro&title=Quinoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInukai%26aufirst%3DT.%26atitle%3DQuinoline%2520derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inukai, T.</span>; <span class="NLM_string-name">Takeuchi, J.</span>; <span class="NLM_string-name">Yasuhiro, T.</span></span> <span> </span><span class="NLM_article-title">Quinoline derivative</span>. <span class="NLM_patent">WO 2015012298 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+Inukai&author=J.+Takeuchi&author=T.+Yasuhiro&title=Quinoline+derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInukai%26aufirst%3DT.%26atitle%3DQuinoline%2520derivative%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1016%2Fj.ejmech.2018.08.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=30216852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWisrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=201-213&author=Q.+Tangauthor=Y.+Duanauthor=H.+Xiongauthor=T.+Chenauthor=Z.+Xiaoauthor=L.+Wangauthor=Y.+Xiaoauthor=S.+Huangauthor=Y.+Xiongauthor=W.+Zhuauthor=P.+Gongauthor=P.+Zheng&title=Synthesis+and+antiproliferative+activity+of+6%2C7-disubstituted-4-phenoxyquinoline+derivatives+bearing+the+1%2C8-naphthyridin-2-one+moiety&doi=10.1016%2Fj.ejmech.2018.08.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety</span></div><div class="casAuthors">Tang, Qidong; Duan, Yongli; Xiong, Hehua; Chen, Ting; Xiao, Zhen; Wang, Linxiao; Xiao, Yueyue; Huang, Shunmin; Xiong, Yinhua; Zhu, Wufu; Gong, Ping; Zheng, Pengwu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">201-213</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 6,7-disubstituted-4-phenoxyquinoline derivs. bearing the 1,8-naphthyridin-2-one moiety were designed, synthesized and evaluated for their biol. activities.  The target compds. exhibited moderate to high antiproliferative activity against three cancer cell lines (A549, HepG2 and MCF-7) and several compds. were evaluated for the activity against c-Met kinase.  The most promising compd. I (IC50 c-Met = 2.36 nM) showed excellent activity against A549, HepG2 and MCF-7 cell lines with IC50 values of 0.23 μM, 0.42 μM and 0.21 μM, resp., which was 1.5-2.1 times of the pos. control.  Furthermore, compd. I was evaluated for the activity against Flt3, PDGFR-α, PDGFR-β, c-Kit, Flt4, ALK and EGFR kinase.  Structure activity relationship studies indicated that mono-EWGs, such as fluorine at 4-position of moiety C was a key factor in improving the antitumor activity.  In addn., further research on compd. I was mainly including concn. dependence, apoptosis (acridine orange staining), apoptosis result analyzing and mol. docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-OR3VdwSo7Vg90H21EOLACvtfcHk0liEMuo7jEqD-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWisrfJ&md5=66e989df578414d1451612d54614574d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.066%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%25206%252C7-disubstituted-4-phenoxyquinoline%2520derivatives%2520bearing%2520the%25201%252C8-naphthyridin-2-one%2520moiety%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D201%26epage%3D213%26doi%3D10.1016%2Fj.ejmech.2018.08.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dandu, R.</span>; <span class="NLM_string-name">Hudkins, R. L.</span>; <span class="NLM_string-name">Josef, K. A.</span>; <span class="NLM_string-name">Prouty, C. P.</span>; <span class="NLM_string-name">Tripathy, R.</span></span> <span> </span><span class="NLM_article-title">Uracil derivatives as axl and c-met kinase inhibitors</span>. <span class="NLM_patent">WO2013074633A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Dandu&author=R.+L.+Hudkins&author=K.+A.+Josef&author=C.+P.+Prouty&author=R.+Tripathy&title=Uracil+derivatives+as+axl+and+c-met+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDandu%26aufirst%3DR.%26atitle%3DUracil%2520derivatives%2520as%2520axl%2520and%2520c-met%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manne, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppenheimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wautlet, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1021/jm801586s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.-W.+Caiauthor=X.-T.+Chenauthor=C.+Clarkauthor=L.+A.+M.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+Met+kinase+superfamily&doi=10.1021%2Fjm801586s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily</span></div><div class="casAuthors">Schroeder, Gretchen M.; An, Yongmi; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors.  Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aq. soly. and kinase selectivity.  Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration.  Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHEvJXf0Fq7Vg90H21EOLACvtfcHk0liEMuo7jEqD-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D&md5=784623be820fcc8b931200ced3a476df</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.-W.%26aulast%3DChen%26aufirst%3DX.-T.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520Met%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254%26doi%3D10.1021%2Fjm801586s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Chemical mechanisms of catalysis by cytochromes P-450: a unified view</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/ar00097a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00097a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADyaL2cXkslCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=9-16&author=F.+P.+Guengerichauthor=T.+L.+Macdonald&title=Chemical+mechanisms+of+catalysis+by+cytochromes+P-450%3A+a+unified+view&doi=10.1021%2Far00097a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical mechanisms of catalysis by cytochromes P-450:  a unified view</span></div><div class="casAuthors">Guengerich, F. Peter; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-16</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with 96 refs. on the mechanism of enzymic O transfer catalyzed by cytochrome P 450-contg. mixed-function oxidases (monooxygenases).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwCjg9zCGUobVg90H21EOLACvtfcHk0lgaLEF6FJ0pWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkslCgug%253D%253D&md5=65f638decb81e414a80468c33f62a325</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Far00097a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00097a002%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DChemical%2520mechanisms%2520of%2520catalysis%2520by%2520cytochromes%2520P-450%253A%2520a%2520unified%2520view%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1984%26volume%3D17%26spage%3D9%26epage%3D16%26doi%3D10.1021%2Far00097a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.can-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lgaLEF6FJ0pWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.can-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumienny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beer, T. A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rempfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwede, T.</span></span> <span> </span><span class="NLM_article-title">SWISS-MODEL: homology modelling of protein structures and complexes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">W296</span>– <span class="NLM_lpage">W303</span>, <span class="refDoi"> DOI: 10.1093/nar/gky427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1093%2Fnar%2Fgky427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=29788355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVyru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=W296-W303&author=A.+Waterhouseauthor=M.+Bertoniauthor=S.+Bienertauthor=G.+Studerauthor=G.+Taurielloauthor=R.+Gumiennyauthor=F.+T.+Heerauthor=T.+A.+P.+de+Beerauthor=C.+Rempferauthor=L.+Bordoliauthor=R.+Leporeauthor=T.+Schwede&title=SWISS-MODEL%3A+homology+modelling+of+protein+structures+and+complexes&doi=10.1093%2Fnar%2Fgky427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SWISS-MODEL: homology modelling of protein structures and complexes</span></div><div class="casAuthors">Waterhouse, Andrew; Bertoni, Martino; Bienert, Stefan; Studer, Gabriel; Tauriello, Gerardo; Gumienny, Rafal; Heer, Florian T.; de Beer, Tjaart A. P.; Rempfer, Christine; Bordoli, Lorenza; Lepore, Rosalba; Schwede, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W296-W303</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Homol. modeling has matured into an important technique in structural biol., significantly contributing to narrowing the gap between known protein sequences and exptl. detd. structures.  Fully automated workflows and servers simplify and streamline the homol. modeling process, also allowing users without a specific computational expertise to generate reliable protein models and have easy access to modeling results, their visualization and interpretation.  Here, we present an update to the SWISS-MODEL server, which pioneered the field of automated modeling 25 years ago and been continuously further developed.  Recently, its functionality has been extended to the modeling of homo- and heteromeric complexes.  Starting from the amino acid sequences of the interacting proteins, both the stoichiometry and the overall structure of the complex are inferred by homol. modeling.  Other major improvements include the implementation of a new modeling engine, ProMod3 and the introduction a new local model quality estn. method, QMEANDisCo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9ZhQAzPVe7Vg90H21EOLACvtfcHk0lgaLEF6FJ0pWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVyru70%253D&md5=651b55ade2d4f354f5d6699f318424d0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky427%26sid%3Dliteratum%253Aachs%26aulast%3DWaterhouse%26aufirst%3DA.%26aulast%3DBertoni%26aufirst%3DM.%26aulast%3DBienert%26aufirst%3DS.%26aulast%3DStuder%26aufirst%3DG.%26aulast%3DTauriello%26aufirst%3DG.%26aulast%3DGumienny%26aufirst%3DR.%26aulast%3DHeer%26aufirst%3DF.%2BT.%26aulast%3Dde%2BBeer%26aufirst%3DT.%2BA.%2BP.%26aulast%3DRempfer%26aufirst%3DC.%26aulast%3DBordoli%26aufirst%3DL.%26aulast%3DLepore%26aufirst%3DR.%26aulast%3DSchwede%26aufirst%3DT.%26atitle%3DSWISS-MODEL%253A%2520homology%2520modelling%2520of%2520protein%2520structures%2520and%2520complexes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DW296%26epage%3DW303%26doi%3D10.1093%2Fnar%2Fgky427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0liojP3lYCwoig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8','PDB','3LQ8'); return false;">PDB: 3LQ8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3F82','PDB','3F82'); return false;">PDB: 3F82</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i109"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02093">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77682"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02093?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02093</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Preparation of intermediate compounds, NMR spectra, and HPLC determination of compound <b>13c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Table of molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_002.csv">CSV</a>)</p></li><li><p class="inline">Axl DFG-out homology model in the PDB format and docking poses for <b>10g</b> and <b>13c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_003.zip">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_001.pdf">jm0c02093_si_001.pdf (1.36 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_002.csv">jm0c02093_si_002.csv (4.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02093/suppl_file/jm0c02093_si_003.zip">jm0c02093_si_003.zip (116.65 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02093&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02093%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02093" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b6ae5b8773d42","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
